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‘The brain is a tissue. It is a complicated, intricately woven tissue, like nothing else 
we know of in the universe, but it is composed of cells, as any tissue is. They are, to 
be sure, highly specialized cells, but they function according to the laws that govern 
any other cells. Their electrical and chemical signals can be detected, recorded and 
interpreted and their chemicals can be identified; the connections that constitute 
the brain's woven feltwork can be mapped. In short, the brain can be studied, just 
as the kidney can.’ 
 
By David H. Hubel  
(1981 Nobel Prize Winner) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii
ABSTRACT 
 
Homocysteine (Hcy) is a sulfur containing amino acid and is a potent neurotoxin. It 
has been shown that elevated levels of Hcy, termed hyperhomocysteinemia, plays a 
role in the pathologies of Alzheimer’s disease (AD) and age-related cognitive decline. 
Hcy is a glutamate agonist, which causes in increase in Ca2+ influx via the activation 
of NMDA class of excitatory amino acid receptors, which results in neuronal cell 
death and apoptosis. 
 
Estrogen and progesterone are female hormones that are responsible for reproduction 
and maternal behaviour. However, in the last decade, it is evident that both female 
hormones have neuroprotective properties in many animal models of 
neurodegeneration. Collectively, both estrogen and progesterone reduce the 
consequences of the oxidative stress by enhancing the antioxidant defence 
mechanisms, reducing excitotoxicity by altering glutamate receptor activity and 
reducing the damage caused by lipid peroxidation. However, the mechanisms by 
which estrogen and progesterone provide such neuroprotection probably depend on 
the type and concentration of hormone present. Moreover, numerous studies have 
shown that hormone replacement therapy (HRT, estrogen and progestins) or 
estrogen-only replacement therapy (ERT) may prevent or delay the onset of AD and 
improve cognition for women with AD. Clinical trials have also shown that women 
taking HRT may modify the effects of Hcy levels on cognitive functioning. 
 
Oxidative stress increases in the aging brain and thus has a powerful effect on 
enhanced susceptibility to neurodegenerative disease. The detection and measurement 
of lipid peroxidation and superoxide anion radicals in the brain tissue supports the 
 iii
involvement of free radical reactions in neurotoxicity and in neurodegenerative 
disorders.  
 
The hippocampus is an important region of the brain responsible for the formation of 
memory. However, agents that induce stress in this area have harmful effects and 
could lead to dementia. This study aims to investigate and clarify the neuroprotective 
effects of estrogen and progesterone, using Hcy-induced neurodegenerative models. 
The initial studies demonstrate that estrogen and progesterone have the ability to 
scavenge potent free radicals. Histological studies undertaken reveal that both 
estrogen and progesterone protect against Hcy-induced neuronal cell death. In 
addition, immunohistochemical investigations show that Hcy-induced apoptosis in the 
hippocampus can be inhibited by both estrogen and progesterone. However, estrogen 
also acts at the NMDA receptor as an agonist, while progesterone blocks at the 
NMDA receptor. These mechanisms reduce the ability of Hcy to cause damage to 
neurons, since Hcy-induced neurotoxicity is dependent on the overstimulation of the 
NMDA receptor. 
 
SOD and GPx are important enzymatic antioxidants which can react with ROS and 
neutralize them before these inflict damage in the brain. Hcy can increase oxidative 
stress by inhibiting expression and function of these antioxidants. However, it has 
been shown that the antioxidant abilities of both estrogen and progesterone can 
up-regulate the activities of SOD and GPx. These results provide further evidence that 
estrogen and progesterone act as antioxidants and are free radical scavengers.  
 
The discovery of neuroprotective agents is becoming important as accumulating 
evidence indicates the protective role of both estrogen and progesterone in 
 iv
Hcy-induced neurodegeneration. Thus further work in clinical trials is needed to 
examine whether reducing Hcy levels with HRT can become the treatment of 
neurodegenerative disorders, such as Alzheimer’s disease.  
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Conclusion 
CHAPTER 9 
 
CONCLUSION 
 
The results of this study illustrate the neuroprotective effects of pre- and 
post-treatments of 17β-estrogen and progesterone against Hcy-induced 
neurodegeneration. Initial studies were conducted to investigate the effects of estrogen 
and progesterone of both regimes on lipid peroxidation induced by Hcy. These results 
demonstrate that estrogen and progesterone significantly decrease lipid peroxidation 
in vitro and in vivo. The effects of lipid peroxidation may be harmful to plasma 
membrane of the cells, resulting in damage to membrane proteins and disturbance of 
membrane fluidity. However, it has been shown that high Hcy concentrations, is 
responsible for the production of oxygen free radicals and a consequent increase in 
lipid peroxidation (Heinecke, 1988), which is an implication in several 
neurodegenerative disorders. Estrogens and progesterone have been shown to be 
potent inhibitors of lipid peroxidation; therefore, both hormones may be a therapeutic 
advantage to Hcy-induced neurodegeneration. 
 
Hcy is a sulphur-containing amino acid and auto-oxidation of Hcy results in 
generation of O2․¯ in the brain and which initiates lipid peroxidation. Therefore, the 
neuroprotective effects of estrogen and progesterone as antioxidants against 
Hcy-induced O2․¯ were investigated. The antioxidant properties of estrogen and 
progesterone allow them act as O2․¯ scavengers and thus cause a significant decrease 
in Hcy-induced O2․¯. However, these results correlate with the abilities of both 
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hormones to reduce of Hcy-induced lipid peroxidation, shown in the first part of this 
study. 
 
Hcy is an endogenous ligand and an agonist at the glutamate site of the NMDA 
receptor and causes Ca2+ influx via the stimulation of NMDA receptor, this results in 
neuronal cell death and apoptosis. Histological investigation of hippocampal neurons 
demonstrates that Hcy causes neuronal cell swelling and both estradiol and 
progesterone are able to protect these neurons. Moreover, the Hcy-induced neuronal 
cell damage was investigated further by the detection of apoptotic cell death. These 
photomicrographs demonstrate that estradiol and progesterone of both treatment 
regimes protect the neurons against Hcy-induced apoptosis in both CA1 and CA3 
regions of the hippocampus. However, the cell damage induced by Hcy is dependent 
on the NMDA receptor. Hcy results in a reduction in the number of binding sites. 
However, treatment with either 17β-estradiol or progesterone prior to and after the 
intrahippocampal injection of Hcy results in up-regulation in the number of binding 
sites of the receptor. Therefore, the protection of either hormone against Hcy-induced 
damage is mediated by an interaction with the NMDA receptor.  
 
Prevention of apoptosis by antioxidants indicates that oxidative stress plays an 
essential role in the neurotoxic effects of Hcy. Hcy can increase oxidative stress by 
inhibiting expression or function of key antioxidant enzymes such as SOD and GPx, 
which might potentiate the toxic effects of oxidative stress. However, both estradiol 
and progesterone are able to increase both SOD and GPx activities which are 
suppressed by Hcy. Thus, the ability of both hormones to modify the antioxidant 
defence mechanism of SOD and GPx, in the presence of Hcy provides further 
evidence that 17β-estradiol and progesterone act as antioxidants and free radical 
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scavengers. 
 
17β-estradiol and progesterone are potent antioxidants and free radical scavengers, 
and are able to reduce Hcy-induced oxidative stress significantly. However, the 
neuroprotective mechanisms of 17β-estradiol and progesterone can be multifactorial. 
This includes the ability of both hormones to reduce lipid peroxidation and formation 
of superoxide anion radicals induced by Hcy. Finally, both hormones act on the 
NMDA receptors thus up-regulating the number of binding sites. It is evident that 
these hormones appear to be effective at protecting neurons from Hcy-induced 
neuronal damage investigated in the histological studies in chapter 4.  
 
The neuroprotective effects of estradiol and progesterone may lead to an improved 
understanding of the mechanisms of several neurodegeneration diseases, such as 
Alzheimer’s disease, and to the identification of novel pharmacological 
neuroprotective strategies. As a result of this thesis from the following areas have 
been identified as possible questions which need to be understood and future studies: 
 
1. Further research is needed to determine the clinical efficacy of both female 
hormones in neuroprotection. 
2. Reduction of the level of Hcy by estradiol, either indirectly by its effect on gene 
expression or directly by effects on Hcy synthesis might account for the 
neurodegeneration induced by Hcy. 
3. Age is associated with a decreased antioxidant capacity of the brain. The 
possibility of a combination of female hormone therapy with antioxidant therapy, 
such as Vitamin C and E, may lead to a new therapeutic implication for AD. 
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Appendix 1  MDA (malondialdehyde) standard curve 
    (y=0.0333x – 0.0484, R2=0.9972) 
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Nitroblue Diformazan Standard Curve
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Appendix 2  Nitroblue Diformazan Standard Curve 
    (y=0.0041x + 0.0256, R2=0.9988) 
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Protein Assay Calibration Curve
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Appendix 3  Protein Standard Curve generated from BSA 
    (y=0.0009x + 0.0171, R2=0.9986) 
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CHAPTER 1 
 
LITERATRUE REVIEW 
 
1.1. Neuroanatomy 
 
1.1.1. Introduction 
 
Neuroscience is a field of study which deals with the structure, function, development, 
genetics, biochemistry, physiology, pharmacology and pathology of the nervous 
system. The study of behavior and learning is also a division of neuroscience. Over 
the years, neuroscientists have shown increasing interests into the pathophysiology 
and etiology of neurodegenerative disorders. This has led to the current research of 
neuroprotective agents for therapeutic intervention. 
 
The population of the world is aging. By the year 2010, the proportion of people aged 
more than 65 years will have increased by 30%. Thus, an increasing number of people 
will experience significant age-related cognitive decline, stroke and late-onset 
neurodegenerative disorders, such as Alzheimer’s disease (AD).  
 
Increasing evidence has demonstrated striking sex differences in the pathophysiology 
of these age-related disorders. Lesser susceptibility to post-ischemic and 
post-traumatic brain injury in females has been observed in experimental models. 
Additional evidence suggests this gender difference extends to human as well. The 
greater neuroprotection afforded to females is likely due to the effects of circulating 
female hormones, estrogen and progesterone. However, most patients being treated 
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for menopausal symptoms will be receiving progesterone in addition to estrogen. The 
exogenous administration of both hormones has been shown to improve outcome after 
cerebral ischemia and traumatic brain injury in experimental models. The mechanisms 
by which estrogen and progesterone provide such neuroprotection are likely 
multifactorial. There is a large body of literature documenting the effects of gonadal 
hormones, estrogen and progesterone, on brain structure, function and metabolism. 
An understanding of the effects of both female hormones is therefore of central 
importance.  
 
In order to understand the mechanisms of action that both hormones have on the brain, 
it is necessary to give a brief outline of the processes involved in the structural 
features of the brain and the role of oxidative stress in the brain, particular the 
hippocampus. 
 
1.1.2. The structure and function of the hippocampus 
 
The hippocampus is a medial temporal lobe brain structure that is thought to 
contribute to learning and memory. The hippocampus is one of several brain 
structures classified as being part of the limbic system, which is involved in various 
emotions such as fear, aggression, pleasure, and also in the formation of memory. 
Although the precise role of the hippocampus remains controversial, it is generally 
agreed that it is involved in certain forms of learning and for acquiring new memories. 
 
The hippocampus is essential in memory consolidation — a process in which short 
term memory is converted into long-term memory (Cohen & Eichenbaum, 1993; Kim 
& Fanselow, 1992). Long-term memory allows people to recall information, days, 
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weeks, or years after learning. In addition, damage to the hippocampus can cause 
anterograde amnesia, which prevents a person from forming new declarative 
memories, yet leaves procedural memories intact. Procedural memory (implicit 
knowledge) refers to skills and procedures essential for human motor performance. 
Yet, unlike procedural memory, declarative memory stores events and facts that can 
explicitly be recalled. 
 
The rat hippocampus is located approximately 1mm anterior to the starting point of 
the cerebellum (dorsal view) and extends about 4mm posterior and approximately 
2.5mm lateral of the midline separating the two hemispheres (figure 1.1.). 
 
Figure 1.1. A range of sections of the rat brain displaying the hippocampus shown 
in brown. (Left and Right) A dorsal view of the rat brain; (Middle, Top) A midsaggital 
section through the brain; (Middle, bottom) A coronal section through the brain 
(Heron, 2002). 
 
The hippocampus is made of two thin sheets of neurons named, the dentate gyrus and 
the Ammon’s horn. There are four divisions in the Ammon’s horn, of which the most 
important are the CA1 and CA3. CA stands for Cornu Ammonis which means 
Ammon’s horn in Latin. The entorhinal cortex sends information to the hippocampus 
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via the perforant path, which is a bunch of axons. In the CA3 region, the dentate gyrus 
neurons give rise to axons, called mossy fires. The CA3 cells give rise to axons that 
branch; one branch leaves the hippocampus via the fornix and the other branch called 
Schaffer collateral, forms synapses on the neurons of CA1 (figure 1.2). 
 
Figure 1.2.  Illustration of microcircuits of the hippocampus (Bear et al., 2001). 
 
The hippocampus has long been thought to play a key role in the formation of new 
memories (Scoville et al., 1957) and has been extensively studied for both its role in 
learning and memory (Silva, 2003) and its susceptibility to excitotoxicity (Ben-Ari et 
al., 1980; Golarai et al., 2001; Grady et al., 2003; Olsson et al., 2003). The main 
pathway involved in hippocampal function is the glutamatergic system, requiring 
glutamate as the major neurotransmitter, which causes the activation of postsynaptic 
receptors such as N-methyl–D-aspartate (NMDA) receptors involved in memory. 
However, the hippocampus is one of the first regions of the brain to be affected by 
AD where disorientation and memory problems are the primary symptoms (Rossler et 
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al., 2002; Kauffman et al., 1998). 
 
1.2. Excitotoxicity 
 
1.2.1. Introduction 
 
Excitotoxicity, which was first described by Olney et al., (1972) in the 
nineteen-seventies, involves the activation of glutamate receptors in the central 
nervous system (CNS). Excitotoxicity is the process by which excess or prolonged 
stimulation of neurons by excitatory amino acids (EAA), glutamate, through 
postsynaptic receptors, which leads to neuronal cell death (Schinder et al., 1996).  
 
Glutamate, an excitatory amino acid, activates different types of ion channel-forming 
receptors (ionotropic) and G-protein-coupled receptors (metabotropic) to develop 
their essential role in the brain. However, high concentrations of glutamate or 
neurotoxins acting at the same receptors, cause cell death through the excessive 
activation of these receptors. In physiological conditions, the presence of glutamate in 
the synapse is regulated by active, adenosine triphosphate (ATP)-dependent 
transporters in neurons and glia. Several disorders such as cardiac arrest, stroke, brain 
trauma and seizures, can initiate excess glutamate release. This occurs when the 
oxygen and glucose supply to the brain is dramatically decreased in cases where 
blood flow ceases such as during a stroke. As a result, neurons cannot generate 
enough ATP to drive membrane ion pumps. Depolarization of the membrane occurs 
and consequently calcium leaks into the cell. This calcium triggers the synaptic 
release of glutamate from vesicles, which further depolarizes neurons and raises 
intracellular calcium. Glutamate exerts its physiologic actions on several distinct 
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families of glutamate receptors, located principally on postsynaptic neurons. The 
actions of glutamate are terminated when glutamate is removed from the synaptic 
cleft by sodium-dependent, high-affinity glutamate uptake carriers, which are located 
primarily on glial cells (Rothstein et al., 1996; Schousboe et al., 1981), but 
presynaptic terminals also sequester glutamate directly from the synaptic cleft 
(Savolainen et al., 1995). Within the glial cells, glutamate is converted to glutamine 
via the enzyme glutamine synthetase (Savolainen et al., 1995; Yudkoff et al., 1993). 
Glutamine can then be recycled back to the glutamatergic nerve terminals, where it is 
converted to glutamate by the mitochondrial enzyme, phosphate-activated 
glutaminase (Bradford, 1986; Nicklas et al., 1986). Glial cells and neurons possess a 
similar plasma membrane glutamate uptake carrier, which keeps the extracellular 
glutamate concentration below levels that damage neurons (Nicholls & Attwell, 
1990). 
 
However, the mechanism by which glutamate raises the intracellular calcium is 
through the activation of several types of receptors, which allow excessive amounts of 
Na+, K+ and Ca2+ to flow across the membrane (figure 1.3.). The NMDA receptor 
once activated results in an influx of calcium into the cell. This causes neuronal 
damage due to the stimulation of intracellular enzymes that degrade lipids, proteins, 
and nucleic acids. In addition to this, neurons are damaged due to swelling that occurs 
resulting from water uptake (Bear et al., 2001). 
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Figure 1.3. The mechanism of glutamate raises the intracellular calcium through 
the activation of several types of receptors and allows excessive amounts of Na+, K+ 
and Ca2+ to flow across the membrane. (soma.npa.uiuc.edu/ 
courses/bio303/Image129.jpg). 
 
1.2.2. N-methyl-D-aspartate Receptors 
 
The NMDA receptors play a critical role in excitotoxicity and are classified as 
ionotropic glutamate receptors. The NMDA receptor channel is a complex molecular 
entity consists of a number of distinct recognition sites for endogenous and exogenous 
ligands, each has distinct binding domains (Cooper et al., 1996). These receptors are 
ligand-gated, voltage-dependent ion channels (Mayer et al., 1984), which at resting 
potential is blocked by a magnesium ion that is only displaced following 
depolarization of the neuron by the binding of glutamate to the receptor along with a 
co-agonist, glycine, to a modulatory site (Carfagno et al., 2000). 
 
Activation of the NMDA receptor is modulated by polyamines, such as spermine and 
spermidine (Williams et al., 1991). The polyamine site needs not be occupied for 
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receptor activation, but the presence of polyamines increases the ability of glutamate 
and glycine to open the NMDA-receptor ion channel (Yoneda et al., 1991). The 
voltage-dependent blockade of the receptor ion channel by Mg2+ is one of the most 
important factors of the NMDA receptor (Greenamyre et al., 1994; Mayer et al., 1984; 
Monaghan et al., 1986; Nutt, 1993; Couratier et al., 1996). When the glutamate and 
glycine sites are occupied, at resting potential (about -70mV), normal extracellular 
concentrations of Mg2+ block the NMDA-receptor ion channel and prevent current flow. 
However, because the Mg2+ blockade is voltage-dependent, when a neuron becomes 
depolarised, the degree of Mg2+ block is reduced (Dodd et al., 1994), allowing more 
movement of ions. 
 
Besides allowing intracellular influx of Ca2+, the NMDA receptor also permits 
exchange of Na+ and K+ across the cell membrane (Tilson et al., 1995; Yudkoff et al., 
1993; Gonzales, 1990).  However, the Ca2+ permeability of NMDA receptor is 
important to the initiation of long term potentiation as the increase of Ca2+ 
concentration activates a number of cellular and second messenger systems (Mayer et 
al., 1990; Collingridge et al., 1990; Madison et al., 1991). 
 
Extracellular Zn2+ acts as an inhibitory divalent cation at the site near the “mouth” of 
the ion channel, to produce a voltage-independent block. There are a number of 
competitive and non-competitive inhibitors present for the NMDA receptor. The most 
common competitive inhibitor is 2-amino-5-phosphonovalerate (AP5), which 
competes directly with glutamate for the binding site (Tilson et al., 1995), while the 
non-competitive inhibitors dibenzocyclohepteneimine (MK-801), phencyclidine (PCP) 
and remacemide act within the ion channels to block current flow (Greenamyre et al. 
1994, Tilson, 1995). High concentrations of the NMDA receptors can be found in the 
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cerebral cortex and CA1 regions of the hippocampus (Monaghan et al., 1986). Figure 
1.4 shows that structure of NMDA receptor. 
Figure 1.4.  Diagrammatic representation of NMDA receptor (Cooper et al., 1996). 
 
1.2.3. NMDA Receptor Activation and Cell death 
 
1.2.3.1. Acute NMDA Toxicity 
 
Acute toxicity occurs due to the rapid influx of Na+ into the neuron. This causes 
passive Cl¯ and water entry into the cell via osmotic pressure. This toxic process 
occurs within minutes and depends on the presence of extracellular Na+ and Cl¯ ions. 
It may be associated with abnormalities in membrane permeability and may be lethal, 
via osmotic lysis. Under certain circumstances, the neuron may be able to restore 
osmotic pressure and thus survive. This process can be mimicked by depolarizing 
agents like veratridine (Churchwell et al., 1996) or by raising extracellular K+ 
concentrations. Activation of non-NMDA receptors can cause such neurodegeneration, 
with both kainic acid and α-2-amino-3-hydroxy-5-methylisoxazole-4-proprionate 
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(AMPA) being examples of potent neurotoxins (Collingridge et al., 1989). The 
process that takes place may be direct, by over-excitation of the neuron leading to 
prolonged depolarization and depletion of energy reserves, or indirect, for example by 
excessive Na+ ion influx resulting in Ca2+ build up via Na+ - Ca2+ exchange. 
 
1.2.3.2. Delayed NMDA Toxicity 
 
When injected into rat hippocampus in amounts not immediately toxic, NMDA 
induces a gradual neurodegeneration over several hours, which can be inhibited by 
delayed administration of NMDA antagonists. Several factors contribute to this slow 
degeneration: 1) There may be a failure of inhibition due to preferential loss of 
function of inhibitory interneurons, which would amplify ongoing NMDA receptor 
activation, and 2) neurons may undergo a period of enhanced vulnerability to further 
NMDA receptor activation. Neurons in cerebellar slices given one non-lethal 
exposure to NMDA can be rendered necrotic by a second, non-lethal exposure an 
hour later. This may be related to the time required to reinstate normal intracellular 
calcium buffering following the first insult (Meldrum & Garthwaite, 1990). 
 
1.2.4. The Effects of Ca2+ Influx in Excitotoxic Neuronal Damage 
 
Ca2+ influx and subsequent calcium overload following NMDA receptor activation 
triggers cytotoxic processes responsible for neuronal degradation. In most cases Ca2+ 
influx does not actively initiate cell death, but rather activates a number of enzymatic 
and metabolic processes that set in motion a process that can prove neurotoxic. In part, 
these changes are reversible, as shown by the ability of glutamate receptor antagonists 
to confer neuroprotection several hours after an excitotoxic insult (Leigh et al., 1996). 
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However, in most cases, once the process has begun, neuronal cell death results. 
 
Among the processes triggered by increased Ca2+ concentrations, is the activation of 
proteases calpain-1. The enzyme can degrade major neuronal structural proteins, and 
induce cytoskeletal breakdown (Seubert et al., 1988). Calpain also cleaves xanthine 
dehydrogenase to convert it to xanthine oxidase (Meldrum & Garthwaite, 1990; 
Atlante et al., 1997) enzyme converts hypoxanthine to uric acid while also producing 
superoxide radical (O2˙) (Wie et al., 1997). 
 
Phospholipases (Meldrum & Garthwaite, 1990; Himmelseher et al., 1996) are capable 
of breaking down cell membranes and liberating arachidonic acid may also be 
activated by Ca2+. Protein kinase C is an enzyme responsible for a prolonged phase of 
Ca2+ influx following EAA receptor activation (Mayer & Miller, 1990). 
Phospholipase A2 leads to the production of arachidonic acid, which can be 
metabolised to give free radicals. This enzyme also potentiates synaptic transmission, 
increases glutamate release, decreases glutamate uptake into glia and activates protein 
kinase C (Meldrum & Garthwaite, 1990). However, phospholipase C generates IP3 
(inositol 1,4,5-triphosphate), which raises cytosolic Ca2+ release from internal stores, 
and DAG (diacylglycerol), which activate protein kinase C and enhances glutamate 
release (Mayer & Miller, 1990).  
 
Ca2+ can also bind to calmodulin to form Ca2+-calmodulin complexes. The role of this 
complex in mammalian cells is to modulate the activity of a large number of enzymes 
(Ross, 1980). Among the processes activated are Ca2+-calmodulin-linked protein 
kinases, which disrupt the cytoskeleton (Wang et al., 1996), cause mitochondrial 
dysfunction and activate lipases (Wang et al., 1996). Ca2+-calmodulin complexes can 
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also activate nitric oxide synthase (NOS) (Scatton et al., 1994), which produces nitric 
oxide (NO˙), a toxin that has been implicated in a number of neurological diseases 
(Dodd, 1992). Activation of Ca2+-sensitive kinases (proteases) could also result in 
over-phosphorylation of cytoskeletal proteins such as tau, hyperphosphorylated forms 
of which are found in neurofibrillary tangles (Mattson et al., 1992a, b). 
 
Dykens et al., (1994) reported that isolated cerebral and cerebellar mitochondria 
produce free radicals when exposed to elevated Ca2+. Mitochondria play an important 
role in the removal of Ca2+from cells after a glutamate insult (White et al., 1997; 
Khodorov et al., 1996a). Ca2+is sequestered to the mitochondrial matrix (Budd & 
Nicholls, 1996; Wang & Thayer, 1996; Schinder et al., 1996), driven by the proton 
electron chemical gradient generated by the electron transport chain (Ankarcrona et 
al., 1996). The reduction in the electrochemical gradient (Ankarcrona et al., 1996) 
caused by the Ca2+ influx decreases ATP synthesis (Khodorov et al., 1996b), at a time 
when there is great demand for ATP by the plasma membrane Ca2+ pump, and 
indirectly by the Na2+ / Ca2+ exchanger (Schinder et al., 1996). Mitochondrial Ca2+ 
accumulation and the subsequent permeability transition may therefore be a critical 
early event specific to the NMDA receptor mediated excitotoxic cascade (White & 
Reynolds, 1996; Isaev et al., 1996). 
 
1.2.5. NMDA Receptor Antagonists 
 
NMDA receptor antagonists have potential therapeutic benefits in a number of 
neurodegenerative disorders such as stroke and trauma; chronic neurodegeneration 
such as Alzheimer’s disease and symptomatic treatment such as epilepsy, Parkinson’s 
disease, depression, anxiety. Neuroprotective agents which completely block NMDA 
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receptors also impair normal synaptic transmission and thereby cause numerous side 
effects. Therefore, it is a challenge to develop antagonists that prevent the 
pathological activation of NMDA receptors but allow their physiological activity.  
 
However, memantine is a clinically well tolerated uncompetitive NMDA receptor 
antagonist with strong voltage-dependency and rapid blocking/unblocking kinetics 
and is effective in the treatment of dementia. The action of memantine has been 
showed potential profile in animal models of chronic neurodegenerative disease 
(Parsons et al., 1999). Since then, clinical research has focused on uncompetitive 
NMDA receptor antagonist in the treatment of dementia (Ditzler et al., 1991). 
 
(+)-MK-801(Dizocilpine,(+)-5-methyl-10,11-dihydro-5H-dibenzocyclo-hepten-5,10-i
mine maleate) is the most potent NMDA antagoinst, which binds to the receptor when 
the receptor channel is open. The binding of MK-801 is dependent on the existence of 
NMDA receptor agonist. Therefore, an agonist or positive modulator would result in 
an increase of MK-801 binding (Foster & Wong, 1987). The binding of this antagonist 
is illustrated in Figure 1.5. By combining with the transmitter recognition site, an 
agonist such as NMDA activates the receptor. This causes a transformation of the 
receptor to the open state. The opening state of the receptor allows the conductance of 
Na+, Ca2+ and K+, which initiate the neuronal response. In contrast, the 
non-competitive antagonists act upon the ion channel such as Mg2+. Mg2+ blocks the 
channel directly and prevents ionic conductance. When the channel is in the open 
state, MK-801 binds to sites within the channel. However, the binding site that 
MK-801 binds to is separated from but interacts with those for divalent cations, thus 
preventing the passage of ions (Kemp et al., 1987). 
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Figure 1.5. Model of the NMDA receptor complex and propsed sites of action of 
non-competitive antagonists (Kemp et al., 1987). Once an agonist (D-AP5) has bound 
the channel opens allowing antagonists such as MK-801 and PCP to bind. 
 
1.3. Oxidative Stress 
 
1.3.1. Introduction 
 
For years researchers have known that free radicals can cause cell degeneration, 
especially in the brain. Scientists have implicated the unstable molecules as a cause of 
neurodegenerative disorders such as Alzheimer’s disease, Parkinson's disease and 
Huntington's disease. Now researchers are unraveling the pathways of free radical 
destruction in order to create targeted therapies for these disorders. 
 
Oxygen, because of its bi-radical nature, readily accepts unpaired electrons to give rise 
to a series of partially reduced species collectively known as reactive oxygen species 
(ROS) including, superoxide (O2˙-), hydrogen peroxide (H2O2) (Hoyt et al., 1997), 
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hydroxyl radical (Cheesman & Slater, 1993), peroxyl radical, nitric oxide (NO˙) and 
peroxynitrite, until it is itself completely reduced to water. Most of the superoxide 
radicals are formed in the mitochondrial and microsomal electron transport chain. 
However, not all of these species are particularly active in aqueous biological 
soloutions (Dawson & Dawson, 1996). These reactive oxygen species cause an 
oxidative stress that could lead to cell damage or death (Hoyt et al., 1997). 
 
Oxygen (O2) can cause damage to DNA, proteins, essential or protective enzymes, 
provoke lipid peroxidation and dissolution of plasma and mitochondrial membranes via 
transformation to more reactive forms. However, about 1- 4% of the O2 taken up into 
cells forms are partially reduced O2 species, the ROS. Some of these reduced O2 species 
contain unpaired electrons and are therefore classified as free radicals. Leigh et al., 
(1990) states that the word ‘free’ preceding ‘radical’ is unnecessary because all radicals 
are free. The diatomic oxygen molecule, O2, possesses two unpaired electrons, each 
electron locates in a different orbital and both have the same spin quantum number and, 
thus qualifies as free radical itself. In living cells, there is a balance between oxidative 
stress and an antioxidative effect exists generally. When this balance is disturbed in the 
cells, either by defeat of reducing agents (e.g. glutathione) or protective enzymes (e.g. 
SOD and GPx) or by the increased production of reactive oxygen species (e.g. 
superoxide and hydrogen peroxide) or by both actions concurrently, the cells are then 
under oxidative stress (Fahn & Cohen, 1992). As a consequence, cell damage induced 
by free radicals or reactive oxygen species is referred as oxidative stress. 
 
1.3.2. Free radicals 
Free radicals are highly reactive molecules or chemical species capable of independent 
existence. Generation of highly ROS is an integral feature of normal cellular function 
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like mitochondrial respiratory chain, phagocytosis, arachidonic acid metabolism. Their 
production however, multiplies several folds during pathological conditions. The 
release of oxygen free radicals has also been reported during the recovery phases from 
many pathological noxious stimuli to the cerebral tissues (Halliwell & Gutteridge, 
1989).  
 
There are different ROS found in living cells (Table 1.1). When two free radicals react, 
both radicals are eliminated; on the other hand, if a radical reacts with a non-radical, 
another free radical is produced. This characteristic allows free radicals to play a part in 
chain reactions, and cause thousands of actions (McCord, 1985).  
 
Table 1.1. Formation of different types of ROS by reduction of molecular oxygen 
(Cui et al., 2004). 
(i) O2 + e + H+ → HO2 (hydroperoxyl radical) 
(ii) HO2 → H+ + O2˙ (superoxide radical) 
(iii) O2˙+ 2H+ + e → H2O2 (hydrogen peroxide) 
(iv) H2O2 + e → OH¯ + OH (hydroxyl radical) 
(v) OH + e + H+ → H2O 
(vi) O2˙ + H2O2 →OH¯+ OH + O2 (Haber–Weiss reaction) 
(vii) Fe2++ H2O2 →OH¯+ OH + Fe3+ (Fenton reaction) 
 
The majority of superoxide radicals generated by mitochondrial electron transport 
chain are enzymatically dismutated to H2O2. The hydroxyl and alkoxy free radicals are 
very reactive species and rapidly attack the macromolecules in cells (Boveris et al., 
1972). The superoxide anion, lipid hydroperoxides, and nitric oxide are comparatively 
less reactive. A limited number of enzymes like xanthine-oxidase, tryptophan 
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dioxygenase, and indole-amine dioxygenase produce the superoxide free radical 
directly. Reactions catalysed by enzymes, such as monoamine oxidase and L-amino 
acid oxidase, also produce hydrogen peroxide, directly (Stohs et al., 1995). Further, 
nitric oxide free radical (NO˙) can react with superoxide radical to form highly toxic 
peroxynitrite (ONOO˙). When peroxynitrite reacts with human body fluids and tissues, 
nitrotyrosines are generated, which have been detected in human brain and may be 
increased in neurodegenerative diseases, especially because glial cells and 
macrophages generate nitric oxide (Halliwell & Gutteridge, 1985). There has been 
speculation that nitric oxide is implicated in many of the neurodegenerative disorders. 
 
1.3.3. Defense Mechanisms Against ROS Neurotoxicity 
 
Biological systems have evolved with defence mechanisms to help protect against free 
radical linduced cell damage. (Machlin & Bendich, 1987) see table1.2. Glutathione 
peroxidase (GPx), catalase (CAT) and superoxide dismutases (SOD) are antioxidant 
enzymes, which metabolize toxic oxidative intermediates. These require micronutrient 
as cofactors such as selenium, iron, copper, zinc, and manganese for optimum catalytic 
activity and effective antioxidant defence mechanisms (Halliwell, 2001; Halliwell & 
Gutteridge, 1992). These enzyme systems are normally distributed evenly inside cells 
(McCord, 1985), and under normal circumstances these defence mechanisms can deal 
with the production of ROS in the neuron. Antioxidants usually refer to molecules that 
inhibit the chain reaction of lipid peroxidation by scavenging intermediate peroxy 
radicals (Halliwell, 1992a). The toxicity of free radicals can be mitigated by direct free 
radical scavengers and by indirect antioxidants (Sies et al., 1993). These protective 
mechanisms can be classified into two main categories (Dawson & Dawson, 1996), 
namely the enzymatic defence antioxidants and non-enzymatic cellular antioxidants. 
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SOD and GPx are among the most important members of the enzymatic defence 
antioxidants. Non-enzymatic cellular antioxidants, such as the lipophilic free radical 
scavenger α-tocopherol (Vitamin E), or the hydrophilic compound ascorbate (Vitamin 
C), are the most prominent antioxidants of their class, can directly interact with ROS 
at the molecular level (Sies et al., 1993). 
 
Table 1.2. Cellular defence/anti-oxidant mechanisms accessible to neurons to 
protect against ROS species (Dawson & Dawson, 1996). 
 
Enzymatic 
 
 
Non-Enzymatic 
 
Cu / Zn – O2. Dismutase Ascorbic Acid (Vitamin C) 
 
Mn – O2. Dismutase 
 
α-tocopherol (Vitamin E) 
 
Glutathione Peroxidase 
 
Glutathione 
 
Glutathione-S-Transferase 
 
 
Glutathione Reductase 
 
 
Catalase 
 
 
 
SOD, catalase, and glutathione peroxidase are three primary enzymes, involved in 
direct elimination of active oxygen species (hydroxyl radical, superoxide radical, and 
hydrogen peroxide). Glutathione is the most significant component which directly 
quenches ROS such as lipid peroxides and plays a major role in xenobiotic metabolism. 
When an individual is exposed to high levels of xenobiotics, more glutathione is 
utilised for conjugation making it less available to serve as an antioxidant. It also 
maintains ascorbate (vitamin C) and alpha-tocopherol (vitamin E), in their reduced 
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form, which also exert an antioxidant effect by quenching free radicals. Table 1.3 
shows a list of neutralising antioxidants against ROS (Anderson, 1996; Meister et al., 
1994a; Sies & Stahl 1995). 
 
Table 1.3.  Reactive oxygen species and their corresponding neutralising 
antioxidants. 
ROS Antioxidants 
 
Hydroxyl radical 
 
Glutathione peroxidase and vitamin C 
Lipid peroxide 
 
Glutathione peroxidase and vitamin E 
Superoxide radical Superoxide dismutase and vitamin C 
 
Hydrogen peroxide 
 
Catalase and vitamin C 
 
The breakdown of by SOD yields hydrogen peroxide and oxygen (reaction 1). There 
are two distinct SOD’s in eukaryotes; the manganese-containing SOD found and 
copper-zinc-containing SOD, which found in the mitochondrial matrix and the 
cytoplasm, respectively. 
 
2O2˙+ 2H+ → H2O2 + O2      (1) 
2GSH + H2O2 → GSSG + 2H2O    (2) 
GSSG + NADPH + H+ → 2GSH + NADP+  (3) 
2H2O2 → O2 + 2H2O      (4) 
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Hydrogen peroxide is decomposed by two reactions. At low concentrations, H2O2 is 
removed by reacting with reduced glutathione to form oxidized glutathione and water, 
catalyzed by glutathione peroxidase (reaction 2). Reduced glutathione is regenerated 
by the action of glutathione reductase (reaction 3). At high concentrations, however, 
H2O2 is removed by the enzyme catalase (reaction 4), (Fahn & Cohen, 1992). 
 
1.3.4. Superoxide Radical 
 
Acceptance of a single electron by an O2 molecule forms the superoxide radical, O2˙, 
has one unpaired electron. McCord et al., (1985) shows that O2˙ is a major agent 
responsible for O2 toxicity and that SOD appears to have evolved specially to 
scavenge O2˙. Superoxide is formed in vivo in a variety of ways. A major source is the 
activity of electron transport chains in mitochondria and endoplasmic reticulum 
(Halliwell, 1992a). Some of the electrons passing through these chains “leak” directly 
from intermediate electron carriers onto O2. Because O2 accepts electrons one at a 
time, O2˙ is formed (Halliwell, 1992a). The rate of leakage at physiological O2 
concentrations rise as O2 concentration is increased (Fridovich et al., 1989). Some 
leakage of O2˙ can occur, however, mitochondria normally contain high levels of the 
protective enzymes, SOD and GPx to remove toxic species (Jesberger & Fichardson, 
1991). Hence the toxicity of excess O2 may be due to increased formation of O2˙, 
beyond the ability of antioxidant defenses to cope. 
 
It is generally held that O2˙ is not highly reactive in an aqueous environment. Moreover, 
once formed, O2˙ quickly undergoes dismutation to generate H2O2; this reaction is 
markedly accelerated by a family of enzymes, the SOD (Fridovich et al., 1989). Since 
SOD removes an oxidant, O2˙, from the cell, it is generally considered as an important 
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antioxidative enzyme (Touati, 1989). The reduction of cytochrome c by xanthine and 
xanthine oxidase is mediated by O2˙ (McCord & Freidovich, 1968) and this reduction is 
used as the basis of assays for both O2˙and SOD. The SOD enzymes are catalysts that 
have evolved a surface charge arrangement to facilitate the specific use of O2˙ as a 
substrate (Benovic et al., 1983). 
 
The evidence supporting the superoxide theory of O2 toxicity is important, but the 
exact mechanism by which the excessive O2˙ generation at increased O2 levels could 
exert toxic effects is not completely clear. The reduction of molecular oxygen to form 
O2˙ occurs in normal biochemical oxidation-reduction reactions, both enzymatic 
(xanthine oxidase) and non-enzymatic (autoxidation of catecholamines). In addition, 
activated phagocytic cells (such as monocytes, neutrophils, eosinophils and 
macrophages including microglia) produce superoxide, which plays an important part 
in the mechanism by which bacteria are engulfed and destroyed (Colton and Gilbert, 
1987). Thus excessive activation of phagocytic cells (as in chronic inflammation) can 
lead to free radical damage. The O2˙ can also be generated chemically by 
auto-oxidative reactions with catecholamines, tetrahydrofolates and reduced flavins. 
The Ca2+-dependent activation of phospholipase A2 also yields O2˙ through the 
metabolism of arachidonic acid by the lipoxygenases and cyclooxygenases to form 
eiconasoids (Chan & Fishman, 1980). Most of the O2˙ generated in a cell is converted 
to H2O2 by O2˙ dismutase (DiFiglia, 1990; Halliwell, 1992a). 
 
1.3.5. Hydrogen Peroxide 
 
SOD removes O2˙ by converting it into H2O2. H2O2 can act as an oxidizing agent, 
although it is poorly reactive. However, unlike O2˙, H2O2 crosses cell membranes 
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easily. H2O2 is not itself a free radical and does not contain unpaired electrons. In the 
presence of transition metals, most often Fe2+  but also Cu1+, H2O2 is reduced to the 
hydroxyl radical (˙OH) via either Haber-Weiss or Fenton reactions (Halliwell & 
Gutteridge, 1990). The ultimate fate of H2O2 is not always the ˙OH. H2O2 can be 
removed within human cells by catalases and glutathione peroxidases (Halliwell & 
Gutteridge, 1990). 
 
In the brain GPx are considerably more important than catalase because of the low 
activity of the latter enzyme in most parts of the central nervous system (CNS) (Jain, 
1991). GPx utilizes H2O2 and hydroperoxides as substrates during the conversion of 
reduced glutathione (GSH) to its disulfide oxidized glutathione (GSSG) (Griffith & 
Meister, 1985). 
 
1.3.6. Hydroxyl Radical 
 
Hydroxyl radical (˙OH) is formed when H2O2 reacts with Fe2+ ions, by the Fenton 
reaction, which can be represented by the overall reaction: 
 
Fe2+ + H2O2 → Fe3+ + ˙OH + OH¯               (5) 
 
The ˙OH radical is probably the most reactive of the ROS species (Poeggler et al., 1993; 
Dawson & Dawson, 1996). It will react with almost all molecules in living cells, 
including DNA (causing strand breakage), membrane lipids and carbohydrates.  
(Fridovich, 1996). Most of the DNA damage may be mediated by reaction of H2O2 with 
iron and /or copper ions, bound close to DNA to form ˙OH (Aruoma et al., 1991).  
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However, another devastating effect of ˙OH radical is its action on membrane lipids. 
Various reactive species that are generated on mixing O2˙, H2O2 and iron of copper 
ions are capable of initiating the process of lipid peroxidation (Halliwell, 1992a). 
Alternatively, during excitatory neurotransmitter stimulation of neurons, the large 
increases in intracellular Ca2+ activate nuclease enzymes in the nucleus which results in 
the formation of ˙OH leading to DNA damage (Orrenius et al., 1989). 
 
1.3.7. Nitric oxide and Peroxynitrite Anion 
 
Nitric oxide (NO˙) is another free radical released by several cell types, especially 
vascular endothelial cells and phagocytes (Moncada et al., 1991). NO˙ reacts with O2˙ 
at physiological pH to yield a nonradical product, peroxynitrite (ONOOֿ) (Radi et al., 
1991). Under normal physiological conditions this nitrogen-centered radical has 
important functions as a neuronal messenger molecule and is responsible for relaxation 
of the pyloric sphincter in the gastrointestinal tract (Yun et al., 1996) and vasodilation 
(Holscher et al., 1997); however, when NO˙ increases intracellularly to unusually high 
concentrations it initiates a toxic cascade of events which can lead to the death of 
neurons (Zhang et al., 1994). A common example of NO˙ toxicity is seen in glutamate 
neurotransmission in the CNS where N-methyl-D-aspartate (NMDA) receptor 
activation leads to large rises in intracellular calcium concentration followed by the 
stimulation of neuronal nitric oxide synthase (NOS) (Dawson et al., 1991) leading to 
the generation of NO˙. 
 
ONOO¯ is cytotoxic by oxidizing thiol groups, and also decompose to form ˙OH 
(Beckman, 1991; Radi et al., 1991). Although ONOO¯ is a simple compound, it is 
chemically highly complex. Its reactivity is similar to that of OH˙. The toxicity of 
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ONOO¯ derives from its ability to directly nitrate and hydroxylate the aromatic rings of 
amino acid residues (Beckman, 1992), with zinc-thiolate moieties (Crow, 1995) as well 
as with lipids (Radi et al., 1991), proteins (Moreno & Pryor, 1992) and DNA (King et 
al., 1992). This ubiquitous activity makes the ONOO¯ a molecule that can have 
devastating effects on neuronal physiology as well as viability. 
 
1.3.8. The Involvement of Metal Ions 
 
Ions of transition metals such as copper and iron, in tissues of animals, including 
humans (Choi et al., 1994), are involved in many free radical reactions, and lead to 
generation of highly reactive species (Halliwell & Gutteridge, 1989). Transition metals 
promote lipid peroxidation in two ways: (1) by catalyzing the formation of oxygen free 
radical species capable of initiating lipid peroxidation and (2) by catalyzing the 
decomposition of preformed lipid peroxides to propagate lipid peroxidation. 
 
Evidence suggests that iron is involved in lipid peroxidation (Lauffer et al., 1992). 
However, only free iron is able to stimulate free radical reactions, whereas iron bound 
to protein such as transferrin found in human plasma, is not normally available to 
stimulate such reactions. Iron (II) reacts with hydrogen peroxide in the Fenton reaction 
to produce the harmful hydroxyl radical and the oxidized form of the metal iron (III) 
(reaction 5). The Fenton reaction can be augmented by the reduction of ferric ion by 
superoxide thus regenerating ferrous ion. However, the net result is the production of 
hydroxyl radicals as in the iron-catalyzed Haber-Weiss type of reaction. 
 
The hydroxyl radical is the most reactive of all oxygen radicals, which is iron 
dependent. The hydroxyl radical is harmful to the cell and no enzyme system uses it as 
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a substrate. Cells attempt to prevent hydroxyl radical formation by removing hydrogen 
peroxide and transition metals to inactive sites (Fahn & Cohen, 1992). However, 
hydrogen peroxide crosses the blood brain barrier and is converted to the hydroxyl 
radical in the brain causing severe damage to brain neurons. 
 
Evidence shows that iron stores increase with age in humans and animals (Leggett, 
1990). It has been suggested that iron accumulated in human and rat brain during aging 
can accelerate the degeneration in brain functions that occur during aging and in certain 
pathologies of CNS degenerative disorders (Viani et al., 1991). However, the 
endogenous iron stores are available for participating in peroxidative process in tissue 
(Halliwell & Gutteridge, 1986). 
 
1.3.9. Iron Source for Fenton Chemistry 
 
Iron is a remarkably useful metal in nature. It is essential for the transport of 
haemoglobin, the storage of myoglobin and oxygen for cytochromes and cytochrome 
oxidase in respiration. In addition, it is also an essential component in the active sites 
of many enzymes and antioxidant defense enzyme catalase. In mammals, iron is 
absorbed from the gut and originates from food and beverages we consume that are 
prepared with iron. Iron not required for these is stored as ferritin, which can hold up 
to 45 000 ions of iron (Halliwell & Gutteridge, 1992). Transferrin enters cells by 
endocytosis in a vacuole, which is acidified to release the iron. The unloaded 
transferrin is ejected from the cell and the iron ions released from it are used for the 
synthesis of intracellular iron proteins. Excess iron is stored in the protein ferritin. In 
this way the cells minimize the size of the intracellular iron pool (Halliwell & 
Gutteridge, 1989).  
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Oxidant stress can provide the iron necessary for Fenton chemistry by mobilizing iron 
from ferritin or by degrading haeme proteins to release iron. Reports have stated that 
the formation of OH ֿP  in vivo may be limited by the supply of iron ions, and tissue 
injury can exacerbate radical reactions if it liberates metal ions from broken cells into 
the surrounding environment. This is especially true in brain, since cerebrospinal fluid 
(CSF) has no significant iron-binding capacity, and mechanical disruption of the brain 
releases iron that can stimulate radical reactions such as lipid peroxidation. 
 
1.3.10. Lipid Peroxidation 
 
Lipid peroxidation is one of the major outcomes of free radical–mediated injury to 
tissue. Membrane phospholipids are biomolecules which are the most susceptible to 
oxidative attack by free radicals, because of the high levels of polyunsaturated fatty 
acids (PUFA) present in these macromolecules. Lipid peroxidation can be extremely 
damaging because self-perpetuating chain reactions are caused by ROS attack. Table 
1.4 illustrates the three well-described phases which characterise the lipid 
peroxidation process: initiation, propagation, and termination. During the initiation 
step (reaction 1) the free radical attacks a methylene group in the PUFAs (In˙), 
leading to a rearrangement of the double bonds to the conjugated diene form, and 
simultaneously producing a carbon-centered alkyl radical. The alkyl radical reacts 
with molecular oxygen to give rise to a peroxyl radical (RH) and the formation of a 
lipid-derived radical (R˙). The propagation step (reaction 2) the peroxyl radical, in its 
turn, starts a self-perpetuating chain reaction in which most of the membrane lipids 
are converted to a variety of lipid peroxyl radical (ROO˙) and cyclic peroxides. The 
lipid hydroperoxides (ROOH) can be further degraded to hydrocarbons, alcohols, 
ether, epoxides, and aldehydes. Of these products, malondialdehyde and 
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4-hydroxynonenal have the additional ability to inactivate phospholipids, proteins, 
and DNA by bringing about cross-linking between these molecules (Esterbrauer et al., 
1990). A self perpetuating autocatalytic reaction then follows with reactions 2 and 3 
undergoing a number of cycles (Biziere et al., 1980). The last step is a termination 
step, which results when two ROO˙ radicals react together to form a non-radical 
product (Krinsky, 1992). An important aspect of these reactions is that lipid 
peroxidation will proceed until substrate is consumed or termination occurs. There are 
two broad outcomes to lipid peroxidation, viz., structural damage to membranes and 
generation of secondary products. Membrane damage derives from the generation of 
fragmented fatty acyl chains, lipid-lipid cross-links, endocyclization to produce novel 
fatty acid esters, and lipid-protein cross-links (Farber et al., 1995). In total, these 
processes combine to produce changes in the biophysical properties of membranes 
that can have profound effects on the activity of membrane-bound proteins. 
Secondary products from lipid peroxidation may be divided conceptually into those 
generated by fragmentation or rearrangement of oxygenated lipid. However, lipid 
peroxidation is an indiscriminate process and formation of both types of products 
occurs simultaneously.  
 
Table 1.4.  Chain sequence for free radical auto-oxidation (Krinsky, 1992). 
Initiation In˙ + RH → InH˙+ R˙           (1)
Propagation R˙ + O2 → ROO˙              (2)
ROO˙ + RH → R˙ + ROOH      (3)
Termination 2 ROO˙→ Non-radical products   (4)
 
Fragmentation of lipid peroxidation liberates a number of diffusible products, which 
are potent electrophiles (Esterbauer et al., 1991). Thus, the detection and 
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measurement of lipid peroxidation is the evidence cited to support the involvement of 
free radical reactions in toxicology and in human disease. Lipid peroxidation is 
defined as the oxidative deterioration of lipids that contain more than two 
carbon-carbon double covalent bonds (Halliwell, 1992a). Cell membranes are rich in 
polyunsaturated lipids and together with saturated fatty acids which give rise to 
membrane fluidity. Damage to these PUFA side chains reduces membrane fluidity 
and as a result the biological membrane is not able to function properly. The most 
abundant diffusible product of lipid peroxidation is malondialdehyde (MDA). 
Reactive aldeyhdes from lipid peroxidation are biologically active. Most studies have 
focused on their reactivity with a number of cellular nucleophiles, including proteins, 
nucleic acids and some lipids (Esterbauer et al., 1991). Indeed, many of the cytotoxic 
effects of lipid peroxidation can be reproduced directly by electrophilic lipid 
peroxidation products such as 4-hydroxy-2-nonenal (HNE) (Farber et al., 1995). 
These include depletion of glutathione, dysfunction of structural proteins, reduction in 
enzyme activities, and induction of cell deaths.  
 
The removal of ROS by various antioxidant systems is therefore essential to limit 
lipid peroxidation occurring in cells. Numerous antioxidant mechanisms have evolved, 
including several metabolic routes to detoxify fragmentation products from lipid 
peroxidation. The diffusible reactive aldehydes generated from lipid peroxidation are 
excellent substrates from glutathione transferases and a number of oxidoreductases 
that act to detoxify these molecules (Esterbauer et al., 1991). 
 
However, there is compelling evidence that the magnitude of lipid peroxidation in the 
brains of AD patients examined postmortem exceeds that in age-matched control 
individuals without neurologic disease (Montine et al., 2002). These authors 
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demonstrate that there is significantly increased thiobarbiturate reactive substrances 
(TBRAS) in disease regions of AD brain. 
 
1.3.11. Free radicals and Disease 
 
1.3.11.1. Introduction 
 
Free radicals have been reported to be involved in aging as well as many diseases 
such as arthritis, neurological damage, Down’s syndrome and diabetic cataract. The 
mammalian brain is especially vulnerable to oxidative stress (Hall & Braughler, 1989) 
as it consumes 20% of total body oxygen, contains large amounts of PUFA, which is 
relatively deficient in protective mechanisms, and readily accumulates iron (Dawson 
& Dawson, 1996). It is believed that approximately up to 5% of the oxygen taken up 
by an organism may become damaging oxygen-based radicals (Reiter et al., 1995; 
Chan et al., 1993). Therefore, in the human, there could be an equivalent of 2 kg O2˙ 
produced each year (Reiter et al., 1995). As a consequence, it is substantial to 
measure the molecular carnage and cytotoxicity that is in the brain after toxin 
exposure and during aging. This oxidative damage has been considered as a common 
link in the pathogenesis and neuropathology of a variety of neurodegenerative 
disorders, such as AD. 
 
1.3.11.2. Aging 
 
Aging is a natural phenomenon and there are many physiological factors that can 
either advance or slow the aging process. In mammal, aging could be result from 
normal developmental and metabolic processes responsible for the decreases in the 
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rate of wound healing or increases in susceptibility to disease and death. Brain aging 
has become an area of intense research and a subject of much speculation fueled 
largely from the widely recognized fact that age is the biggest risk factor in most 
neurodegenerative diseases. 
 
There are two ideas as to how aging and stress are related (Selye & Tuchweber 1976). 
The first is that as an organism ages so it is less able to adapt to stress. This idea is 
supported by the many physiological systems that function normally in younger life, 
and yet do not adequately respond to the challenge in old age. The second idea is that 
by impairing hippocampal functions, stress can accelerate the aging process like 
learning and memory (Endo et al., 1996). 
 
ROS are believed to be responsible for many of the ageing processes. These 
molecules affect the integrity of the macromolecules in the cell. Although most of the 
ROS produced are rapidly removed from the cell by the antioxidant defense system, 
there is a slow accumulation of damage that occurs during an animal’s life. It is 
estimated that 10 000 oxidative hits occur on DNA in the human per day (Ames et al., 
1993). These damages are repaired by enzymes that remove the lesion; however there 
is a steady increase in the number of lesions as the animal ages. Viani et al., (1991) 
compared young, adult and old rat brains. The group found that old brains were more 
susceptible to lipid peroxidation, demonstrating that peroxidation injury can have 
even more dramatic consequences when it takes place in the aged brain. 
 
1.3.11.3. Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder 
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that occurs gradually and results in memory loss, unusual behavior, personality 
changes, and a decline in thinking abilities. AD is a dementia characterized by 
neurodegeneration; in particular, a loss of acetylcholine in the entorhinal cortex, 
hippocampus, ventral striatum, basal forebrain, and cerebral cortex (Bartus et al., 
1982; Gilman, 1997; Kasa et al., 1997) and behavioral pathologies, such as wandering 
behavior (Ryan et al., 1995). AD accounts for more than 70 percent of all cases of 
dementia, so it is important to identify modifiable risk factors for the disease 
(Brookmeyer et al., 1998). During the past decade, there has been growing interest in 
vascular factors that may underlie AD. It is now recognized that subjects with 
cardiovascular risk factors and a history of stroke have an increased risk of both 
vascular dementia and AD (Hofman et al., 1997; Breteler, 2000; Snowdon, 1997). 
 
In AD, the death of neurons in brain regions critical for learning and memory is 
believed to result from increased production and accumulation of insoluble forms of 
amyloid β peptides (Aβ). It may endanger and kill neurons by inducing oxidative 
stress and disrupting cellular ion homeostasis (Mattson, 2000). Aβ can induce 
oxidative stress and DNA damage in cultured neurons and both oxidative stress and 
DNA damage have been documented in neurons associated with Aβ-containing 
plaques in the brains of AD patients (Mattson, 1997; Mattson, 2000). 
 
A clinical diagnosis of AD is confirmed by observing numerous neuritic (amyloid) 
plaques and neurofibrillary tangles in the hippocampus, amygdala, and cortex 
(Yamaguchi et al., 1988; Tagliavini et al., 1988). The plaques (extracellular) are 
composed of the 42- and 40-residue Aβ proteins (Skovronsky et al., 1998; Walsh et 
al., 2000), whereas the tangles (intraneuronal) are composed of modified forms of the 
microtubule-associated protein, tau. Aβ protein is generated normally throughout life 
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from a large, receptor-like precursor, Aβ precursor protein, (APP) through proteolytic 
cleavages by the β- and γ-secretases. Mutations in 3 genes (APP, presenilin 1, and 
presenilin 2) that cause AD increase cerebral Aβ production (Berezovska et al., 2001), 
whereas inheritance of the apolipoprotein E4 (Apo E4) polymorphism enhances its 
stability, leading to Aβ accumulation. Figure 1.6 shows the sequence of the 
pathogenetic steps of AD based on currently available evidence (Dennis & Selkow, 
2004). 
 
Figure 1.6. The sequence of the pathogenetic steps of AD (Dennis & Selkoe, 
2004). 
Currently, the pharmaceutical treatment of the dementia symptoms of AD is restricted 
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to 2 types of drugs: acetylcholinesterase inhibitors (such as donepezil, galantamine, 
and rivastigmine) (Mayeux & Sano, 1999) and the recently approved 
N-methyl-D-aspartate antagonist, memantine (Zajaczkowski et al., 2000; Jain, 2000). 
These agents temporarily relieve some symptoms for a period of time for a subset of 
patients, but they do not address the underlying pathologic process or substantially 
slow clinical progression. Prospective mechanism-based treatments include inhibitors 
of the β- andγ-secretases (Petersen et al., 1999) and immunotherapeutics (anti-Aβ 
protein monoclonal antibodies and Aβ protein vaccines) (Schenk, et al. 1999). 
 
Another Aβ protein–based approach to treating AD is to administer anti-inflammatory 
drugs that could interfere with aspects of the microglial, astrocytic, and cytokine 
responses found in the brain of a patient with Alzheimer disease. The epidemiologic 
evidence that prolonged use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) 
(specifically inhibitors of cyclooxygenase-1) is associated with a lower risk for AD 
could be explained on this basis (in t’Veld et al., 2001). However, exciting studies in 
cultured cells and APP transgenic mice suggest that some NSAIDs associated with 
protection from AD, such as ibuprofen, can modulate processing of APP to decrease 
Aβ protein 42 productions without lowering overall Aβ protein levels (Weggen et al., 
2001).  
 
Finally, various antioxidants, free radical scavengers, calcium-channel blockers, metal 
chelators, or modulators of certain signal transduction pathways might protect 
neurons from the downstream effects of the accumulation of protein. One problem 
with such approaches may be that neurons respond to Aβ protein and its associated 
inflammatory process in several ways. Blocking cyclooxygenase-1 or -2 of these 
response pathways might not substantially decrease overall neuronal dysfunction and 
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loss. A chelator of copper and zinc ions that may decrease cerebral Aβ protein levels 
(Cherny et al., 2001) is being tested in patients with AD. 
 
In the future, individuals who are nearly 50 years of age or older will probably be 
offered a specific risk-assessment profile to determine their likelihood of developing 
AD. Such an assessment, modeled on that used to predict the risk for serious 
atherosclerotic disease, could include inquiry about a family history of AD; 
identification of specific predisposing genetic factors; structural and functional brain 
imaging to detect evidence of presymptomatic lesions; and measurement of Aβ 
protein 42, tau, and other markers of the neuropathology in cerebrospinal fluid and 
perhaps (in the case of Aβ protein) in blood. Therefore, those individuals who are at 
high risk of developing AD might be offered preventative treatments with 1 or more 
of the agents. Although the achievement of an integrated diagnostic and therapeutic 
approach to this devastating disorder may seem remote, the current rate of scientific 
progress and the recent initiation of further clinical trials suggest that some level of 
practical success may come soon. 
 
1.3.12. Antioxidant Therapy 
 
The term “antioxidant” is frequently used in the literature to mean a chain-breaking 
antioxidant inhibitor of lipid peroxidation. Antioxidants inhibit the chain reaction of 
lipid peroxidation by scavenging intermediate peroxyl radicals. This would prevent 
the peroxyl radicals from attacking adjacent fatty acid side chains or membrane 
proteins. In human brain, α-tocopherol is an important antioxidant. Muller & 
Goss-Sampson et al., (1990) shows that severe and prolonged deprivation of 
α-tocopherol cause severe neurological derangements. However, it takes considerable 
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time (weeks) to increase the α-tocopherol content of brain tissue in mammals 
supplemented with vitamin E.  
 
Antioxidant enzymes, especially human SOD, are now another approach as an 
antioxidant therapy. Endogenous SOD has an important protective role. SOD 
diminishes reperfusion injury after spinal cord ischemia (Lim et al., 1986) and 
oedema induced by low brain temperatures (Chan et al., 1987). Moreover, GPx is 
another antioxidant enzyme which is able to remove H2O2 and inhibit lipid 
peroxidation. 
 
1.3.13. Molecular Targets of Oxidative Stress 
 
Ischemia/reoxygenation injury and traumatic damage to the brain can produce 
liberation of catalytic metal ions and an increase in the formation of reactive radicals, 
thus causing further cellular damage. Several groups have found evidence that 
increased oxidative stress can be the result of CNS lipid peroxidation after ischemia 
(Michel et la., 1987); trauma (Hall & Braughler, 1988). 
 
However, oxidative damage does not always lead to the formation of lipid peroxides 
in injured nervous tissue. DNA and protein damage in vivo are of equal or greater 
importance (Halliwell et al., 1987). Human cells subjected to oxidative stress show 
DNA damage and consequent activation of poly-(ADP-ribose) synthetase and 
decreases in ATP content as well as increases intracellular free Ca2+ (Orrenius et al., 
1989). In addition, generation of excitatory amino acids such as glutamate produced 
by ischemia in brain can cause oxidative stress (Meldrum et al., 1990). However, 
protein damage is also an important consequence of oxidative stress (Halliwell et al., 
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1987). Free radicals can also damage brain proteins (Oliver et al., 1990), including the 
enzyme glutamine synthetase. This enzyme is responsible for glutamate removal 
inactivated by oxidative stress (Oliver et al., 1990). There is evidence suggests that 
protein damage is important in a variety of normal and pathological process, such as 
aging and oxygen toxicity (Oliver et al., 1990). 
 
1.4. Homocysteine 
 
1.4.1. Introduction 
 
Homocysteine (Hcy) is a nonessential sulfur-containing amino acid and an 
intermediary metabolic product derived from the demethylated essential amino acid 
methionine. It is first discovered in 1932 by the 1955 Nobel Prize recipient Vincent 
DuVigneaud (DuVIgneaud et al., 1952) and its association with premature 
arteriosclerotic (fibrotic) vascular disease is then described by Kilmer McCully in 
1969 (McCully, 1969), Hcy has emerged as a novel marker of risk for cardiovascular 
disease. 
 
Hcy is an important metabolite of methionine playing a key role in trans-sulphuration 
and trans-methylation pathways. Hcy can be re-methylated to methionine, and this 
reaction catalysed by Hcy; methionine methyltransferase requires folic acid and 
Vitamin B12. Moreover, Hcy can be catabolised to cystathionine by cystathionine 
β-synthase using Vitamin B6 (Yudkoff et al., 1999; Molloy and Weir, 2001). 
 
An elevated plasma level of Hcy, termed hyperhomocysteinemia, is recognized as an 
independent risk factor for myocardial infarction, coronary artery disease, strokes, 
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genetic disorders, AD and loss of cognitive functions (Schwartz et al., 1997; Whincup, 
1999; Stehouwer et al., 1998). Normal Hcy concentration in human blood does not 
exceed 14µM (Seshadri et al., 2002). Inborn errors of its metabolism or disturbances 
caused by dietary deficiency in folic acid and/or Vitamins B6 and B12, may lead to 
hyperhomocysteinemia in the range of 50-200µM or even higher (Scott and Weir, 
1998; Yudkoff, 1999; Lipton et al., 1997). Elevated plasma Hcy levels are also 
associated with an increased risk of neural tube defect, placental infarcts and 
eclampsia (Wenstrom et al., 2000; Wang et al., 2000; Ray et al., 1999; Sohda et al., 
1997; McCully, 1994), and some reports suggest that hyperhomocysteinemia might be 
a manifestation of an underlying common biologic disorder which is directly 
associated with the process of DNA methylation (Kramer et al., 1990; Yi et al., 2000). 
These observations led to the hypothesis that elevated plasma Hcy may be a risk 
factor for dementia and AD (Seshadri et al., 2002). Direct support for this hypothesis 
was provided recently by Clark et al., (1998), who compared serum Hcy levels in AD 
patients and age-matched controls without neurodegenerative disease. Several studies 
(Andersson, 1992; Joosten et al., 1997; Rasmussen et al., 1996) have shown increased 
plasma Hcy levels in healthy elderly people, which could increase the risk of suffering 
degenerative disease by the impairment of redox processes and the increase of 
oxygen-free radicals during aging. Hcy has been shown to promote low-density 
lipoprotein (LDL) oxidation in vitro (Heinecke et al., 1993; Hirano et al., 1994; Lynch 
et al., 1997), potentiate glutamate excitotoxicity (Kruman et al., 2000), causes 
changes in redox thiol status (Ueland et al., 1996), serves as a source of hydrogen 
peroxide, a harmful free radical (Dimitrova et al., 2002) and together with Cu2+ 
(Hultberg et al., 1997) induces a decrease in the intracellular levels of glutathione in 
HeLa culture cells. There is reported evidence implicating Hcy promotion of in vivo 
lipid oxidation (Roberts & Morrow, 2000) and in men with mild 
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hyperhomocysteinemia (Voutilainen et al., 1999). 
 
1.4.2. Biochemistry of Homocysteine 
 
Hcy is a thiol-containing amino acid derived from methionine, an essential amino acid. 
Hcy is produced entirely from the methylation cycle as it is totally absent from any 
dietary source (Finkelstein et al., 1974; Finkelstein et al., 1998). Hcy occurs in blood 
in three forms, whereby most of it (80-90%) is bound to protein; a smaller part is 
available as free amino acid, and traces are present as disulphide. Normal fasting 
plasma levels (total homocysteine) are between 5 and 15µmol/L. Moderate elevated 
Hcy levels range between 16 and 30µmol/L, intermediate elevated Hcy levels 
between 31 and 100µmol/L, and severe hyperhomocysteinaemia is present at over 
100µmol/L (Graeme & Eikelboom, 1999). In populations without evidence of a 
nutritional deficit (vitamin B12 deficiency, malnutrition), a reference interval of 
between 4.9 and 11.7µmol/L was determined (Ubbink et al., 1995). Under these 
conditions, higher Hcy values probably increase the cardiovascular risk (Andreotti et 
al., 2000). The frequency of re-stenoses in coronary vessels is significantly elevated at 
plasma Hcy levels between 11 and 12µmol/L, but is significantly reduced upon 
lowering of the Hcy values through folic acid substitution (Schnyder et al., 2002). 
Recent data from a meta-analysis has shown that an increased folic acid intake 
(approximately 200µg/day) reduces Hcy levels by approximately 4µmol/L which 
significantly decreases coronary artery disease mortality (Boushey et al., 1995). 
 
1.4.3. Metabolism of Homocysteine 
 
 38
Literature Review 
Hcy is an intermediate metabolite of methionine metabolism. Metabolism of the 
amino acid methionine, a limiting amino acid in the synthesis of many proteins, 
affects several biochemical pathways involving the production of nutrients which are 
essential to the optimal functioning of the cardiovascular, skeletal, and nervous 
systems. Hcy metabolized by two pathways: the trans-methylation pathway where 
Hcy is catalyzed by methionine synthase or betaine homocysteine methyl transferase, 
which regenerates methionine; the trans-sulfuration pathway, Hcy is catalyzed by 
cystathionine beta-synthase leading to cystathionine, which degrades Hcy into 
cysteine and then taurine. However, the intermediate metabolite Hcy is located at a 
critical metabolic crossroad, and therefore both directly and indirectly impacts all 
methyl and sulfur group metabolism occurring in the body. Studies have shown that if 
high enough levels of Hcy and adenosine accumulate in the cell, all methylation 
reactions are completely inhibited (Duerre et al., 1981). 
The trans-methylation pathway is comprised of two intersecting biochemical 
pathways, and results in the transfer of a methyl group (CH3) to Hcy by either 
methylcobalamin or betaine (trimethyl-glycine). Methylcobalamin originally receives 
its methyl group from S-adenosylmethionine (SAM) (Figure 1.8) or 
5-methyltetrahydrofolate (5-methylTHF), an active form of folic acid (Figure 1.7). 
Hcy can be reconverted into methionine by methylation, catalysed by the methionine 
synthase, a process requiring vitamin B12 and folic acid as cofactors. Alternatively, it 
can be transformed to cystathionine catalysed by cystathionine β-synthetase (CβS), a 
vitamin B6-dependent enzyme. However, methionine can also be re-utilized to 
produce SAM, the body's "universal methyl donor," which participates in several key 
metabolic pathways, including methylation of DNA and myelin, synthesis of carnitine, 
coenzyme Q10, creatine, epinephrine, melatonin, methylcobalamin, and 
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phospha-tidylcholine, as well as phase II methylation detoxification reactions. 
Moreover, in the liver, remethylation can also be catalysed by the enzyme 
betaine-homocysteine transmethylase. Cellular export represents an additional 
mechanism of Hcy removal. Excess intracellular Hcy leads to export of Hcy and may 
thus lead to increased plasma Hcy levels in the circulation (Refsum et al., 1998; 
Ueland et al., 1997). 
tetrahydrofolate 
Figure 1.7. Trans-methylation cycle. Cofactors are represented in boxes 
(Teunissen et al., 2002). 
The trans-sulfuration pathway of methionine/Hcy degradation (Figure 1.8) produces 
the amino acids, cysteine and taurine, which are important nutrients for cardiac health, 
hepatic detoxification, cholesterol excretion, bile salt formation, and glutathione 
production. Cysteine is a precursor of glutathione (GSH). However, approximately 
half of the intracellular GSH pool in human liver cells is derived from Hcy via the 
trans-sulfuration pathway (Mosharov et al., 2000). The redox sensitivity of the 
trans-sulfuration pathway can be rationalized as an auto-corrective response that leads 
to an increased level of GSH synthesis in cells challenged by oxidative stress. The 
importance of the Hcy dependent trans-sulfuration pathway is the maintenance of the 
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intracellular GSH pool, and the regulation of this pathway under oxidative stress 
conditions. This pathway is dependent on adequate dietary intake and hepatic 
conversion of vitamin B6 into its active form, pyridoxal 5’-phosphate (P5P). Also the 
amino acid serine is necessary, which is a metabolite generated from betaine via the 
homocysteine-remethylation pathway. 
Figure 1.8. Homocysteine metabolism (Miller et al., 1997). 
1.4.4. The Mechanism of Neurotoxicity and the Role of Hcy 
 
Elevated Hcy levels in the developing nervous system and adverse effects of 
folate/vitamin B12 deficiency, taken together with the fact that 
hyperhomocysteinemia, has prompted examination of potential roles for Hcy and 
deficiencies in one-carbon metabolism in age-related neurodegenerative disorders 
such as AD and PD. Hyperhomocysteinemia has been related to cerebral 
microangiopathy (Fassbender, 1999), endothelial dysfunction (Welch et al., 1998), 
impaired nitric oxide activity (Chao et al., 2000) and increased oxidative stress 
(Starkebaum et al., 1986) and all factors associated with aging of the brain (McCann, 
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1887; Beal, 1995). Hcy also promotes copper-mediated and 
β-amyloid-peptide-mediated toxic effects in neuronal cell cultures (White et al., 2001) 
and induces apoptosis in hippocampal neurons in rats (Kruman et al., 2000). Hcy can 
damage and kill neurons in cell culture and can increase their vulnerability to being 
killed by various excitotoxic, oxidative and metabolic insults (Table 1.5).  
 
Table 1.5. Examples of adverse effects of Hcy on neurons (Mattson & Shea, 
2003). 
Neurodegenerative agent 
or condition 
Impact of Hcy Neuroprotective agents 
ROS 
 
Increased Vitamin E (Shea et al., 
2002) 
Cytosolic Ca2+ Increased Chelators, channel 
blockers (Ho et al., 2002) 
Glutamate excitotoxicity Increased NMDA-receptor channel 
blocker (Ho et al., 2002; 
Lipton et al., 1997) 
Tau phosphorylation Increased NMDA-receptor channel 
blocker (Ho et al., 2002) 
ATP levels Depleted PARP inhibitors (Ho et 
la., 2002; Kruman, 2000) 
Apoptosis Increased PARP inhibitors, SAM, 
antioxidants (Ho et al., 
2002; Kruman, 2000; 
Kruman, 2002; Ho et al, 
2001) 
Aβ-induced 
neurotoxicity 
Increased Vitamin E, 17β-estradiol 
(Kruman, 2002; Ho et al., 
2001) 
 
Hcy induces DNA breakage in cultured neurons (Kruman, 2000) by a mechanism that 
may involve impaired trans-methylation of DNA, since folate and vitamin B12 
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deficiencies retard methionine regeneration, SAM levels are also reduced as a 
consequence of these vitamin deficiencies (Selhub et al., 1992). In cultured neurons, 
Hcy depletes the ATP reserves of DNA, which is attempting to repair Hcy-induced 
DNA damage and thus induces apoptosis (Kruman., 2000). In this regard, depletion of 
cellular ATP is thought to be a key factor in neurodegeneration in AD and PD (Davey 
et al., 1998; Mattson et al., 1999). As with consideration of Hcy-induced oxidative 
stress, this maintains the possibility that moderate or slight hyperhomocysteinemia 
might foster a crucial reduction in ATP in neurons in aging brains in which ATP is 
already depleted. 
 
Hcy acts as a partial antagonist of the glycine site of the N-methyl-D-aspartate 
(NMDA) receptor and therefore inhibits NMDA receptor mediated activity in the 
presence of normal concentrations of glycine.  However, Hcy is also an agonist at 
the glutamate site of the NMDA receptor and is therefore a potential excitotoxin. 
Under normal conditions in the central nervous system, neurotoxicity would not occur 
because glycine levels are in the low micromolar range, whereas Hcy is 0.5µM in the 
cerebrospinal fluid (Hyland & Bottiglieri, 1992) and up to 10µM in certain brain 
regions (Broch & Ueland, 1984). Under conditions of normal glycine concentrations, 
the agonist (excitotoxic) action of Hcy at the glutamate site of the NMDA receptor 
would only prevail if levels approached millimolar concentrations. Indeed, this 
mechanism may contribute to the cognitive changes and markedly increased risk of 
cerebrovascular disease in children and young adults with this disorder. Elevated 
glycine levels synergize with Hcy to over-stimulate NMDA receptors and contribute 
to neuronal damage. Thus in conjunction with elevated glycine, micromolar 
concentrations of Hcy could contribute to neuronal injury if allowed access to the 
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extracellular space during tissue injury (Lipton et al, 1997) and enhance oxidative 
stress (Kim & Pae, 1996). 
 
Oxidative damage resulting from Hcy is caused by increased cytosolic Ca2+ levels 
(Table 1.5) and DNA damage (Ho et al., 2002; Kruman., 2000). In cultured neurons, 
Hcy treatment increases cytosolic Ca2+ and treatment with Ca2+-channel blockers 
attenuates this increase, suggesting that the bulk of the increase results from influx 
across the plasma membrane (Ho et al., 2002). Hcy potentiates glutamate 
neurotoxicity, and the toxicity of Hcy itself is attenuated by antagonisis of 
metabotropic glutamate receptors (Kruman, 2000; Ho et al., 2001). Hcy also 
compromise glutathione peroxidase activity (Huang et al., 2001a; Upchurch et al., 
1997) and reduce tissue levels of vitamins A, C and E (Henning et al., 1997). Indeed 
vitamin C, vitamin E (Huang et al., 2002) and estrogen (Dimitrova et al., 2002) 
reduce Hcy-mediated apoptosis in non-neuronal cells by scavenging hydrogen 
peroxide. However, in the presence of increased Hcy, it causes an accumulation of 
S-adenosylhomocysteine hydrolase (SAH). SAH is a bi-directional enzyme that 
favours hydrolysis of SAH to homocysteine under normal conditions. Moreover, SAH 
is the demethylated product of SAM transmethylation, is itself a potent competitive 
inhibitor of SAM-mediated methylation reactions. Decreased intracellular methylation 
reactions can thus result from either a decrease in formation of SAM or an increase of 
SAH (Cantoni, 1986). Recent evidence demonstrates that Hcy induces DNA breakage 
and resultant apoptosis (Kruman, 2000; Kruman 2002), and that co-treatment with 
SAM prevents Hcy-induced apoptosis (Ho et al., 2002). 
 
Potentiation of neurodegeneration induced by treatments such as glutamate 
excitotoxicity and Aβ toxicity by Hcy maintains the possibility that even moderate 
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hyperhomocysteinemia can exert a deleterious impact on neuronal health far beyond 
what might be anticipated. Figure 1.9 shows the mechanism by which Hcy induces 
the death of neurons, and cell cycle arrest in neural stem cells and glial cells. The 
pathway that has adverse effects on developing and mature neurons is shown in red. It 
involves methyl donor deficiency resulting in increased DNA damage due to deficient 
DNA repair. DNA damage activates poly-(ADP-ribose) polymerases (PARP), 
resulting in ATP depletion and activation of the tumor suppressor protein p53, which 
can trigger cell-cycle arrest of apoptosis. These adverse effects of Hcy can be 
enhanced by oxidative stress and perturbed cellular Ca2+ that occurs during aging and 
in age-related neurodegenerative disorders. The emerging impact of Hcy on the 
nervous system suggests that diagnostic and therapeutic approaches should include 
attention to conditions that promote neurodegeneration. 
 
 
Figure 1.9. Mechanisms of Hcy-induced neuronal cell death (Mattson & Shea, 
2003). 
1.4.5. The Implication of Hcy in Neurodegenerative Diseases 
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Hcy metabolism associated with metabolic disorders resulting in Hcy accumulation 
suggests several possible mechanisms for the observed effects. Either a genetic defect 
in one of the enzymes of Hcy metabolism or a nutritional deficiency of one or more of 
the vitamins that participate in Hcy metabolism can lead to metabolic disruption and 
potentially to hyperhomocysteinemia. The results of clinical studies and experimental 
data accumulated during the last decade demonstrate that hyperhomocysteinemia may 
directly exert neurotoxicity. Even moderate hyperhomocysteinemia has been 
recognized as a strong, independent risk factor in the development of dementia and 
AD (Seshadri et al., 2002). Moreover, increased oxidative stress, DNA damage, the 
triggering of apoptotic and excitotoxic cell death pathways are involved in the 
pathogenesis of each of the major neurodegenerative disorders including AD and 
Parkinson’s disease (PD). The mechanisms occur despite the involvement of different 
disease-specific initiating factors – altered amyloid precursor protein (APP) 
processing in AD and accumulation of dopaminergic toxins in PD. Hcy levels 
increase during normal aging, and a high level of Hcy is an independent risk factor for 
stroke – the most prevalent age-related neurodegenative condition (Hankey et al., 
2001). In homozygous CβS metabolic defect, severely impaired Hcy trans-sulfuration 
and a diversion of the excess of Hcy toward the remethylation pathway to methionine 
has been observed (Figure 1.10). Methionine plays a key role in the generation of 
methyl groups required for the synthesis of DNA, and Hcy can be either remethylated 
to methionine by enzymes that require folate or cobalamin (vitamin B12) or 
catabolized by CβS, a pyridoxine (vitamin B6)-dependent enzyme, to form cysteine 
(Finkelstein et al., 1990; Scott and Weir, 1998). The increased rate of methionine 
synthesis can lead to a temporal magnification of S-adenosylmethionine (SAM) 
concentrations and diminished levels of cysteine (Mudd et al., 1985). Consequently, 
lack of cysteine availability causes impaired formation of glutathione (GSH), the 
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principal antioxidant in cells (Wang et al., 1997). In such hyperhomocysteinemic 
conditions, the combination of the intensified free radical generation and diminished 
GSH formation is the main cause for AD. Hcy levels vary considerably among 
individuals, and reduced dietary intake of folate is associated with increased Hcy 
levels and increased risk for heart disease and stroke (Giles et al., 1995). In addition, 
folate deficiency can cause DNA damage that may result from hypomethylation. As 
shown in figure 1.8, Hcy can also cause synaptic dysfunction and neuronal death by 
promoting DNA damage and activation of apoptotic signaling cascades involving p53, 
Bax, mitochondrial alterations, release of cytochrome c and caspase activation.  
 
Hcy may also have direct actions on glutamate receptors that result in enhanced Ca2+ 
influx. Finally, Hcy induces endoplasmic reticulum stress, which might contribute to 
its pathogenic actions. Patients with severe hyperhomocysteinemia exhibit a wide 
range of clinical manifestations including neurological abnormalities such as mental 
retardation, cerebral atrophy, and seizures (Watkins & Rosenblatt, 1989). 
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Figure 1.10. The roles of Hcy in one-carbon metabolism and neuronal survival and 
death (Mattson & Shea, 2003). 
 
1.4.6. The Involvement of Hcy in Alzheimer’s Disease 
 
Hcy is reversibly formed and secreted during metabolism, is a potent neurotoxin 
(Lipton et la., 1997; Kruman, 2000). An elevated plasma level of Hcy is recognized as 
an independent risk factor for cardiovascular, peripheral vascular and cerebrovascular 
disease (Refsum et al., 1998). Because of the emerging evidence supporting a role for 
vascular disease in the etiology of AD, it has been hypothesized that elevated plasma 
Hcy also plays a role in the pathogenesis of AD and age-related cognitive decline. 
Studies of human populations and experimental models of AD suggest roles for Hcy 
in the disease process (Kruman, 2002; Seshadri et al., 2002). Plasma Hcy has been 
reported to be elevated in some (Joosten et al., 1997; Clark et al., 1998), but not all 
(Fekkes et al., 1998) confirmed cases of AD and represents an early marker of 
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cognitive impairment in the elderly (Lehmann et al., 1999). However, individuals 
with AD exhibit elevated levels of Hcy (Clark et al., 1998; Miller et al., 1999; 
Gottfries et al., 1998; McCaddon et al., 1998), which can occur before disease onset 
(Joosten et al., 1997). In addition to the increased risk of AD, hyperhomocysteinemia 
is also associated with poor performance on objective tests of cognitive function in 
both case-control studies of patients with AD and cross-sectional, population-based 
studies of community-dwelling elderly people (Riggs et al., 1996; McCaddon et al., 
1998). 
 
Factors contributing to the onset and development of AD include genetic 
predisposition, Aβ accumulation, increased oxidative stress, and excitotoxicity 
(Mattson, 1997; Growdon, 2001). Hcy can potentiate Aβ neurotoxicity in cultured 
neurons (Kruman, 2002; White et al., 2001) and in transgenic mice over-expressing 
APP that develop amyloid deposits in the brains (Kruman, 2002). Ho et al., (2001) 
demonstrates that concurrent exposure of cultured neurons to Aβ and Hcy induces 
oxidative stress and apoptosis at concentrations which when Aβ and Hcy are given 
independently. Moreover, increased oxyradical production occurs in cultured neurons 
exposed to Hcy (Kruman, 2000; Ho et al., 2001). The resultant levels of oxyradicals 
and apoptotsis of either Aβ or Hcy alone, indicate a synergistic effect of Hcy and Aβ 
on neurodegeneration (Ho et al., 2001). Since oxidative stress is at the core of 
neuronal degeneration in AD, increased oxidative stress represents one mechanism 
which contributes to neurodegeneration. 
 
Moreover, elevated Hcy levels in subjects with cognitive impairment of dementia 
could be a result of poor nutrition and vitamin deficiencies (Diaz-Arrastia et al., 1998). 
Low serum levels of folate, vitamin B6 and vitamin B12 have been associated with 
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elevated Hcy levels in several studies and with an increased risk of dementia in a few 
investigations (Cole et al., 1984; Karnaze et al., 1987; Ikeda et al., 1990; Levitt et al., 
1992; Wang et al., 2001). Kruman et al., (2000) and Ho et al., (2001) demonstrate 
that abnormal accumulation of Hcy due to vitamin deficiencies promote 
neurodegeneration in AD. 
 
The full range of causes of AD remains unclear, but has been considered to be 
multifactoral (Holscher, 1998). Clinical studies implicate homocysteinemia in 
neurodegeneration, including that related to AD (Clark et al., 1998; Fekkes et al., 
1998; Gottfries et al., 1998; Joosten et al., 1997; Lehmann et al., 1999). Ho et al., 
(2002) demonstrates that Hcy increases: cytosolic Ca2+, generation of ROS, activity of 
calcium-dependent kinases, tau phosphorylation and apoptosis in cell culture. All of 
these pheonomena induced by Hcy in cultured neurons are directly elucidating the 
neuropathyology in AD (Ho et al., 2002). 
 
1.4.7. Neuroprotection Against Hcy 
 
Hcy can impart multiple neuropathological effects, including cytosolic accumulation 
of Ca2+, induction of oxidative stress, hyperphosphorylation of tau and apoptosis, all 
of which are characteristic of affected neurons in AD (Holscher et al., 1998). Hcy is 
an agonist for NMDA channels, therefore co-treatment with NMDA channel blocker, 
MK-801, can prevent Hcy-induced Ca2+ influx (Kim, 1999). Inhibition of Ca2+ influx 
via co-treatment with MK-801 prevents tau phosphorylation and ROS generated in 
response to Hcy treatment. In addition to this finding, there are prior reports (Kruman, 
2000; MacDonald & Wojtowicz, 1980) which suggest that Hcy exerts deleterious 
effects on neurons by acting as an excitotoxin, causing glutamate excitotoxicity. 
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Therefore, Hcy induced Ca2+ influx can be attenuated by antagonists of non-NMDA 
glutamate receptors (Ho et al., 2002). However, the pivotal role of ROS in Hcy 
toxicity can be prevented by superoxide dismutase and/or catalase (Kim & Pae, 1996) 
and by the glutathione precursor N-acetyl cysteine (Ho et al., 2001). 
 
1.5. Estrogen 
 
1.5.1. Introduction 
 
The gonadal steroid hormone 17β-estradiol is a greatly under-appreciated neural 
growth and trophic factor for the mammalian brain of all ages. It is a “traditional” 
estrogen and is responsible for many of the reproductive effects associated with it. 
17β-estradiol influences neurogenesis, neuronal differentiation, and neuronal survival 
of its targets throughout life (Garcia-Segura et al., 2001; Wang et al., 2002; McEwen, 
2002; Behl, 2002). 17β-estradiol has been associated with a decreased risk, delayed 
onset and progression, or enhanced recovery from numerous traumatic or chronic 
neurological and mental diseases. However, recent studies suggest that estrogen 
replacement therapy may help to reduce the risk (Baldereschi et al., 1998; Henderson et 
al, 1996; Kawas et al., 1997; Tang et al., 1996) and severity (Honjo et al., 1995; 
Ohkura et al., 1994; Ohkura et al., 1995) of Alzheimer’s-related dementia in 
postmenopausal women. In addition, studies have shown that estrogen replacement can 
enhance measures of verbal memory and associative learning in young and older 
women (Henderson et al., 1996). These findings raise important questions about the 
potential of hormone replacement therapy to enhance cognitive performance and to 
reduce or prevent age-related cognitive decline in postmenopausal women. The 
neurobiological mechanisms that underlie these effects are currently unknown, but 
most likely reflect effects of estrogen on the survival, connectivity, and function of 
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specific neural systems. 
 
1.5.2. Biosynthesis Pathway and Metabolism of Estrogen 
 
Estrogens are formed from androgenic precursors through an enzymatic process 
known as aromatization. 17β-estradiol, the predominant and most potent estrogen in 
premenopausal women, is synthesized by developing ovarian follicles. Estradiol is 
secreted into the bloodstream, bound partially by circulating sex hormone binding 
globulin, and then transported to cells throughout the body (Lievertz et al., 1987). The 
principle path of estradiol metabolism is reversible oxidation to estrone, a weaker 
estrogen, and then to estriol. Estrone can also be produced in peripheral tissues 
through aromatization of androstenedione, an androgen precursor produced by both 
the ovaries and the adrenal glands (Norman & Litwack, 1987). All of these 
compounds are metabolized into sulphate and glucuronide forms for excretion 
(Lievertz et al., 1987). Several naturally occuring estrogens are typically 18-carbon 
steroids, which have an aromatic A ring with a phenolic hydroxyl. 17β-estradiol is the 
most potent natural estrogen; its stereoisomer, 17α-estradiol being much less potent 
(Emmens et al., 1969). 
 
1.5.3. Mechanism of Action of Estrogen Neuroprotection 
 
1.5.3.1. Genomic and Non-genomic Neuroprotective Effects of 
Estrogen 
 
The general neuroprotective activities of 17β-estradiol are manifold. It is a steroid 
molecule that can bind to specific intracellular estrogen receptor receptors (ERs). In the 
mammalian brain, intracellular ERs are widespread and are found in the cerebral cortex, 
midbrain, hippocampus, brain stem, hypothalamus and pituitary gland. Activation of 
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ERs has long-term genomic effects such as regulation of nerve cell development and 
protection of the brain during aging (McEwen & Alves, 1999), which helps to reserve 
memory and other cognitive functions of hippocampus. The genomic neuroprotective 
activity of estrogen promotes the outgrowth of neurite, sprouting of neurons, 
synaptogensis, and the expression of neurotrophic factors such as nerve growth factor 
(NGF) and increases the synthesis of acetylcholine (McEwen & Alves, 1999; 
Toran-Allerand, 1996). There are two ERs, ERα and ERβ, have been identified. ERα, 
which mediates most of estrogen’s transcriptional actions in the brain (White et al., 
1987) and is expresses in hippocampus. ERβ is abundantly expressed, which the 
neural role remains largely uncharacterized (Kuiper et al., 1996; Tremblay et al., 
1997), but may be modulatory, inhibitory or even reciprocal with ERα (Lindberg et al., 
2003; Toran-Allerand et al., 2004). ERα and ERβ are complementary but not 
redundant and are genetically and functionally distinct. In addition, estrogen affects 
other regions of the brain that express ERs including basal forebrain transmitter 
systems for acetylcholine, serotonin, dopamine and noradrenaline (McEwen & Alves, 
1999). The mechanisms of the neurotrophic activities of estrogen suggest that 
estrogen and its receptors could prove to be important novel targets in the research for 
neuroprotective agents (McEwen & Alves, 1999). 
 
However, not all of the neuromodulaory activities of estrogen are a result of nuclear 
receptor occupation, receptor activation and alteration of gene transcription (McEwen 
& Alves, 1999). In addition to the classical ERs, the neuroprotective functions can be at 
the membrane-binding sites (membrane receptors) by modulating neurotransmission 
(Wetzel et al., 1998) or by modulating the excitability of neuronal membranes (Gu et 
al., 1999), which is independent on ERs (non-genomic). 
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1.5.3.2. Antioxidant Effects of Estrogen 
 
With respect to its chemical structure, estradiol is a steroid but also a monophenolic 
compound. 17β-estradiol possesses an aromatic A ring phenolic moiety at the C3, 
which serves as a radical scavenger (Behl, 1997) and a lipophilic carbohydrate moiety 
(Figure 1.11). 17β-estradiol is a natural antioxidant of membrane phospholipid 
peroxidation (Sugioka, 1987). The phenolic A ring of 17β-estradiol is a powerful 
inhibitor of lipid peroxidation (Moosmann & Behl, 1999; Nakano et al., 1987; Sugioka 
et al., 1987) and 17β-estradiol has been reported to be a more potent inhibitor of the 
propagation of lipid peroxidation in Mongolian gerbils brain tissue than vitamin E (Hall, 
1991). Several in vivo studies show that 17β-estradiol has an ability to act as an 
antioxidant and reduce lipid peroxidative damage (Hall & Sutter, 1998) (figure 1.11).  
 
 
Figure 1.11.  The monophenolic antioxidants structure of 17β-estradiol: the radical 
scavenging headgroup and the lipophilic tail (Behl, 2002). 
 
17β-estradiol also exerts an indirect antioxidant action secondary to its ability to 
increase NO˙. NO˙ can act as an inhibitor of the lipid peroxidation chain reactions by 
scavenging lipid peroxyl radicals (Winkv et al., 1995). Therefore increased NO˙ levels 
will decrease lipid peroxidation damage (figure 1.12). Behl et al.,(1995) showed that 
oxidative cell death caused by Aβ, H2O2, and glutamate in mouse clonal hippocampal 
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cells and demonstrated that preincubation of the cells with 17β-estradiol prevents 
oxidative stress-induced cell damage and cell death (figure 1.12). However, the 
antioxidant activity of estrogen is not dependent on estrogen receptors and is therefore, 
non-genomic in nature. 
 
However, the over-expression of the antioxidant enzyme Cu, Zn superoxide dismutase 
(Cu, Zn SOD) by estrogen is further evidence for in vivo antioxidant neuroprotective 
effect of estrogen (Hall & Sutter, 1998). 
 
1.5.3.3. Neuroprotective Effects of Estrogen on β-Amyloid 
Production 
 
Estrogen has been suggested to be beneficial in the prevention of AD (Henderson et al., 
1996; Tang et al., 1996), is known to protect neurons from the cytotoxic effects of Aβ. 
Both high (Goodman et al., 1996a) and physiological (Green et al., 1996) doses of 
17β-estradiol protect hippocampal neurons in vitro against Aβ-induced toxicity. An in 
vivo study (Shi et al., 1998) shows that 17β-estradiol decreases production the Aβ 
precursor APP. Therefore, 17β-estradiol not only protects against Aβ toxicity, but 
decreases its production as well. 
 
However, some reports (Mattson & Rydel, 1992; Behl, 1994) have demonstrated that 
Aβ toxicity is due to the formation of oxygen radicals and the subsequent initiation of 
membrane lipid peroxidation. It has been suggested that high doses of 17β-estradiol 
attenuate Aβ toxicity by reducing oxidative stress (Behl, 1995; Goodman et al., 1996a) 
(figure 1.13). Thus, the neuroprotective effects of 17β-estradiol against Aβ in AD are 
due to antioxidant action. 
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1.5.3.4. Neuroprotective Effects of Estrogen on Glutamate-induced 
Excitotoxicity 
 
Glutamate is the major excitatory amino-acid neurotransmitter in the brain and spinal 
cord (Wikinski & Acosta, 1995). At normal concentrations, glutamate is an essential 
signal molecule, but excessive glutamate release may have negative effects (Wikinski 
& Acosta, 1995; Hugon et al., 1996a). The activation of glutamate receptors, e.g. 
NMDA receptors, causes a significant Ca2+ influx into neurons (Wikinski & Acosta, 
1995; Scatton, 1993). If the Ca2+ influx is sufficiently large, this may result in cell 
death (Schousboe et al., 1997). Glutamate receptors of the NMDA type are most 
densely concentrated in the cerebral cortex, hippocampus and cerebellum compared to 
other brain regions (Scatton et al., 1993). Both the increased metabolism and 
excitotoxicity resulting from glutamate-induced stimulation of NMDA receptors may 
be reduced by estrogen (Weaver et al., 1997). Several studies have shown that estrogen 
may protect against neuronal death due to excitotoxicity. 17β-estradiol attenuates the 
toxicity of glutamate exposure to hippocampal cell line culture (Behl, 1995; Goodman 
et al., 1996a) and murine hippocampal HT-22 cells (Behl, 1995). Moreover, these data 
suggest that the neuroprotective effects against glutamate-mediated excitotoxicity are 
due to the steroidal chemical antioxidant action of 17β-estradiol rather than its ability 
to produce a genomic effect via the estrogen receptor that is critical for 
neuroprotection against excitotoxicity. 
 
1.5.3.5. Neuroprotective Effects of Estrogen on MAP Kinase 
Pathways 
 
Singer et al., (1999) suggest that in addition to an antioxidant effect, estrogen 
protection against glutamate toxicity is mediated by activation of signalling pathways 
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by mitogen-activated protein kinase (MAPK) (Figure 1.12). MAPK plays an important 
role in both growth factor signalling and stress signalling (Seger & Kreb, 1995) and 
expression of MAPK is involved in blocking apoptosis (Sakata et al., 1995). 
 
1.5.3.6. Neuroprotective Effects of Estrogen on bcl-2 Expression 
 
Bcl-2 is an anti-apoptotic protein (Hockenberry et al., 1990) and is a survival factor that 
can block both necrotic and apoptotic cell death (Bredesen, 1995) and over-expression 
of bcl-2 protects neurons from glutamate toxicity (Zhong et al., 1993; Singer et al., 
1998). Estrogen up-regulates bcl-2 expression in brain (Garcia-Segura et al., 1998). 
Figure 1.12 shows the neuroprotective actions of estrogen on bcl-2. 17β-estradiol 
includes the prevention of activation of caspases, inhibition of free radical formation 
and increases in regulation of calcium sequestration (MacManus & Linnik, 1997). 
17β-estradiol pre-treatment increased bcl-2 levels and enhanced survival of NT 
neurons in vitro after exposure to glutamate (Singer et al., 1998). Therefore, bcl-2 
induction may be a mediator of neuroprotection of estrogen. 
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17β-Estradiol-mediated Neuroprotection 
Figure 1.12. Mechanisms by which 17β-estradiol may exert its neuroprotective 
effects. PCS, prostacyclin synthetase (Roof & Hall, 2000). 
 
 
1.5.4. Neuroprotective Effects of Estrogen and Alzheimer’s Disease 
 
AD afflicts more women than men, has an earlier onset in women, and progresses 
more rapidly in women. Many epidemiological studies have pointed to the protective 
role of estrogen in AD. One extensive clinical study assessing the protective role of 
estrogen in AD was conducted by Paganini-Hill and Henderson (1996). These authors 
found an inverse relationship between estrogen use and AD; the risk of AD decreased 
with increasing dose and duration of estrogen replacement therapy. Exogenous 
estrogen treatment appears to be the key, because there was no relationship between 
AD and age at menarche or age at the last menstrual period. However, due to the 
formation in adipose tissue, women who have high body weight, are presumably have 
high levels of estrogen, thus conferred some decreased risk for AD. 
 
One of the earliest clinical trials assessing the potential impact of estrogen on AD was 
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a small pilot study of seven women who had been diagnosed with senile dementia of 
the Alzheimer's type (Fillit, 1986). Low-dose estrogen therapy modestly improved 
cognitive function and mood in some of the women. However, the study of 
Henderson et al., (1994) also shows that estrogen not only protects against the onset 
of AD, but also helps to maintain the cognitive function of those women who already 
have AD. The cognitive function of women with AD who had received estrogen 
replacement therapy was well below non-demented control subjects, but better than 
the cognitive function of those AD patients not taking estrogen. A double-blind study 
of 12 women with mild to moderate AD, estrogen (0.05 mg/day of 17β-estradiol, 
delivered via a skin patch), improved attention and verbal memory within the first 
week of treatment, but the effects were temporary, and diminished once estrogen 
treatment was stopped (Asthana et al., 1999). Estrogen increased activation of cortical 
regions involved in verbal memory tasks during storage and retrieval of verbal 
material, without altering verbal or nonverbal performance, in postmenopausal 
women given estrogen treatment (1.25 mg/day, oral dose, 21 days, double-blind) and 
assessed using functional magnetic resonance imaging. 
 
Figure 1.13 shows the potential cellular mechanisms that underly estrogen's 
neuroprotective actions in AD. 17β-estradiol may affect Aβ deposition by the 
regulation of Aβ metabolism and ApoE expression (Jaffe et al., 1994; Chang et al., 
1996; Xu et al., 1998a, 1998b), which deposition of amyloid in the neuritic plaques 
are one of the neuropathological hallmarks of AD. 17β-estradiol increases cognitive 
function by enhancing cholinergic neurotransmission. Cholinergic neurons in the 
basal forebrain degenerate in AD patients (Whitehouse et al., 1981) and 17β-estradiol 
can up-regulate the expression of choline acetyltransferase in AD in the rat brain 
(Luine et al., 1985). Finally, 17β-estradiol may influence affective disorders 
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associated with AD by acting on serotonin receptor signaling (Halbreich et al., 1995). 
17β-estradiol decreases the G proteins that couple serotonin receptors to intracellular 
signaling molecules (Raap et al., 2000) or via alterations in serotonin transporter 
expression (McQueen et al., 1997). 
 
 
Figure 1.13. Mechanisms of actions of 17β-estradiol in Alzheimer's disease 
(Garcia-Segura et al., 2001). 
 
However, the etiology of AD is clearly multifactorial, but for many of the factors, 
estrogen may provide protective value, and estrogen receptor malfunction may 
increase risk of AD. Considerable support is therefore available for the use of 
estrogen replacement therapy to decrease vulnerability to AD, and in those individuals 
who are already diagnosed with AD to maintain cognitive function (Henderson, 1994; 
2000; Mulnard et al., 2000) 
 
1.6. Progesterone 
 
1.6.1.  Introduction 
 
While the majority of researchers have focused on estrogen as the source of 
neuroprotection observed in females, there is evidence that another female hormone, 
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progesterone, may also play a beneficial role in the injured brain. Progesterone is 
known to play an important role in the regulation of behavioural and neuroendocrine 
functions by modulating brain neurotransmission, such as the inhibitory 
γ-aminobutyric acid (GABA) (Bureau & Olsen, 1990; Kokate et al., 1994) and EAA 
systems (Wu et al., 1991). Over recent years, research has revealed that multiple 
actions of progesterone in the central and peripheral nervous system. Progesterone is an 
important signalling molecule in the nervous system, regulating neuron and glial 
functions by multiple mechanisms of action. However, in nerve cells, the actions of 
progesterone are exerted classically through cytosolic/nuclear receptors specific for the 
steroid (Pfaff & McEwen, 1983). Progesterone has potent anti-convulsant, anxiolytic 
and seizure suppression activity (Belelli et al., 1989; Bitran et al., 1991; Twyaman & 
Macdonald, 1992). Treatment of experimental traumatic brain injury with progesterone 
reduces functional deficits and secondary neuronal loss (Roof, 1994; Roof, 1997). 
Progesterone reduces cerebral oedema (Betz & Coester, 1990a) and facilitates 
cognitive recovery after acute global cerebral ischemia (Gonzalez-Vidal et al., 1998). 
 
The presence of receptors and sources of progesterone within the nervous system as 
well as its modulation of inhibitory and EAA suggest a broader role for progesterone 
than simply as a gestational hormone. Thus, progesterone may be involved in the 
process of brain damage after ischemic insult and the administration of progesterone 
may be beneficial to the neuronal tissue. 
 
1.6.2.  Biosynthesis Pathway and Metabolism of Progesterone 
 
Progesterone is synthesized by the ovaries and placenta. The adrenal glands contribute 
significant amounts of circulating progesterone in humans of both genders. 
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Progesterone is a precursor of gluco- and mineralocorticosteroids in the adrenal glands. 
Progesterone is secreted into the bloodstream (Feder et al., 1968; Holzbauer et al., 
1969). Because of the lipid solubility, progesterone crosses the blood brain barrier 
easily and it diffuses throughout nervous tissues. Progesterone can be synthesized by 
neurons and glial and some of the progesterone present in brain, spinal cord and 
peripheral nerves is derived from local synthesis. 
 
Figure 1.14 shows the biosynthesis and metabolism of progesterone. The first step in 
the biosynthesis is the conversion of cholesterol to pregnenolone, the precursor of all 
steroid hormones. The cholesterol moves from intracellular stores to the inner 
mitochondrial membrane, where the cytochrome P450scc is located. The cytochrome 
P450scc catalyzes the conversion of cholesterol to pregnenolone. Pregnenolone then 
moves from the mitochondria to the microsomal compartment, where it is converted 
to progesterone by the 3β-hydroxy- steroid dehydrogenase (3βHSD). Progesterone 
can be converted to 5a-dihydroprogesterone by 5α-reductase and the 
3α-hydroxysteroid oxidoreductase (3αHSD) catalyzes the conversion of 
5α-dihydroprogesterone to 3α,5α,tetrahydroprogesterone (allopregnanolone) 
(Schumacher, 2001). 
 
 62
Literature Review 
 
Figure 1.14. Biosynthesis and metabolism of progesterone (Schumacher et al. 2001). 
 
1.6.3.  Mechanism of Action of Progesterone Neuroprotection  
 
The mechanism underlying neuroprotection against brain trauma and ischemia by 
progesterone has received less attention. The neuroprotective effects of progesterone 
have been reported to include improved blood-brain barrier integrity, limitation of free 
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radical induced lipid peroxidation and reduction of cerebral oedema (Betz & Coester, 
1990a, b; Roof, 1994). Figure 1.15 summarizes the neuroprotective mechanisms of 
progesterone. Progesterone reduces membrane lipid peroxidation by promoting 
neuronal membrane stabilization (Roof et al., 1994; Roof et al., 1997) (figure 1.15) and 
acts as a free radical scavenger (Betz & Coester, 1990a). Progesterone, acts like other 
steroids, intercalates between the polyunsaturated fatty acid residues of the membrane 
phospholipids (Anderson, 1982). This causes cell membranes to be less fluid and 
protects them from ROS attack and calcium toxicity (Hall, 1993). 
 
Progesterone binds to the intracellular progesterone receptor (PR) and activates the 
transcription of hormone-sensitive genes. High levels of PR mRNA and binding are 
found in brain regions involving in reproductive functions such as hypothalamus and 
the receptor is present in the brain, spinal cord and peripheral nerves (Hagihara et al., 
1992; Jung-Testas et al., 1996; Lacor et al., 1996; Lauber et al., 1991; MacLusky & 
McEwen, 1980). Progesterone not only regulates nervous functions by activating gene 
transcription (‘genomic effects’), they also modulate the activity of neurotransmitter 
receptors by acting directly on the neuronal membrane. Inhibition of EAA acid 
receptors or potentiation of GABA receptors can be neuroprotective. Excitotoxicity is 
reduced by progesterone’s inhibition of excitatory amino acid receptors such as 
glutamate (Bergeron, 1996) (figure 1.15) and by its ability to depress spontaneous 
firing of neurons that could lead to post-injury seizures (Mohammad et al., 1998). 
Physiological levels of progesterone enhance GABA-mediated inhibition of neuronal 
activity (Smith, 1994) and can alter the excitability of neurons by potentiation of 
GABA-evoked Cl¯ currents. However, it has been shown recently that progesterone 
and its metabolites produce an antagonistic effect at the GABA receptor (Roof & Fritts, 
1997). 
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Progesterone also attenuates EAA responsiveness (Smith, 1987; Smith, 1991). 
Progesterone depresses both kainite and NMDA responses of cerebellar neurons. 
Progesterone provides neuroprotection by NMDA antagonism, thus preventing 
neuronal death that caused by glutamate-induced excitoxicity (Hara et al., 1993). Thus, 
progesterone may lower glutamate-induced excitotoxic cell death by potentiating 
inhibitory GABA receptor activation and by inhibiting excitatory EAA receptors 
(figure 1.15).  In addition, progesterone also mediates anti-apoptotic actions through a 
progesterone-binding protein with GABAA receptor feature (Peluso et al., 1998). 
 
 
Progesterone-mediated Neuroprotection 
Membrane  Glutamate Receptor 
inhibition 
GABA Receptor 
potentiation stabilization 
↓ Lipid peroxidation 
↓ Excitotoxicity 
Figure 1.15.  Mechanism by which progesterone may exert its neuroprotective 
effects (Roof & Hall, 2000). 
 
1.7. Hormone Replacement Therapy and Alzheimer’s Disease: The 
role of Homocysteine 
 
Although estrogen and progesterone have neuroprotective properties in many animal 
models of neurodegeneration, the results from hormone replacement therapy (HRT, 
Maintained ion 
homeostasis 
↓ Cell Death 
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estrogens and progestins) or estrogen-only replacement therapy (ERT), in women, are 
not yet conclusive. Most studies suggest that ERT increase memory and cognitive 
function in healthy women (Wise, 2003). ERT may also prevent or delay the onset of 
AD and improve cognition for women with AD (Asthana et la., 2001; Paganini-Hill 
& Henderson, 1996), reduce the motor disability associated with PD (Dluzen & 
Horstink, 2003, Saunders-Pullman et al., 2003) and decrease the risk of stroke in 
postmenopausal women (Paganini-Hill et al., 2001). However, other studies indicate 
that ERT or HRT have no effect on PD (Saunders-Pullman et al., 2003) and do not 
improve cognition of women with AD (Wise, 2003). Several explanations for 
discrepant results among different studies, such as differences in dose, formulation, 
route of administration, length of treatment, sample size, and age of the women 
receiving the treatment, have been proposed (Wise, 2003). However, the Women’s 
Health Initiative (WHI) randomized trail studies show that long-term hormonal 
therapy started in women aging 65 or more years have beneficial effects in decrease 
the risk in AD and PD. WHI also shows that the highest efficacy of hormonal therapy 
is during the peri-menopause. During this period, the brain may be adapting local 
steroid synthesis to the new situation created by the loss of ovarian function; thus the 
steroid receptor machinery is not yet familiar and adjusted to the new physiological 
condition.  In any case, the results of the WHI study emphasize the need for a better 
understanding on the effects of sex hormones in the brain. 
 
However, reports from observational and clinical trials show that those women who 
are on HRT have lower plasma levels of Hcy (Barnabei et al., 1999; Mijatovic et al., 
1998; van der Mooren et al., 1994). Observational studies have found an increased 
risk of myocardial infarction and stroke associated with modestly elevated blood 
levels of Hcy (Aronow et al., 2000; Bostom et al., 1999). Hcy is a risk factor for AD, 
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dementia or poor cognitive function. Case control studies have found higher levels of 
Hcy in AD patients (Clark et al., 1998; Nilsson et al., 1996), and among AD patients, 
those with higher levels of Hcy have a greater extent of atrophy of the medial 
temporal lobe (Clark et al., 1998). High levels of Hcy are associated with poorer 
cognitive function in population-based studies of community-dwelling elderly people 
and AD patients seen in clinics (Lehmann et al., 1999; Riggs et al., 1996). A recent 
report based on the Framingham study demonstrated that high levels of Hcy 
(14µmol/L or greater) are positively associated with the risk of developing AD and 
dementia (Seshadri et al., 2002) and Hcy is associated with poorer cognitive 
performance only among postmenopausal women not taking HRT (Whitmer et al., 
2003). However, evidence indicates that Hcy plays a role in the progression of AD 
and neurological function in those without AD. The in vivo studies suggest that Hcy 
plays a neurotoxic role in cell injury (Althausen & Paschen, 2000). Hcy has been 
found to elicit DNA damage in rat hippocampal neurons (Kruman, 2000) and to 
potentiate Aβ and copper-mediated toxicity in mouse neuronal cultures (White et al., 
2001; Ho et al., 2001). These findings demonstrate that in animal models, Hcy 
increases the vulnerability of hippocampal neurons to excitotoxic and oxidative injury. 
Thus, the neurophysiological mechanism for HRT and improved cognition may be a 
reduction of serum Hcy levels (Christodoulakos et al., 2003). 
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1.8. Objectives 
 
The study was undertaken to investigate the neuroprotective properties of estrogen 
and progesterone against damage induced by Hcy in the hippocampus. Hcy is known 
to be a neurotoxic and the concentration of Hcy in the brain increases with age. A 
high level of Hcy is associated with AD and loss of cognitive functions. Hcy is known 
to be an endogenous agonist at the NMDA receptor, causing neuronal damage due to 
massive calcium influx into the cell and induces apoptosis in hippocampal neurons. 
Accumulating evidence has suggested an action of estrogen and progesterone on 
excitatory amino acid receptors. Since the hippocampus is the primary region 
involved in memory formation and cognitive functions, and estrogen and 
progesterone have been reported to improve cognitive performance and memory, the 
hippocampus was chosen as the area of the brain to study. 
 
The objective of the study was to investigate the protective effects of estrogen and 
progesterone against Hcy-induced oxidative stress and resultant neuronal damage and 
also to elucidate the cellular mechanisms whereby estrogen and progesterone may 
exert any protective effects in hippocampal neurons. In order to achieve these 
objectives, the following experiments were performed: 
 
Chapter 2: Lipid peroxidation studies. This was done in order to show that both 
estrogen and progesterone reduce Hcy-induced lipid peroxidation in rat brains. Thus, 
the neuroprotective actions of both hormones are dependent on the antioxidant effects. 
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Chapter 3: Superoxide anion generation. In this chapter, NBT assay was employed. 
This was done to show both hormones have ability to reduce the superoxide anion 
neurodegeneration induced by Hcy in the rat hippocampus in vivo. 
 
Chapter 4: Histology studies. In this chapter, Nissl staining was used for evidence of 
morphological changes in the rat hippocampus after treatment. This experiment was 
performed to show that both hormones have shown neuroprotection against 
Hcy-induced intrahippocampal lesions in the rat brain.  
 
Chapter 5: Apoptosis. The TUNEL assay for programmed cell death was employed. 
This study indicated that both hormones were able to prevent against the Hcy-induced 
apoptotic cell death in both CA1 and CA3 regions of the rat hippocampus. 
 
Chapter 6: Enzymatic antioxidants: Defense system. SOD and GSH are the most 
important antioxidant enzymes in the ROS defense system. Therefore, this chapter 
was to evaluate whether both hormones altered the effects of Hcy on both enzymatic 
antioxidant activities. 
 
Chapter 7: Radioligand binding studies. NMDA receptor binding in isolated synaptic 
membranes was investigated. It was done to show that both hormones offered 
protection against Hcy-induced neurotoxicity via a NMDA receptor-dependent 
mechanism. 
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CHAPTER 2 
 
LIPID PEROXIDATION STUDIES 
 
2.1. INTRODUCTION 
 
Biological membranes are vital for the existence of cellular integrity. The plasma 
membranes serve as barriers, protecting the cells from harmful compounds produced 
in the extracellular environment. These also function as compartmentalizing structures, 
which are essential for cellular function. Membranes are dynamic systems which are 
responsible for the production of ATP, and the binding of neurotransmitters which 
mediate transmission of nerve impulses (Bohinski et al., 1987). Membranes also have 
the binding sites for regulatory molecules, such as hormones and function as 
permeable barriers for selective transport of substances in and out of the cells.  
 
Lipid peroxidation, via the action of radical species, results in the attack of membrane 
lipids which cause destruction of the cell membrane, ultimately destroying the 
integrity of the cell (Southgate, 1999). The nervous system consists of substantial 
membranes and fatty acids (Halliwell & Gutteridge, 1989; Halliwell, 1992b). This 
implies an increased vulnerability of membrane lipid constituents in the nervous 
system to oxidative injury, either directly by cellular free radicals (Coyle & 
Puttfarcken, 1993; Olanow et al., 1993; Bondy, 1995; Frölich & Riederer, 1995) or 
via other indirect or exogenic mechanisms (Nohl, 1993; Piotrowski et al. 1996). An 
increase in cellular load of free radicals results in an increase of lipid peroxidation and 
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loss of cellular compartmentalization (Gutteridge, 1988). 
 
The presence of transition metals such as iron and any tissue injury results in the 
formation of highly reactive radical species such as the hydroxyl radical, capable of 
participating in the Fenton reaction. Thus, these events can lead to the initiation and 
propagation of lipid peroxidation.  
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2.2. THE COMPARATIVE EFFECTS OF       
17β-ESTRADIOL AND PROGESTERONE ON          
HCY-INDUCED LIPID PEROXIDATION IN VITRO 
 
2.2.1. INTRODUCTION 
 
The brain is more susceptible to peroxidation because it is one of the most 
metabolically active organs in the body (McArdle et al., 1986). Lipid peroxidation is 
able to cause extensive damage and play a major role in the deterioration of the brain 
and spinal cord that occurs after traumatic or ischemic injury.  
 
The aim of the study was to determine whether 17β-estradiol and progesterone are 
able to protect against lipid peroxidation induced by the neurotoxin, homocysteine 
(Hcy). It is believed that Hcy exerts its effects through mechanisms involving free 
radical generation and as a result, oxidative damage (Mujumdar et al., 2001). A 
comparative study was performed to determine whether 17β-estradiol and 
progesterone offer protection against Hcy-induced lipid peroxidation. 
 
Male rats were selected to test the effect of exogenously administered estrogen and 
progesterone instead of the female rat in order to exclude complicating effects on 
ischemic cell damage of hormonal fluctuations during the estrus cycle. The assay used 
to measure lipid peroxidation is the Thiobarbituric acid (TBA) test. This assay 
involves the reaction of malondialdehyde (MDA) with TBA to yield a pink coloured 
complex, which can be measured colorimetrically at 532nm using a 
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spectrophotometer. MDA is the end product of lipid peroxidation from cell 
membranes, and is taken as a reliable indicator of oxidative stress (Halliwell & 
Gutteridge., 1990; Reiter et al., 1995).  
 
2.2.2. MATERIALS AND METHODS 
 
2.2.2.1. Chemical and Reagents 
 
All reagents used were of analytical grade. 17β-estradiol, progesterone 
(4-Pregnene-3,20-dione), DL-homocysteine, 2-thiobarbituric acid (98%) (TBA), 
1,1,3,3-tetramethoxypropane (98%), butylated hyroxytoluene (BHT), were purchased 
from the Sigma Chemical Corporation (St Louis, MO, USA.). Tricholoracetic acid 
(TCA) and butanol were obtained from Saarchem (PYT) Ltd. (Krugersdorp, South 
Africa). All reagents were of the highest quality available. 
 
2.2.2.2.  Animals 
 
Adult male rats of the Wistar strain, weighing between 250-300g were used. The 
animals were housed in a controlled environment with a 12:12 hour light: dark cycle, 
and were given access to standard laboratory chow and water ad libitum. Protocol for 
the experiments was approved by the Rhodes University animal ethics committee. 
 
2.2.2.3. Brain Removal 
 
Rats were sacrificed by neck fracture and decapitated. The brain was exposed by 
making an incision through the bone on either side of the parietal suture, from the 
 73
Lipid Peroxidation 
foramen magnum to near the orbit. The calvarium was removed, exposing the brain 
which was easily removed for use in experiments. 
 
2.2.2.4.  Preparation of Brain Homogenate 
 
The brains were weighed and rapidly homogenised with 0.1M Phosphate buffer saline 
(PBS), pH 7.4, so as to give a final concentration of 10% w/v. This is necessary to 
prevent lysosomal damage of the tissue. The homogenate was centrifuged twice at 
8000g for 10 minutes. 
 
2.2.2.5.  Lipid Peroxidation Assay 
 
Lipid peroxidation was determined using the thiobarbituric acid (TBA) assay. This 
assay involves the reaction of malondialdehyde (MDA) equivalents with TBA to yield 
a pink complex. A modified method of Halliwell and Gutteridge (1990) was used in 
this set of experiments. 
 
Homogenate (1ml) containing varying concentrations of DL-homocysteine (0, 0.25, 
0.5, 1, 1.5 or 2mM) alone or in combination with varying concentrations of 17β- 
estradiol (0.05, 0.1, 0.2, 0.25, 0.5, 0.75 or 1mM) or progesterone (0.25, 0.5, 1mM) 
was incubated in a shaking water bath for 1 hour at 37°C. At the end of incubation, 
0.5ml BHT (0.5g/L in absolute methanol) and 1ml 25% TCA were added to the 
mixture. The samples were centrifuged at 2000g for 20 minutes at 4°C to remove 
insoluble proteins. Following centrifugation, 2ml of protein free supernatant was 
removed from each tube and a 0.5ml aliquot of 0.33% TBA was added to this fraction. 
All tubes were heated for one hour at 95°C in a water bath. After rapidly cooling the 
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tubes on ice 2ml of butanol was added and the tubes vortexed and centrifuged at 
2000g for 10 minutes. An aliquot of 2ml of the top layer of the mixture was carefully 
removed with an autopipette and placed into separate tubes. This faction contained the 
extracted TBA-MDA complexes, which were then read at 532nm using a GBC 
UV/Vis 916 spectrophotometer. The MDA level was determined from a standard 
curve generated from 1,1,3,3-tetramethoxypropane. Final results were expressed as 
nmoles MDA/mg tissue. 
 
2.2.2.6. Preparation of the Standard Curve 
 
1, 1, 13, 3-tetramethoxypropane was used as a standard. A series of reaction tubes 
each containing appropriate aliquots of water and standard solution were prepared 
with Milli-Q water to a final volume of 1ml.  A calibration curve was generated by 
measuring the absorbance at 5nmoles/ml intervals. No incubation at 37°C followed 
and the rest of the reagents and procedures were performed as described in 2.2.2.5. 
The absorbance was read at 532nm and plotted against the molar equivalent weight of 
MDA in the complex assayed. (Appendix 1). 
 
2.2.2.7. Statistical Analysis 
 
The results were analysed using a one-way analysis of variance (ANOVA). If the F 
values were significant, the Student Newman-Keuls test was used to compare the 
treated and control groups. The level of significance was accepted at p<0.05 (Zar, 
1974). 
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2.2.3. RESULTS 
 
The in vitro exposure of brain homogenate to increasing concentrations of Hcy caused 
a significant increase in lipid peroxidation in a concentration-dependent manner in 
comparison to the control (figure 2.1). 
 
Co-treatment of this homogenate with Hcy and increasing concentrations of 17β- 
estradiol or progesterone resulted in a significant reduction in lipid peroxidation 
(figure 2.2 and figure. 2.3 respectively). 17β- estradiol or progesterone at all 
concentrations tested, reduced the amount of MDA formed to the same level, i.e. 
±0.04 nmoles/mg or ±0.06 nmoles/mg tissue respectively, at concentration of Hcy 
(1mM) tested. The results suggest that 17β- estradiol and progesterone protect against 
Hcy-induced lipid peroxidation in a manner that is independent of the concentration 
of 17β- estradiol or progesterone, at least within the concentration range tested. 
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Figure. 2.1.  Concentration-dependent effect of Hcy-induced lipid peroxidation in 
whole rat brain homogenate. Each bar represents the mean ±SEM; n=4. *(p<0.05), 
*** (p<0.001) in comparison with control. Student-Newman-Keuls Multiple Range 
Test. 
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Figure. 2.2.  The effect of 17β-estradiol on Hcy (1mM)-induced increase in MDA 
production in rat brain homogenate in vitro. Each bar represents the mean ±SEM; n=5. 
*(p<0.05), ** (p<0.01), *** (p<0.001) in comparison to Hcy; ### (p<0.001) in 
comparison to the control. Student Newman Keuls Multiple Range test. 
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Fig. 2.3.  The effect of progesterone on Hcy (1mM)-induced increase in MDA 
production in rat brain homogenate in vitro. Each bar represents the mean ±SEM; n=5. 
*(p<0.05), ** (p<0.01), *** (p<0.001) in comparison to Hcy; ### (p<0.001) in 
comparison to the control. Student Newman Keuls Multiple Range test. 
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2.2.4. DISCUSSION 
 
The results of the study demonstrate that both 17β-estradiol and progesterone reduce 
Hcy-induced lipid peroxidation markedly in vitro. At concentration of 1mM Hcy, 
both 17β-estradiol and progesterone reduced the level of MDA formation in a 
concentration-independent manner. Furthermore, 17β-estradiol not only reduced the 
amount of MDA formed in the presence of Hcy but was also able to decrease MDA 
production to levels lower than those attained in samples without Hcy. 
 
Previous studies show that Hcy induces lipid peroxidation at concentrations of 1mM 
and promotes iron-dependent oxidation of LDL (Alul et al., 2003). Heinecke et al. 
(1993), Hirano et al., (1994) and Lynch et al. (1997) reported that Hcy alone is 
incapable of oxidizing LDL; rather LDL oxidation is dependent upon the availability 
of free ferric (Fe3+) iron. Oxidation of LDL by Fe3+ requires the presence of reduced 
thiols (Lynch et al., 1997) to convert Fe3+ to Fe2+ (Lynch et al., 1993 & 1995). Hcy is 
a thiol compound which is well-recognized biological reductant. Jocelyn et al., (1972) 
and Lynch et al., (1997) has shown that Fe3+ is reduced to Fe2+ when incubated with 
LDL in the presence of Hcy. Wood and Graham (1995) noted that the ability of Hcy to 
facilitate Fe3+ -dependent LDL oxidation was directly related to autooxidation. As 
Hcy autooxidation generates superoxide (Jocelyn, 1972), it is conceivable that the 
superoxide also contributes to Fe3+ reduction and thus, initiation of LDL oxidation 
(Lynch et al., 1993; Lynch et al., 1995). 
 
Vedder et al., (1999) showed that both 17β-estradiol and progesterone decrease 
Fe3+-induced lipid peroxidation in rat brain and hippocampal HT22 cell homogenates. 
However, this author also showed that 17β-estradiol inhibits Fe3+-induced lipid 
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peroxidation accompanied by an increased survival of primary neuronal culture cells, 
whereas progesterone reduces lipid peroxidation due to the membrane stabilizing 
effect (Roof et al., 1997). One way in which both 17β-estradiol and progesterone 
could protect from Hcy-induced lipid peroxidation in vitro is by the antioxidant 
effects of these agents (Behl, 1995; Roof et al., 1997) and the ability to bind Fe3+, 
thereby preventing the conversion to Fe2+.  
 
In fact, high concentrations of 17β-estradiol (0.05-1nm) and progesterone (0.25-1nm) 
are used in this study. Roof and Hall, (2000) suggest that for both estrogen and 
progesterone, the neuroprotective actions involved can be dependent on the 
exogenous dose administered or the endogenous level of estrogen and progesterone 
employed in the case of pharmacological studies. 
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2.3. THE COMPARATIVE EFFECTS OF       
17β-ESTRADIOL AND PROGESTERONE ON          
HCY-INDUCED LIPID PEROXIDATION IN VIVO 
 
2.3.1.  INTRODUCTION 
 
The results obtained from section 2.2 shows that both 17β-estradiol and progesterone 
protect against lipid peroxidation in rat brain homogenates following exposure to Hcy. 
Baydas et al. (2003) showed that injection of Hcy directly into the rat brain causes a 
significant rise in MDA levels in the hippocampus. Therefore, it was decided to 
investigate whether both 17β-estradiol and progesterone could offer neuroprotection 
by determing lipid peroxidation before and after the intrahippocampal injection of 
Hcy in vivo. 
 
Moreover, in postmenopausal women, the concentration of circulating estrogen and 
progesterone decrease dramatically. Several reports suggested that females may be 
more neuroprotected than male due to higher levels of circulating estrogen and 
progesterone (Groswasser et al., 1998). Clinical trials have shown that estrogen 
replacement therapy or estrogen/progestin replacement therapy decreases Hcy level in 
postmenopausal women (Barnabei et al., 1999). Hormone replacement therapy may 
protect the brains of these women against oxidative stress. 
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2.3.2. MATERIALS AND METHODS 
 
2.3.2.1. Chemicals and Reagents 
 
As in section 2.2.2.1. 
 
2.3.2.2. Animals 
 
As described in section 2.2.2.2. 
 
2.3.2.3. Dosing of the Animals 
 
Animals were divided into four groups of five animals each in two treatment regimes. 
In treatment regime 1 (Table 1), the animals in group 3 and 4 received single daily 
doses of 100µg 17β- estradiol or 100µg progesterone in 100µl olive oil injected 
subcutaneously respectively, for 5 days prior to bilateral intrahippocampal Hcy 
(0.14µmol/µl) injection. Similarly, the animals in groups 1 and 2 received vehicle for 
17β- estradiol and progesterone, viz. olive oil. On the 6th day, the animals in group 1 
were injected with phosphate-buffered saline (PBS); groups 2 to 4 were injected with 
Hcy, directly into the hippocampal region, bilaterally. Hcy was dissolved in PBS at 
pH7.4. Following the bilateral intrahippocampal injections, the animals of groups 1 
and 2 received subsequent daily doses of olive oil, each day for 5 days, while as 
before, the animals in group 3 and 4 received daily doses of 17β-estradiol or 
progesterone in olive oil for 5 days respectively. 
 
In treatment regime 2 (Table 2), on the 1st day the animals in group 1 were injected 
with PBS; group 2 to 4 were injected with Hcy, directly into the hippocampal region 
bilaterally. The animals in group 3 and 4 received single daily doses of 100µg 
progesterone in 100µl olive oil injected subcutaneously respectively, for 7 days after 
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bilateral intrahippocampal Hcy (0.14µmol/µl) injection. Similarly, the animals in 
groups 1 and 2 received vehicle for 17β-estradiol and progesterone, viz. olive oil. 
Table 2.1. Treatment regime 1 for each group of animals. 
Treatment Group Daily treatment for 
5 days prior to 
sterotaxic surgery 
(subcutaneous) 
Bilateral 
intrahippocampal 
injection 
Daily treatment for 
5 days after 
sterotaxic surgery 
(subcutaneous) 
1 [Control] 100µl Olive oil PBS 100µl Olive oil 
2 [Hcy only] 100µl Olive oil 0.14µmol/µl Hcy 
in PBS 
100µl Olive oil 
3 [Est + Hcy] 100µg 
17β-estradiol 
in 100µl Olive oil 
0.14µmol/µl Hcy 
in PBS 
100µg 
17β-estradiol 
in 100µl Olive oil 
4 [ Prog + Hcy] 100µg 
Progesterone 
in 100µl Olive oil 
0.14µmol/µl Hcy 
in PBS 
100µg 
Progesterone 
in 100µl Olive oil 
 
Table 2.2. Treatment regime 2 for each group of animals. 
Treatment Group Daily treatment for 7 days 
after stereotaxic surgery 
(subcutaneous) 
Bilateral intrahippocampal 
injection 
1 [Control] 100µl Olive oil PBS 
2 [ Hcy only] 100µl Olive oil 0.14µmol/µl Hcy in PBS 
3 [Est + Hcy] 100µg 17β-estradiol 
in 100µl Olive oil 
0.14µmol/µl Hcy in PBS 
4 [Prog + Hcy] 100µg Progesterone 
in 100µl Olive oil 
0.14µmol/µl Hcy in PBS 
 
2.3.2.4. Surgical Procedure 
 
2.3.2.4.1.  Anaesthesia 
Ether anaesthesia was employed for all surgical procedures carried out. Animals were 
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placed, one at a time, in a dessicator containing cotton wool soaked in ether. Once the 
animals were sedated, they were removed and placed on the operating surface as 
shown in figure 2.4. A small conical flask containing cotton wool soaked in ether was 
placed approximately 3cm from the rats’ nose. This flask remained in this position 
throughout surgery, except in cases where respiration became too weak. A good 
indication of the depth of anaesthesia was monitored by the colour of the limbs and 
tail, which displaced a faint, almost pale pinkness. This was indicative of the optimum 
level of anaesthesia, meaning a satisfactory rate and depth of respiration with good 
narcosis. A purple colour of the limbs was an indication of cyanosis. 
 
Diethylether is a desirable anaesthetic to use because the mortality rate of the animals 
is lower than with halothane or phenobarbitone. Ether is also easy to administer and it 
is easy to monitor the depth of anaesthesia. 
  
2.3.2.4.2. Bilateral Intrahippocampal Hcy Injection 
 
Hcy (0.14µmol/µl) was injected intrahippocampally using stereotaxic surgery 
techniques. Female rats were anaesthetised with diethyl ether and placed into a 
stereotaxic apparatus (figure 2.4). The skull was orientated according to the König 
and Klippel stereotaxic atlas (1963). After a saggital cut in the skin of the skull, the 
bregma and lambda sutures were located (figure 2.5) and holes were drilled with a 
Bosch electrical drill fitted with a drill bit of 0.5mm in diameter at the following 
coordinates; 2.58mm anterior, 3.5mm lateral of the sagittal suture. Care was taken not 
to lesion the meninges. Hamilton syringe, with a cannula of diameter 0.3mm, was 
used to inject 0.14µmol/µl of Hcy in 8µl of PBS bilaterally, 4mm ventral of the dura.  
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The injection was administered at a rate of 1 µl per minute and the cannula was left in 
situ for a further 3 minutes following the drug injection, to allow for passive diffusion 
away from the cannula tip and to minimise spread into the injection tract. The cannula 
was then slowly removed and the scalp was closed with sutures. Animals recovered 
from the anaesthesia after approximately 15 min. The rats used as controls were 
subjected to the same surgical procedures. The rats of group 1 were used as controls 
and subjected to the same surgical procedure. However, stereotaxic injections into the 
hippocampus were free of Hcy and comprised of PBS. 
 
Figure 2.4. A view of the stereotaxic apparatus used for the bilateral 
intrahippocampal injection of Hcy (Stoelting, IL, USA). 
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Figure 2.5 A view of the rat skull after the skin has been cut. The sutures shown 
are used as a reference point for the measurement of the coordinates for the 
intrahippocampal injection (Heron, 2001). 
 
2.3.2.5. Homogenate Preparation 
 
As described in section 2.2.2.4 
 
2.3.2.6. Lipid Peroxidation Assay 
 
An assay of lipid peroxidation was performed on each treated brain. Since no drugs 
were added to the homogenate in this assay, one hour incubation at 37°C was excluded  
because no drugs were added to the homogenate. The homogenate (1ml) containing 
0.5ml BHT and 1ml TCA was then boiled for 30 min to release protein bound MDA. 
The rest of the assay was followed according to the protocol outlined in section 
2.2.2.5. 
 
MDA, a product of lipid peroxidation, is known to form adducts with protein, nucleic 
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acids and other substances in vivo. Since each brain was assayed for lipid peroxidation 
seven days following the intrahippocampal injection of Hcy, the MDA formed as a 
result of Hcy-induced lipid peroxidation would have bound to such molecules 
(Gutteridge & Halliwell, 1990). As a result, the MDA had to be released from its 
bound forms. This can be done by hot acid or alkali digestion or hydrolysis by 
oxidation of polyunsaturated fatty acids. However, pigments generated during 
hydrolysis interfere in the colorimetric assessment of MDA. Thus, an alternative 
method is to boil the homogenate in the presence of BHT and TCA. Thereafter, as 
before, to avoid adsorption of the TBA-MDA complexes onto insoluble protein, any 
solid particulate material observed after cooling to room temperature is removed by 
centrifugation at 2000 g for 10min (Halliwell & Gutteridge, 1989) 
 
2.3.2.7. Statistical Analysis 
 
As described in section 2.2.2.7. 
 
2.3.3. RESULTS 
 
The intrahippocampal injection of Hcy at 0.14µmol/µl in vivo caused a significant 
increase in lipid peroxidation (Figure 2.6) assessed by the formation of TBARS (TBA 
reacting substances during the assay). Pre-treatment and post-treatment of 
17β-estradiol or progesterone (Figure 2.7), caused a significant reduction in Hcy 
(0.14µmol/µl)-induced TBARS formation with a p-value less than 0.01 and 0.001 
respectively. Furthermore, 17β-estradiol and progesterone reduced the level of 
TBARS formed, which were below that of the control. 
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Figure 2.6. The effects of bilateral intrahippocampal injection 0.7, 0.14 and 
0.28µmol/µl of Hcy on of TBARS formed. Each bar represents the mean ±SEM; n=5. 
*(p<0.05), ** (p<0.01), *** (p<0.001) in comparison to Hcy 0.7µmol/µl. @ (p<0.01) 
in comparison to control. Student Newman Keuls Multiple Range test. 
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Figure 2.7.   The effects of 17β-estradiol and progesterone on Hcy-induced lipid 
peroxidation in vivo. Values represent the mean +SEM (n=5), (*p<0.05 for Hcy in 
comparison to the control; ***p<0.001 for estradiol/progesterone in comparison to 
Hcy) 
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2.3.4. DISCUSSION 
 
The results obtained show that either 17β-estradiol or progesterone are able to protect 
against Hcy-induced lipid peroxidation in vivo. Hcy is an agonist at the glutamate site 
of the NMDA receptor and is therefore a potential excitotoxin. Overstimulation of 
NMDA receptors by Hcy results in excessive calcium influx and reactive oxygen 
generation that cause neuronal damage (Lipton et al., 1997; Kim et al., 1998; Kruman 
et al., 2000). In addition to the antioxidant ability of both hormones, it is possible that 
both hormones also act on the NMDA receptor. This assumption is based on the 
results of the present study that both hormones (pre- and post-treatment) decrease the 
level of lipid peroxidation to below that of the control and thus show total protection 
against Hcy. Nevertheless, if both hormones only act as an antioxidant, cell damage 
due to Hcy would still arise and can only prevent further damage. However, this needs 
to be investigated further. 
 
2.4.   CONCLUSION 
 
The results in this chapter demonstrate that Hcy-induced lipid peroxidation is 
markedly inhibited by both 17β-estradiol and progesterone in vitro and in vivo.  
 
Hcy is a sulfur-containing amino acid which is formed during the metabolism of 
methionine (Nygard O et al., 1999). It is an excitatory amino acid which markedly 
enhances the vulnerability of neuronal cells to oxidative injury in vitro and in vivo 
(Outinen et al., 1998; Kruman et al., 2000). Moreover, there is reported evidence 
implicating Hcy promotion of in vivo lipid oxidation (Young et al., 1997; Roberts and 
Morrow, 2000). 
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Alul et al., (2003) and Lynch et al., (1997) reported that Hcy promotes iron-dependent 
oxidation of LDL and is dependent upon the availability of Fe3+. These authors further 
reported that in the presence of Hcy, Fe3+ is reduced to Fe2+ when incubated with LDL. 
In chapter 3, it is also shown that intrahippocampal Hcy injection causes a significant 
induction of O2․¯ radicals, which initiates lipid peroxidation (Heinecke et al., 1987). 
 
The possible mechanisms by which 17β-estradiol offers protection against lipid 
peroxidation have been reported by Heron, (2000) and Ayres et al., (1998). 
17β-estradiol offers protection against lipid peroxidation in vitro due to its antioxidant 
activity or interaction with iron. It is also reported that 17β-estradiol inhibits LDL 
oxidation (Negre-Salvayre et al., 1993). An interaction between 17β-estradiol and 
Fe3+ which is induced in the presence of Hcy would cause a decrease in Hcy-induced 
lipid peroxidation. Alternatively, progesterone has membrane stabilising effects and 
that could contribute to the reduction in damage due to lipid peroxidation (Roof, 
1994).  
 
From the in vivo results obtained (Fig. 2.7), both 17β-estradiol and progesterone also 
reduce the amount of TBARS production to levels lower than those attained in 
samples without Hcy. This demonstrates that 17β-estradiol is able to protect against 
Hcy-induced neurotoxicity completely. High concentrations of Hcy is a source of 
hydrogen peroxide, which estrogen, by enhancing glutathione content can act as a free 
radical scavenger by neutralizing hydrogen peroxide. It also reduces peroxides and 
maintains protein thiols in the reduced form (Dimitrova et al., 2002a, b). Thus 
estradiol appears to offer protection against lipid peroxidation.  
 
However, progesterone does not exert its neuroprotective effects via interaction with 
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hydrogen peroxide related cellular mechanisms (Vedder et al., 2000). It has been 
shown that progesterone modulates γ-aminobutyric acid (GABA) and excitatory 
amino acid neurotransmitter systems and has neuroprotective properties (Lockhart et 
al., 2002). It has been shown that progesterone decreases necrotic and apoptotic cell 
death in an in vitro system of N-methyl-D-aspartate (NMDA)- mediated neuronal 
injury and protects hippocampal cells against neuronal cell damage induced by 
amyloid β protein and glutamate (Lockhart et al., 2002). Foy et al., (1999) reported 
that 17β-estradiol enhances NMDA receptor-mediated excitatory postsynaptic 
potentials. The results of this report show that estradiol appears to act on NMDA 
receptors but it is not yet known whether estrogen acts directly on the receptors or 
indirectly via second messenger processes that in turn influence NMDA receptor 
processes. As shown in Chapter 7, both 17β-estradiol and progesterone offer 
protection against Hcy-induced neurotoxicity via a NMDA receptor-dependent 
mechanism. Therefore, it is possible that the protective effect of 17β-estradiol and 
progesterone on Hcy-induced lipid peroxidation in vivo (Fig. 2.7) is due to the action 
of estradiol and progesterone on the NMDA receptor, since Hcy is an agonist at the 
glutamate site of the NMDA receptor and is therefore a potential excitotoxin (Lipton 
et al., 1997). Thus estradiol and progesterone could possibly act as NMDA receptor 
antagonists in vivo. 
 
In conclusion, the present study shows that 17β-estradiol offers protection against 
Hcy-induced lipid peroxidation in vitro via a free radical scavenging mechanism. 
Both estrogen and progesterone have been shown to suppress lipid peroxidation 
induced by amyloid β-peptide (Goodman et al., 1996b; Lockhart et al., 2002). It is 
well known that estrogen and progesterone are no longer synthesized in the female 
after menopause, while concentrations of Hcy increase with age (Hernanz et al., 
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2000). These effects occurring at the same time, could contribute to 
neurodegeneration that occurs predominantly with an increase in age. Further studies 
are presently underway to investigate the exact mechanism responsible for estrogen 
and progesterone’s protective activity against Hcy-induced lipid peroxidation in vitro 
and in vivo. 
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CHAPTER 3 
 
SUPEROXIDE RADICAL GENERATION 
 
3.1 INTRODUCTION 
 
Reactive oxygen species (ROS) are produced in the course of normal metabolism and 
serve important physiological functions. However, because of their high reactivity, 
accumulation of ROS beyond the immediate needs of the cell may affect cellular 
structure and functional integrity, by bringing about oxidative degradation of critical 
molecules, such as DNA, proteins, and lipids (Hugon et al., 1996b). Although cells 
possess an intricate network of defense mechanisms to neutralize excess ROS and 
reduce oxidative stress, some tissues, especially the brain, are much more vulnerable 
to oxidative stress because of their elevated consumption of oxygen and the 
consequent generation of large amounts of ROS. For the same reason, the 
mitochondrial DNA of brain cells is highly susceptible to structural alterations 
resulting in mitochondrial dysfunction. Several lines of evidence strongly suggest that 
these effects of ROS may be etiologically related to a number of neurodegenerative 
disorders. 
Cells possess highly effective antioxidant defence mechanisms to protect neurons 
against free radical species (Braughler & Hall, 1989). Under normal conditions these 
defense mechanisms are quite capable of protecting neurons, but under conditions of 
excessive ROS production, these mechanisms may not be able to cope and 
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neurotoxicity may result (DiFiglia, 1990). These protective mechanisms can be 
classified into two main categories (Dawson & Dawson, 1996), the enzymatic defence 
mechanisms, which include superoxide dismutase (SOD) and glutathione peroxidase 
(GPx), and the non-enzymatic cellular antioxidants, which include Vitamins A and E. 
ROS are generated by the addition of a single electron to O2. The radical is usually 
generated as a result of electron “leakage” from the electron transport chain located in 
the mitochondria (McCord,1985), and by activation of certain enzymes. 
 
Superoxide anions can be very reactive and can lead to neurodegeneration (Patel et al., 
1996). It has been proposed (Fahn et al., 1992) that the excitatory amino acids are 
neurotoxic because these lead to increased production of. Overstimulation of excitatory 
amino acids receptors results in the influx of Ca2+, Na+, and K+ into neuron 
(Poeggeler et al., 1993). As these ions cause a change in the osmotic pressure, the 
neuron attempts to pump the ions out of the cell. The transport of ions is an active 
process that requires energy. Mitochondria are forced to produce more ATP, and so 
there is a chance of greater electron leakage. One of the by-products of the above 
activity is the production of  
O2․¯. 
 
The aim of the present chapter is to investigate the ability of 17β-estradiol and 
progesterone to reduce Hcy-induced O2․¯  generation in the rat hippocampus in vivo. 
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3.2 THE COMPARATIVE EFFECTS OF       
17β-ESTRADIOL AND PROGESTERONE ON 
HCY-INDUCED SUPEROXIDE RADICAL 
GENERATION IN THE RAT HIPPOCAMPUS 
 
3.2.1 INTRODUCTION 
 
Previous experiments (see Chapter 2) have demonstrated that Hcy-induced lipid 
peroxidation in vitro and in vivo. Hcy is a sulphur-containing amino acid and 
auto-oxidation of Hcy resulting in generation of ROS, such as superoxide anion 
radicals and hydroxyl radicals and thus initiates lipid peroxidation (Heinecke et al., 
1987). 
 
Several studies have shown that auto-oxidation of Hcy generates superoxide, which 
contributes to Fe3+ reduction and cause initiation of LDL oxidation (Lynch et al., 1993 
& 1995). Lipton et al., 1997 also stated that Hcy interacts with NMDA receptors, 
acting as an agonist at the glutamate binding site. In addition, the results obtained 
from chapter 7 also show that Hcy acts on the glutamate binding sites. The activation 
of NMDA receptors causes accumulation of Ca2+, thus causing excitotoxicity and 
oxidative stress (Hoffman et al., 1990; Kim & Pae, 1996). 
 
The nitro-blue tetrazolium (NBT) assay, which is generally accepted (Halliwell & 
Gutteridge, 1985) to be a reliable method for assaying for superoxide anions, was 
used. The assay involves the reduction of the NBT ion to the insoluble diformazan 
form, which can be extracted with glacial acetic acid. 
 96
Superoxide Anion Generation 
3.2.2 MATERIALS AND METHODS 
 
3.2.2.1  Chemicals and Reagents 
 
All reagents used were of analytical grade. 17β-estradiol, progesterone 
(4-Pregnene-3,20-dione), DL-homocysteine and nitro-blue tetrazolium (NBT) and 
nitro-blue diformazan (NBD) were purchased from Sigma Chemical Corporation (St. 
Louis, MO, USA). Glacial acetic acid was purchased from Saarchem (PTY) Ltd. 
(Krugersdorp, South Africa). 0.1% of NBT reagent was prepared by dissolving the 
NBT in ethanol before making up the solution to the required volume with Milli-Q 
water. All reagents were of the highest quality available. 
 
3.2.2.2 Animals 
 
Adult male rats of the Wistar strain, weighing between 250-300g were used for the 
experiment, and were housed and maintained under the conditions described in 
section 2.2.2.2. 
 
3.2.2.3 Dosing of the Animals 
 
As described in section 2.3.2.3 
 
3.2.2.4 Surgical Procedures 
 
As described in section 2.3.2.4 
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3.2.2.5 Homogenate Preparation 
 
As described in section 2.3.2.5. 
 
3.2.2.6 Preparation of Standards 
 
NBD was used as a standard. A series of reaction tubes, each containing appropriate 
aliquots of NBD dissolved in glacial acetic acid was prepared to a final volume of 1ml. 
A calibration curve (Appendix two) was generated by measuring the absorbance at 
20µmoles/ml intervals. The absorbance was read at 560nm using a Shimadzu 
UV-160A UV-visible recording spectrophotometer. 
 
3.2.2.7 Nitroblue Tetrazolium Assay (NBT) 
 
A modified method of Halliwell and Gutteridge (1985) was used for this assay. The 
lipid source viz. rat hippocampal homogenate (0.5ml) was incubated with 0.4ml of a 
0.1% NBT solution in an oscillating water bath for 60 minutes at 37˚C. Termination 
of the assay and extraction of reduced NBT was carried out by centrifugation of the 
suspension at 2000 x g for 10 minutes. The supernatant was decanted and the pellet 
was resuspended with 2ml glacial acetic acid. The relative absorbance of the glacial 
acetic acid fraction was measured at 560nm and converted to µmoles Diformazan 
using a standard curve generated from nitroblue diformazan (NBD) in appendix two. 
Final results are expressed as µmoles Diformazan/mg protein. 
 
The protein content of each homogenized rat brain tissue was determined by carrying 
out protein assays as described in section 3.2.2.8. All results were analyzed to show 
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statistical significance as described in section 2.2.2.7. 
 
3.2.2.8 Protein Determination 
 
All protein determinations were performed using the method described by Lowry et 
al., (1951). A standard curve was generated using bovine serum albumin (BSA) as a 
standard at concentration intervals of 60µg/ml, described in appendix three.  
 
3.2.2.9 Statistical Analysis 
 
As described in section 2.2.2.7. 
 
3.2.3. RESULTS 
 
The intrahippocampal injection of Hcy at 0.14µmol/µl in vivo caused a significant 
increase in hippocampal O2․¯ production in comparison to the control value (Figure 
3.1). Both groups treated with of 17β-estradiol or progesterone showed a significant 
reduction in Hcy-induced O2․ ¯ production. Furthermore, both hormones in both 
treatment groups are able to decrease the O2․¯ levels below that observed for the 
control treated rats.  
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Figure 3.1.  The effects of 17β-estradiol and progesterone on Hcy-induced O2․¯ 
generation in rat hippocampal homogenate in vivo. Values represent the mean +SEM 
(n=4), (*** p<0.001 in comparison to the control; ** p<0.01 in comparison to the 
control; #p<0.001 for estradiol/progesterone in comparison to Hcy). 
 
3.2.4. Discussion 
 
The results obtained in this experiment show that the intrahippocampal Hcy injection 
causes a significant induction of O2․¯ generation in rat hippocampus. The increase in 
O2․¯ production could be caused by increased intracellular Ca2+ due to overstimulation 
of the glutamate receptors. O2․¯ is toxic to neurons (Fahn et al., 1992) and could lead 
to neuronal death. Hcy is a sulphur-containing amino acid and Heinecke et al., (1987) 
have shown that Hcy causes generation of hydrogen peroxide, hydroxyl radicals and 
O2․¯ during the auto-oxidation reaction. In addition, Hcy causes Ca2+ influx via the 
stimulation of the NMDA receptor (Lipton et al., 1997); a reduction in the number of 
binding sites of receptor (Chapter 7) and changes in the nature of the receptors in the 
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neurons (Chapter 7). Thus, Hcy is a potential neurotoxic agent due to its ability to 
increase O2․¯ generation in the brain. 
 
However the Hcy-induced O2․¯ generation is reduced significantly by both regimens 
of either 17β-estradiol or progesterone. The neuroprotective effects of progesterone 
have been reported to include improved blood-brain barrier integrity and also free 
radical scavenging, which limit cell death by reducing lipid peroxidation (Betz et al., 
1990; Roof et al., 1992; Shallert et al., 1986; Yu, 1989). In addition, the results 
obtained in chapter 2 also show that progesterone has the ability to protect against 
Hcy-induced lipid peroxidation. Roof et al., (1994) and Carlson et al., (1990) showed 
that progesterone has membrane stabilising effects and antioxidant action. This causes 
the cell membrane to be less fluid and protects these from free oxygen radical attack 
and calcium toxicity.  
 
Alternatively, 17β-estradiol has a protective effect in response to superoxide anions 
and hydrogen peroxide (Sawada et al., 1998). The antioxidant activity of estradiol has 
been attributed to the presence of the hydroxyl group in the C3 position on the A ring 
of the steroid molecule (Behl, 1995). Hcy is a sulphur-containing amino acid and the 
auto-oxidation of this compound results in peroxynitrite anion. The superoxide anion 
interacts with nitric oxide to form peroxynitrite. It is also known that 17β-estradiol 
detoxifies peroxynitrite by increasing glutathione (GSH) levels (Pechanova et al., 
1999). Moreover, 17β-estradiol can modulate intracellular calcium levels through 
interactions with NMDA receptors (Joels et al., 1995) and is able to up-regulate the 
number of binding sites (Chapter 7). 
 
This experiment investigated the O2․¯ scavenging properties of 17β-estradiol and 
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progesterone induced by Hcy.  
 
3.2.5. Conclusion 
 
These results demonstrate that both 17β-estradiol and progesterone of both regimens 
are able to reduce Hcy-induced O2․- level in the hippocampus. Moreover, both 
hormones are able to reduce an Hcy-induced O2․-  level, which is lower than the 
control treated group.  
 
In conclusion the results of the present studies imply that both 17β-estradiol and 
progesterone are potent scavengers of O2․- and that these hormones have a definite 
role to play as antioxidants and in the protection of the brain against oxidative stress. 
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CHAPTER 4 
 
HISTOLOGICAL STUDIES 
 
4.1. INTRODUCTION 
 
In chapter 2, it was shown that both 17β-estradiol and progesterone protect against 
Hcy-induced lipid peroxidation both in vivo and in vitro. However, these studies were 
only measurements of degraded lipid products, the TBA reacting substances.  
Although the decline in the formation of these degraded lipid products is an indication 
of decreased cell damage, it is important to examine the cells following Hcy 
administration. 
 
Homocysteine induces neuronal cell death by activating N-methyl-D-aspartate 
(NMDA) receptor (Lipton et al., 1997; Kim et al., 1996; Ho et al., 2002). Kruman, et 
al., 2000 reported that intrahippocampal injection of Hcy markedly increases the 
vulnerability of hippocampal neurons to neuronal cell death and oxidative injury in 
cell culture and in vivo. 
  
The present study aims to examine the hippocampal neurons following an 
intrahippocampal injection of Hcy, and post- and pre-treatment with subcutaneous 
injection of 17β-estradiol or progesterone. Histological techniques were employed 
and the cells examined under a light microscope attached with a camera. 
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4.2. THE EFFECT OF 17β-ESTRADIOL AND 
PROGESTERONE AGAINST HCY-INDUCED 
DAMAGE TO HIPPOCAMPAL NEURONS 
 
4.2.1.   INTRODUCTION 
 
Histology is the study of tissues and cells under a microscopea. It is also called 
microscopic anatomy, as opposed to gross anatomy which involves structures that can 
be observed with the naked eye. It also involves of the examination of preserved, 
sectioned and stained tissue (Hodgeson & Bernard, 1992).The Nissl stain, introduced 
by the German neurologist Franz Nissl in the late nineteenth century, and is 
commonly used to study neurons under the light microscope.  
 
Neural tissues have a wide distribution throughout the body, innervating most viscera 
and peripheral tissues. Neurons are highly specialized cells that conduct nerve 
impulses and are easily excited to produce them. Typical neurons show a large cell 
body with a large central nucleus and many cytoplasmic extensions. The stain is 
extremely useful since it distinguishes neurons and glia from one another and allows 
histologists to study the arrangement or cytoarchitecture of neurons in different parts 
of the brain (Bear et al., 2001). 
 
In this experiment it was decided to investigate whether 17β-estradiol or progesterone 
offers neuroprotection against Hcy-induced intrahippocampal lesions in the rat brain. 
After treatment, the brains of the rats were sectioned and the hippocampus of the rats 
was examined microscopically for evidence of any morphological changes 
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4.2.2.    MATERIALS AND METHODS 
 
4.2.2.1. Chemicals and Reagents 
 
17β-estradiol, progesterone (4-Pregnene-3,20-dione), DL-homocysteine were 
purchased from Sigma St. Louis, MO, U.S.A. Paraffin wax was obtained from Lasec 
(South Africa). Cresyl violet stain was purchased from BDH Chemicals Ltd (England), 
while DPX was purchased from Philip Harris Ltd (England). Haupt’s adhesive 
consisted of the following: 1 g gelatine, 100 ml water, 2 g phenol and 15 ml glycerol. 
All other chemicals were of the highest quality available and were purchased from 
commercial distributors. 
 
4.2.2.2. Animals 
 
Adult male rats of the Wistar strain, weighing between 250-300g were used for the 
experiment, and were housed and maintained under the conditions described in 
section 2.2.2.2. 
 
4.2.2.3. Dosing of Animals 
 
As described in section 2.3.2.3. 
 
4.2.2.4. Surgical Procedures 
 
As described in section 2.3.2.4. 
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4.2.2.5. Histological Techniques 
 
The histological techniques were followed according to the methods described by 
Southgate et al., 1999. 
 
4.2.2.5.1. Fixing the brain 
 
The animals were sacrificed and the brains removed as in section 2.2.2.3. Immediately 
after death, animal tissues begin to break down as a result of autolysis and bacterial 
attack. Fixation functions to chemically stabilise proteins, and thus preserve structures 
(Southgate, 1999). Brains were rapidly fixed in a mixture of formol (30%), glacial 
acetic acid, and ethanol (2:1:7 v/v) for 2 hours. After fixation, the brains were stored 
in 70% ethanol. 
 
4.2.2.5.2. Specimen Preparation and Embedding 
 
In order to be cut, the slices need to be supported. Imbedding involves the infiltration 
and orientation of tissue in the paraffin wax support medium. The tissue was 
dehydrated (using increasing concentrations of ethanol), followed by the removal of 
the ethanol using xylene. Finally the tissue was immersed in molten paraffin wax, 
which removed the xylene, while infiltrating the tissue without encountering water. 
The method used is shown in Table 4.1 
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Table 4.1.    Procedure for embedding brains in paraffin wax. 
 
Step Processing Agent Time (Hours) 
1 70% Ethanol 1 
2 90% Ethanol 1 
3 Absolute Ethanol 1 
4 Absolute Ethanol 1 
5 Xylene 1 
6 Xylene 1 
7 Melted Paraffin Wax 1 
8 Melted Paraffin Wax 1 
 
 
4.2.2.5.3. Blocking Out 
 
The brain material was fixed into a block so that it could be cut with a microtome. 
The mould used was a plastic ice tray. This was coated with ethanol-glycine to 
prevent the block sticking to the mould. The brain was removed from the final molten 
wax stage (previous section) and placed into the mould with warmed forceps. The 
brain was then completely covered in molten wax. Air was gently blown over the 
surface of the wax until the top solidified. The blocks were left overnight to ensure 
that the wax had completely solidified. 
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4.2.2.5.4. Sectioning 
 
The wax block was trimmed with a razor blade so that two of the sides were parallel, 
while the other two converged slightly. The sides were cut so as to leave about 2 mm 
of wax around the tissue. The wax block was attached to a small wooden block with a 
small amount of molten wax. 
 
Sectioning was done using a rotary microtome. The microtome was set to cut sections 
of 10µm thickness. As sections were cut these would stick to one another, so as to 
form long ribbons. When the part of the brain containing the hippocampus was 
reached, every second section was removed and placed in a water bath (40° C) using 
forceps. 
 
4.2.2.5.5.    Transferring Sections to Slides 
 
Three sections at a time were removed from the water bath and placed onto 
microscope slides containing a thin layer of Haupt’s adhesive. The slides were left 
overnight in an oven at 40°C. 
 
4.2.2.5.6.    Staining 
 
The sections were Nissl stained using cresyl violet. This stains Nissl substances 
intense purple, the nuclei purple, and leaves the background clear (Bauer, 1974). 
Before the section could be stained, it first had to be dewaxed and rehydrated as the 
stain is water soluble. This was done as per Table 4.2. 
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Table 4.2.    Procedure for dewaxing and rehydrating brain sections. 
 
Step  Processing Agent Time (minutes) 
1 Xylene (dewaxing) 5 
2 Xylene   5 
3 Xylene / Absolute Ethanol 
(1:1)  
3 
4 Absolute Ethanol 5 
5 Absolute Ethanol Overnight at 30°C 
 
Sections were stained by placing in a 0.1% cresyl violet solution for 2 hours. The 
cresyl violet solution contained 0.25g cresyl voilet, 250 ml MilliQ water, 0.75 ml 
glacial acetic acid and 0.0512g sodium acetate. The pH was adjusted to 3.5 before use. 
The slides were differentiated rapidly in 95% ethanol by rinsing in a flat dish until the 
background was clear. Sections were then dehydrated again as shown in Table 4.3. 
 
Table 4.3.    Procedure for dehydrating brain sections after staining. 
 
Step  Processing Agent Time (minutes) 
1 Absolute Ethanol 5 
2 Absolute Ethanol 5 
3 Xylene 5 
4 Xylene 5 
 
4.2.2.5.7.   Mounting of the Slides 
 
While the slides were kept moist with xylene, enough DPX was added to just cover 
the tissue. A cover slip was placed over the tissue. The slides were allowed to dry on a 
flat surface for 48 hours. 
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4.2.2.5.8.   Photo-microscopy 
 
The slides were photographed using a combination Olympus camera and light 
microscope. 
 
4.3 RESULTS  
 
The results from figure 4.1 show that both 17β-estradiol and progesterone protect the 
neurons in both CA1 and CA3 regions of the hippocampus in Hcy-induced 
neurodegeneration. The hippocampal neurons in control group from both the CA1 
(figure 4.1 (a)) and CA3 region (figure 4.1 (g)) appear to be undamaged. The neurons 
appear to have a pyramidal shape, continuous cell membrane lining and the cell 
nucleus is visibly observed. 
 
However, the neurons of animals treated with Hcy in the CA1 region (figure 4.1 (b)) 
and the CA3 region (figure 4.1 (h)) show signs of neuronal damage and degeneration 
as evident by the roundness and swelling. The cell nucleus is absent and the cell 
membrane is scattered. However, the neurons in CA1 (figure 4.1 (c)) and CA3 (figure 
4.1 (i)) regions of the 17β-estradiol post-treated animals appear to be undamaged and 
show significant protection in comparison to the neurons of Hcy only treated animals. 
Similar results are obtained in the CA1 (figure 4.1 (d)) and CA3 (figure 4.1 (j)) 
regions of 17β-estradiol pre-treated animals. 
 
Furthermore, figure 4.1 (e), (k), (f) and (l) demonstrate that the neurons are 
undamaged in CA1 and CA3 regions of post-treatment or pre-treatment of 
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progesterone. It is also evident that the neurons of the both regimes of progesterone 
treated animals healthier than the neurons of the Hcy treated animals. 
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(a) (g) 
 
(b) (h)  
 
 
 
 
 
 
 
(c) (i) 
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(d) (j)  
 
 
 
 
 
 
(e) (k) 
 
 
 
 
 
 
(f) (l) 
Figure 4.1.   Hcy toxicity and the protective effects of 17β-estradiol or progesterone 
on rat hippocampal neurons. Micrographs (a-f) show cells in the CA1 region of the 
hippocampus from a control animal (a), an animal treated with Hcy (b), an animal 
treated with Hcy and 17β-estradiol (post-treatment) (c), an animal treated with Hcy 
and17β-estradiol (pre-treatment) (d), an animal treated with Hcy and progesterone 
(post-treatment) (e) and an animal treated with Hcy and progesterone (pre-treatment) 
(f). Micrographs (g-l) indicate cells in the CA3 region of the hippocampus from a 
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control animal (g), a Hcy treated animal (h), an animal treated with Hcy and 
17β-estradiol (post-treatment) (i), animal treated with Hcy and 17β-estradiol 
(pre-treatment) (j), an animal treated with Hcy and progesterone (post-treatment) (k) 
and an animal treated with Hcy and progesterone (pre-treatment) (l). (Bar = 10µm) 
 
4.4 DISCUSSION 
 
These results (figure 4.1.) demonstrate that the structural damage of neurons that Hcy 
causes in CA1 and CA3 regions of the hippocampus. The results also demonstrate 
that 17β-estradiol or progesterone appears to protect against Hcy-induced 
neurotoxicity. The cell damage induced by Hcy is dependent on the NMDA receptor, 
since pretreatment with an antagonist prevents this damage. Overstimulation of 
NMDA receptors by Hcy results in Ca2+ to enter the neurons (Kim, 1999; Kruman et 
al., 2000; Lipton et al., 1997). The influx of these ions disturbs the ionic balance of 
the neurons, which result in swelling and lysis of neurons (Coyle et al., 1993). This 
phenomenon is shown in figure 4.1. The influx of Ca2+ into the cell can also cause 
free radical production, thus causing neurotoxicity of neurons.  
 
However, AMPA, a non-NMDA glutamate receptor, must be activated before 
activating NMDA receptors. This activation results in an influx of Na+ ions in the cell, 
causing a depolarization of the membrane. Depolarization of the membrane results in 
removal of the magnesium block, allowing the opening of the channel once Hcy has 
bound. Once the channel is opened, Ca2+ influx occurs in the neuron.  
 
High concentrations of glutamate within the synapse result in acute toxicity. Acute 
toxicity occurs because of the rapid influx of Na+ ions into the neuron, which causes 
passive Cl¯ and water entry via osmotic pressure. This toxic process may be 
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associated with abnormalities in membrane permeability and may be lethal, via 
osmotic lysis (Southgate & Daya, 1999). In addition, the activation of the NMDA 
receptor by Hcy results in an influx of Ca2+ ions. This together with the water uptake 
results in the swelling of the cells evident in the photomicrographs. 
 
4.5 Conclusion 
 
Hcy is an excitatory amino acid (EAA) and causes direct neurotoxicity by activating 
the NMDA subtype of glutamate receptor. Excessive stimulation of these receptors is 
known to mediate brain damage (Lipton et al., 1997). Thus Hcy participates in the 
ensuing neurotoxic response in the brain.  
 
Several studies have shown that 17β-estradiol protects against neuronal death due to 
excitotoxicity. Behl et al., (1995) and Goodman et al., (1996) reported that 
preincubation with 17β-estradiol attenuates the toxicity of glutamate exposure to a 
hippocampal cell line culture, as measured by cell viability and lysis. In addition, 
progesterone also attenuates EAA responsiveness (Smith et al., 1987; Smith 1991). 
These authors showed that progesterone reduces excitotoxic cell death by inhibiting 
excitatory EAA receptors.  
 
From the results obtained in this chapter, it is evident that 17β-estradiol and 
progesterone attenuate Hcy insult in the rat hippocampus. This protection elicited by 
both hormones as well as that shown against the increase in lipid peroxidation, could 
be due to its antioxidant property, in this way preventing further damage induced by 
the free radicals formed during the Hcy damage. However, it is more likely that the 
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protection of both hormones against Hcy-induced neuronal damage involves the 
NMDA receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116
Apoptosis 
CHAPTER 5 
 
APOPTOSIS 
 
5.1. INTRODUCTION 
 
Apoptosis is an ancient Greek word used to describe the "falling off" of leaves from 
trees or petals from flowers, referring to the particular morphology of physiological 
cell death (Kerr et al., 1972). It refers to the morphologic features of programmed cell 
death, which is characterized by cell shrinkage, nuclear condensation, nucleosomal 
DNA fragmentation (DNA ladder), membrane blebbing and fragmentation into 
membrane bound apoptotic bodies (Saikumar et al., 1999).  
 
Apoptosis has important biological roles in the development and homeostasis of cell 
populations, and in the pathogenesis and expression of disease processes. Excessive or 
insufficient apoptosis contributes to the pathogenesis of a wide variety of 
neurodegenerative diseases, such as Alzheimer’s disease (AD). One hallmark of AD is 
the accumulation of β-amyloid (Aβ) (Haas et al., 1992; Seubert et al., 1992). 
Exposure of neuronal cells to aggregated Aβ induces multiple neurodegenerative 
events, including accumulation of cytosolic calcium, generation of reactive oxygen 
species and apoptosis; however, prevention of accumulation of calcium within the 
cytosol also prevents all of these other neurotoxic events (Ekinci et al. 1999, 2000). 
Moreover, DNA damage, which is a potent trigger of neuronal apoptosis, has been 
documented in studies of AD patients and animal models of AD (Mullaart et al., 1990; 
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de la Monte et al., 1998; Torp et al., 1998). 
 
A number of methods have been described to identify apoptotic cells (Afanasyev et al., 
1993; Bryson et al., 1994). One of the methods is the TUNEL (TdT-mediated dUTP 
nick end labelling) method. It was designed as a histochemical technique to detect 
internucleosomal DNA fragmentation at the level of individual cells (Ben-Sasson et 
al., 1995). The TUNEL reaction preferentially labels DNA strand breaks generated 
during apoptosis and this allows discrimination of apoptosis from necrosis and from 
primary DNA strand breaks induced by cytostatic drugs or irradiation (Gorczyca et al., 
1993).  
 
Thus, in this chapter it was decided to investigate the ability of Hcy to promote 
apoptosis in the hippocampus and protection offered by the treatment with 
17β-estradiol and progesterone using the In Situ Cell Death Detection Kit, POD. This 
kit is designed as a precise, fast, and simple, non-radioactive technique for the 
detection and quantification of apoptosis at single cell level in cells and tissues, based 
on labeling of DNA strand breaks (TUNEL technology) using light microscopy. 
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5.2. THE EFFECTS OF 17β-ESTRADIOL AND 
PROGESTERONE AGAINST HCY-INDUCED 
APOPTOSIS 
 
5.2.1. INTRODUCTION 
 
Hcy inhibits the expression of antioxidant enzymes as well as the synthesis of radical 
scavengers (e.g. glutathionine peroxidase, superoxide dismutase) which might 
potentiate the toxic effects of ROS (Huang et al., 2001b). Homocysteine-induced 
ROS accumulation enhances the activation of NF-kappaB (Chern et al., 2001). 
NF-kappaB is a redox-sensitive transcriptional factor which is crucial in the control of 
ROS-mediated apoptosis. Under these conditions, neuronal damage derives from 
excessive calcium influx and ROS leading to excitotoxicity. Moreover, primary 
inhibition of the mitochondrial respiratory chain indirectly induces NMDA receptor 
stimulation, which is termed secondary excitotoxicity (Greene & Greenamyre, 1995).  
As shown in figure 5.1, the endoplasmic reticulum (ER) is an intracellular target of 
Hcy toxicity (Outinen et al., 1998; Althausen & Paschen, 2000; Kokame et al., 2000; 
Nonaka et al., 2001; Zhang et al., 2001; Mattson & Shea, 2003). ER stress is a 
condition in which misfolded proteins accumulate in the ER lumen. Homocysteine 
enhances the expression of both ER chaperone proteins (e.g. grp78, grp94, gadd153) 
(Outinen et al., 1998; Althausen & Paschen, 2000; Nonaka et al., 2001) and the novel 
homocysteine-induced unfolded non-chaperone Herp (Kokame et al., 2000). The 
close relationship between the extent of cell injury and increase in ER stress response 
proteins may contribute to the homocysteine-induced apoptotic features. 
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Homocysteine induces apoptosis by mitochondrial dysfunction (Austin et al., 1998; 
Mercie et al., 2000; Bessede et al., 2001). Calcium overload inside the cell damages 
mitochondria and causes neurotoxicity. Because of the collapse of the mitochondrial 
membrane potential, the production of ATP is compromised. This causes further 
accumulation of Ca2+, since Ca2+ pumps need ATP to eliminate excess Ca2+ from of 
the cell (figure 5.1). However, Hcy is an endogenous ligand for the NMDA receptor 
(Zeise, 1988), and a portion of its neurotoxicity in cortical neurons is achieved by 
overstiumlation of NMDA receptors and resultant calcium influx (Lipton et al., 1997; 
Kim, 1999; Kruman et al., 2000) and leading to apoptosis (Lipton et al., 1997). 
Furthermore, the consecutive leakage of cytochrome c from mitochondria as well as 
ROS (Huang, 2001b) activates the caspase-3 pathway. Caspases are a family of 
aspartate-specific cysteine proteases that are an important part of various apoptotic 
processes. The homocysteine-induced activation of the caspase-3 pathway (Kruman et 
al., 2002) leads to DNA fragmentation which is a hallmark of apoptosis. This 
homocysteine-induced DNA damage (e.g. DNA strand breaks) in neurons further 
triggers a cell death cascade involving degradation or activation of poly-(ADP-ribose) 
polymerase (PARP) and induction of the tumor suppressor protein p53 (Kruman et al., 
2000). ROS accumulate in response to mitochondrial damage and in response to the 
activation of the arachidonic acid pathway by both homocysteine and Ca2+. 
Autooxidation of homocysteine is known to generate ROS, whereby the prevention of 
homocysteine-induced toxicity by SOD, GPX and catalase suggest that hydrogen 
peroxide acts as a mediator of oxidative injury, leading to apoptosis (Austin et al., 
1998; Outinen et al., 1998; D'Emilia & Lipton, 1999). Furthermore, Ekinci et al., 
(1999, 2000) suggests that calcium accumulation is an early and pivotal event in Aβ 
neurotoxicity. Hcy enhances the neurotoxicity of β-amyloid which is known to cause 
neurodegeneration (Ho et al., 2001; Mattson et al. 1992a; Gray & Patel 1995). It has 
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also been shown that Hcy induces an increase in phospho-tau immunoreactivity and 
externalised phosphatidylserine which is indicative of apoptosis (Ho et al., 2002). 
 
 
Figure 5.1.  Extra- and intracellular neurotoxic mechanisms induced by 
homocysteine (Bleich et al., 2004). 
 
Since the ability of Hcy to induce damage in the CA1 and CA3 hippocampal neurons 
was shown in chapter four, it was decided to investigate whether Hcy results in 
apoptotic cell death as well. Thus, the aim of this chapter was to investigate whether 
damage of the hippocampus with Hcy results in apoptotic neuronal death and if 
co-treatment of rats with Hcy and 17β-estradiol or progesterone results in a reduction 
in positive apoptotic neurons, using the in situ cell death detection kit, POD.  
 
5.2.2. MATERIAL AND METHODS 
 
5.2.2.1. Chemicals and Reagents 
 
17β-estradiol, progesterone (4-Pregnene-3,20-dione), DL-homocysteine were 
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purchased from Sigma St. Louis, MO, U.S.A. Aminopropyltriethoxysilane (APES) 
was purchased from NT lab Fluka. Paraffin wax was obtained from Lasec (South 
Africa). In situ cell death detection kit, POD, proteinase K (nuclease free), DNase 1, 
grade 1 (positive control), and DAB substrate were purchased from Roche 
Diagnostics, (Nonnenwald, Penzberg). Formaldehyde, glacial acetic acid, absolute 
ethanol, xylene, and chloroform were purchased from Saarchem, Gauteng, SA while 
the aqueous mountant, SHUR/MOUNT™ was purchased from Triangle Biomedical 
Sciences Inc, Durham, USA. All other chemicals were of the highest quality available 
and were purchased from commercial distributors. 
 
5.2.2.2. Animals 
 
Adult male rats of the Wistar strain, weighing between 250-300g were used for the 
experiment, and were housed and maintained under the conditions described in 
section 2.2.2.2. 
 
5.2.2.3. Dosing of Animals 
 
As described in section 2.3.2.3. 
 
5.2.2.4. Surgical Procedure 
 
As described in section 2.3.2.4. 
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5.2.2.5. Histological Techniques for Apoptosis Detection 
 
The histological techniques were followed according to the method described by the 
in situ cell death detection kit, POD instruction manual 
(www.roche-applied-science.com/pack-insert/1684817a.pdf) and Maharaj, 2003. 
 
5.2.2.5.1. Fixing the brain 
 
The animals were sacrificed and the brains removed as in section 2.2.2.3. Immediately 
after death, animal tissues begin to break down as a result of autolysis and bacterial 
attack. Fixation functions to chemically stabilize proteins, and thus preserve structures 
(Southgate, 1999). The role of the fixative is to maintain the morphology of the 
tissues as close to in vivo morphology as possible and to prevent post-sampling 
necrosis. A recommended fixative used for the study of brain tissue is Davidson’s 
solution. The ratio of fixative to tissue volume should be at least 10:1 to ensure good 
fixation.  
 
There is no universal fixative and choice should be made taking into account later use 
of fixed material as well as practical aspects of fixative use (price, component 
availability, etc). Davidson’s solution is an excellent choice for preserving the 
structure of the tissues (Lighter, 1996). In addition, tissue sections fixed with 
Davidson’s solution can be stained later by different histochemical methods, as well 
as in-situ hybridization with DNA proteins. Davidson’s alcohol formalin acetic acid 
fixative consists of 220mL of formalin (100%), 115mL of glacial acetic acid, 330mL 
of ethanol, and 335mL of water. This mixture is stored at room temperature prior to 
use (Lighter, 1996). 
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Brains were rapidly fixed in the Davidson’s fixative mixture for 48 hours. After 
fixation, a slice of brain, 2mm thick was prepared to exclude the location of the 
injection track, which was normally apparent from the residual dimpling of the 
cortical surface produced by the needle penetration. Exclusion of the tissue directly 
below the site of the injection ensured that all damage was due to neurotoxin or drug 
and not due to the physical damage caused by the cannula needle. The 2mm block of 
brain tissues were then stored in 70% ethanol. 
 
The fixation process was terminated by dehydrating the brain tissue. For apoptosis 
detection, traditional processing and embedding techniques cannot be used as 
described in chapter four, section 4.2.2.5.1. Thus, in order to reduce residual damage 
and improve the fluorescence of the tissue, reagents that could affect the fluorescence 
were eliminated from the procedure. Moisture was extracted from the tissue fragments 
by bathing them successively in a graded series of mixtures of ethanol, and this step 
was followed by the clearing and defatting process that involves the removal of 
ethanol by immersing the tissue in chloroform. The tissue was then submerged in 
molten paraffin wax (MP 57-58°C) at 60°C for one hour, which facilitated the removal 
of chloroform and while infiltrating the tissue without encountering water. At the end 
of this 1 hr period the brain tissue was placed under vacuum to remove any air that 
was trapped in the wax for 15min. Thereafter, the brain tissues were placed in new 
wax twice for a period of 1hr each. Finally the brain tissue was embedded in molten 
wax and this stage provides the hardness and support that the tissue requires for 
sectioning. The method used here is a modification of the method described by Geiger 
et al., (1997) and is described in Table 5.1. The tissues can be stored in paraffin 
indefinitely without visible influence on the quality of TUNEL reactions (Geiger et al., 
1997).  
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Table 5.1. Fixation and Processing of Tissues for Paraffin Embedding.  
Step  Processing Agent  Time (Hours)  
Fixation  Davidson’s Fixative solution  48 hrs  
Dehydration  50% Absolute Ethanol  1 x 2 hrs  
 70% Absolute Ethanol  1 x 2 hrs  
 80% Absolute Ethanol  1 x 2 hrs  
 90% Absolute Ethanol  1 x 2 hrs  
 96% Absolute Ethanol  2 x 2 hrs  
 100% Absolute Ethanol  3 x 2 hrs  
Clearing  Absolute Ethanol: Chloroform (1:1)  1x 2 hrs  
 Chloroform  1 x 2 hrs  
 Xylene: Chloroform (1:1) at 60°C  1 x 1 hr  
Wax Immersion Melted Paraffin Wax (MP 57-58°C) at 60°C  1x 1 hr  
 Vacuum at 60°C  15min  
 Melted wax  2 x 1hrs  
Embedding  In molten Wax  Overnight  
 
5.2.2.5.2.   Sectioning  
Paraffin sections were cut by standard methods as described in chapter twelve, section 
4.2.2.5.2. The sections of paraffin-embedded tissue was cut 5µm thick and placed on 
the APES coated slides. The treatment procedure for the slides is described below.  
5.2.2.5.3. Treatment of Slides 
 
When mounting paraffin sections on slides, it is important to use an appropriate 
adhesive to avoid loss of sections during the subsequent washing procedures. Sections 
can be mounted on Superfrost slides or on glass slides that have been coated (subbed) 
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with either aminopropyl triethoxysilane (APES) or poly-L-lysine. APES has been 
shown to be superior to poly-L-lysine in preventing tissue detachment from the glass 
(Ben-Sasson, 1995) and thus, APES was use to treat the glass slides prior to use. The 
slides were subbed at least 2 days prior to the application of the paraffin sections.  
The method described by Herrington and McGee (1992) was used for treating the 
slides. Briefly, the slides were placed in a rack and cleaned by immersion for 30 min 
in 2% Decon 90 made in warm (60°C) distilled water. This was followed by rinsing in 
distilled water, and then in acetone and finally air dying. The slides were then 
immersed into 2% APES made in acetone for 30 min. Finally the slides were rinsed 
with acetone, washed in distilled water and air dried at 37°C. The slides were then 
stored in a dry place for 2 days prior to use.  
5.2.2.5.4. Transferring Sections to Slides 
 
One or two sections at a time were removed from the water bath and placed onto glass 
microscope slides using a thin paint brush. The paraffin slides were stored at room 
temperature until use to enable the section to adhere to the slide. 
 
5.2.2.5.5. Deparaffinising Sections 
 
Deparaffination should be as complete as possible, since remaining paraffin adversely 
affects the TUNEL reaction. The sections were heated 60°C for 20 min and then 
hydrated through several baths of xylene and a graded series of ethanol at 
concentrations ranging from 100 to 70% with an immersion time of 3 min per bath as 
shown in table 5.2. Thereafter, the sections were rinsed in PBS (pH 7.4) for 30 sec. 
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Care was taken to ensure that the slides did not dry out during the deparaffinising.  
Table 5.2. Procedure for dewaxing and rehydrating brain sections.  
Step   Processing Agent  Time  
1   Heat at 60°C  20 min  
2   Xylene  2 x 5 min each  
3   100% Ethanol  2 x 3 min each  
4   90% Ethanol  1 x 3 min  
6   80% Ethanol  1 x 3 min  
7   PBS  30 sec  
 
5.2.2.5.6. In situ Cell Death Detection Kit, POD 
For the TUNEL reaction, tissue sections were processed according to the procedure 
described below. 
5.2.2.5.6.1. Deproteinisation with Proteinase K 
 
After the PBS wash, the tissue sections were partially deproteinised by incubation 
with Proteinase K. Proteinase K treatment digests cross-linked proteins and thereby 
increases cell permeability and access to the nucleic acid targets i.e. DNA. Proteinase 
K is preferred because it does not require predigestion to reduce residual nucleases 
(Willson & Higgins, 1990). The concentration, incubation time, and temperature of 
proteinase K are extremely important and have to be optimized for each type of tissue 
as high concentrations can cause tissue damage and increase nonspecific staining 
(Tornusciolo, 1995). The slides were incubated in 20µg/ml proteinase K which was 
made up in 10mM Tris-HCl buffer, pH 8, for 15min at 37°C in a humidified chamber. 
Care was taken to ensure that the sections did not dry out. 
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Since the final immunohistochemical stain is peroxidase-independent (Geiger et al., 
1997), no inhibitions of endogenous peroxidases that can produce high levels of 
background staining and interfere with the interpretation of the results, was performed 
because H2O2 weakens TdT activity (Migheli et al., 1995) and induces DNA breaks 
(Wijsman et al., 1993). Thus, incubation step was terminated by washing the slides 
four times in PBS for 3min each. The experimental slides were kept in PBS while the 
positive control slide was removed for DNase treatment as described below.  
 
5.2.2.5.6.2. Positive DNase Controls 
 
There is a substantial amount of variation in positive staining when using the TUNEL 
method; therefore, at least two DNase control slides should be included with each 
experimental run. The type, size and fixation of the tissue are contribution factors to 
the variation in staining. Since DNA fragmentation is characteristic of apoptosis, 
application of DNase to control slides is ideal. DNase is an endonuclease that 
introduces breaks by hydrolyzing double-stranded or single-stranded DNA, 
preferentially at sites adjacent to pyrimidine nucleotides (Sambrook et al., 1989); 
therefore, pretreatment with DNase results in intensive labelling of all nuclei. If the 
DNase controls do not stain, staining on the experimental slides may be artifact and 
not positive staining.  
 
The concentration of DNase used was 3000U/ml prepared in 50mM Tris-HCl, pH 7.4 
containing 1mg/ml BSA. After finger flicking for 10sec, sufficient DNase mixture 
was applied to the desired DNase control slides in order to cover the entire section 
and incubated for 10min at 25°C. This mixture should not be made until needed, since 
thawing of the DNase I cause its inactivation. After DNase 1 pretreatment, the 
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positive control slides were washed thoroughly with PBS, since residual DNase 
activity can introduce high background.  
 
5.2.2.5.6.3. Labelling Protocol  
 
In the TUNEL method, TdT is used to incorporate biotinylated deoxyuridine at the 
sites of DNA breaks. Both single-stranded DNA and 3’ overhangs of double-stranded 
DNA are good substrates for TdT. The TdT is generally inefficient at catalyzing the 
transfer of biotinylated dUTP to blunt or recessive ends (Deng & Wu, 1983). The in 
situ cell death detection kit, POD (Roche) contains three vials; vial 1 is the enzyme 
solution which contains the TdT from calf thymus (EC 2.7.7.31) in storage buffer; 
vial 2 which is the label solution contains the nucleotide mixture in reaction buffer. 
However, vial 3 is the converter-POD which is an anti-fluorescein antibody, 
conjugated with horseradish peroxidase (POD). 
 
To prepare the reaction mixture 100µl label solution is removed from vial 2 and kept 
away for the 2 negative controls. The total volume of the enzyme solution (vial 1) is 
added to the remaining 450µl of label solution (vial 2) to obtain 500µl of TUNEL 
reaction mixture. The mixture is mixed well to equilibrate the components. To 
maximize efficiency the TUNEL reaction mixture is prepared during the 10min 
DNase treatment step and kept on ice until use. In addition, the TUNEL reaction 
mixture is sensitive to light therefore it was prepared in the dark. 50µl/section of 
TUNEL reaction mixture containing the enzyme and digoxigneninlabeled dUTP was 
added to both the experimental and DNase control slides while, 50µl of the labelling 
solution was added to each of the negative controls. All the slides were covered with a 
zip-lock bag, in order to prevent the slides from drying out and this also imposes an 
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even layering of the reaction mixture over the whole tissue section. All the slides were 
then incubated in a humidified chamber for 60min at 37°C in the dark. TdT is 
temperature-sensitive; temperatures above 40°C inactivate the enzyme (Geiger et al., 
1997) therefore the temperature was constantly monitored in the humidified chamber 
to ensure that a temperature of 37±2°C was maintained throughout the incubation 
period.  
 
The reaction was then terminated by immersing the slides in PBS. The slides were 
washed three times in PBS for 5mins each.  
 
5.2.2.5.6.4.  Signal Conversion 
 
Following the labeling with TUNEL reaction mixture results in fluorescein, POD 
antibody and DAB substrate was added. This allows for the detection of apoptotic cell 
death under light microscopy. The reaction of fluorescein-labeled DNA strand breaks 
with POD and DAB substrate is illustrated in figure 5.2. 
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Figure 5.2.  Illustration of the reaction mechanism of In Situ Cell Death Detection 
Kit, POD. The reaction allows for the viewing of apoptotic cells under light 
microscopy (www.roche-applied-science/pack-insert/1684817a.pdf). 
 
After washing the slides with PBS, 50µl of converter-POD (vial 3) was added to each  
tissue sample. To ensure homogenous spread of converter POD throughout the tissue 
and to avoid evaporative loss the samples were covered with parafilm. The slides was 
incubated in a humidified chamber for 30 min at 37±2°C. The slides were washed 
three times in PBS. 
 
The DAB substrate, metal enhanced utilizes cobalt chloride and nickel chloride in a 
special formulation to produce a dark brown/black precipitate in the presence of 
horseradish peroxidase (POD). A 10% of DAB substrate was prepared by utilizing 
peroxide buffer. 100µl DAB substrate was then added to each tissue sample and was 
covered with parafilm during incubation. The slides were incubated for 10 min at 
15-25°C. Once again, the slides were rinse three times with PBS. 
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5.2.2.5.6.5. Mounting of Slides 
 
In order to prevent the drying out of the sections, the sections need to be mounted. 
However, while the slides were still wet enough SHUR/MOUNTTM was added to 
them. SHUR/MOUNTTM is an aqueous mountant that also assists in preserving the 
fluorescence of the tissue. Tissue sections were then covered with coverslips and 
allowed to dry in the dark.  
 
5.2.2.5.6.6. Photo-microscopy 
 
The slides were photographed using a combination Olympus camera and light 
microscope. 
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5.3. RESULTS  
 
In figure 5.3 (a) and (b), the positive apoptotic cells of CA1 and CA3 regions are 
indicated with arrows. The positive control slides treated with DNase 1 are used as a 
guideline to ensure the experimental slides is not artifact. In the positive apoptotic 
control cells, the neuronal cells appeared scattered and the nuclei are stained in brown 
colour. The DAB substrate stains the apoptotic positive cells brown in colour. 
However, some of the nuclei are absence in the neuronal cells which is an indication 
of nuclear fragmentation. 
 
 
 
 
 
 
 
 
 
  
(a)                                          (b) 
Figure 5.3.  Detection of apoptotic cells (stained brown in colour) in the CA 1 and 
CA3 regions of the hippocampus. (a) CA1 region of positive control tissue, (b) CA3 
region of the positive control tissue (Bar = 10µm). Arrows showing positive apoptotic 
cell death neurons. 
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Figure 5.4 (a) and (b) show the negative control cells of the CA1 and CA3 regions of 
hippocampus respectively. The cells appeared clear, the nuclei can be seen clearly and 
lacking the brown staining. Thus there is no indication of apoptotic cell death 
occurring in the neurons. The neuronal cells appear healthy and undamaged.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(a)          (b) 
Figure 5.4.  Hippocampal neuronal cells from negative control treated rat brain 
section. (a) CA1 region of negative control tissue, (b) CA3 region of negative control 
tissue (Bar = 10µm). Arrows show healthy neurons lacking the brown stained nuclei 
which are investigative of apoptosis. 
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Figure 5.5 (a) and (b) show the CA1 and CA3 of the control treated groups rat brains. 
The neurons are clearly visible with continuous cell membrane. The pyramidal shape 
neuronal cells are observed with the absence of the brown staining nuclei. These 
indicate that there is no apoptotic cell death occurred. The neurons of the control 
group section resemble those from the negative control section as evident in figure 5.4 
(a) and (b).  
 
 
 
 
 
 
 
 
 
 
 
  
(a)   (b) 
Figure 5.5.  Hippocampal neuronal cells from control treated group rat brains. (a) 
CA1 region of control treated group, (b) CA3 region of control treated group. (Bar = 
10µm). Arrows show neurons lacking the brown stained nuclei. 
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Figure 5.6 (a) and (b) show the apoptotic cells in the Hcy treated rats as indicated with 
arrows. The neuronal cells in both CA1 and CA3 regions are stained in brown colour 
intensely. The nucleus is absent in these cells indicating that nuclear fragmentation 
have occurred. These neurons are lack of uniformity in shape; this is result from 
blebbing of the cell membrane. 
 
 
 
 
 
 
 
 
 
 
  
(a)                           (b) 
Figure 5.6.  Hippocampal neuronal cells of Hcy treated rat brains. (a) CA1 region 
of Hcy treated rat group, (b) CA3 region of Hcy treated rat group. (Bar = 10µm). 
Arrows show brown stained apoptotic cells.   
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The pre- and post- treatments of either 17β-estradiol or progesterone rat brains are 
able to prevent against the Hcy-induced apoptotic cell death in CA1 and CA3 as 
evident in figure 5.7, 5.8, 5.9 and 5.10. Lack of brown staining of neuronal cells is an 
indication of non-apoptotic cells. The neurons of both treatments appear lack of 
intense brown staining that can be observed in the Hcy treated group (figure 5.6). 
However, the hippocampal neuronal cells of both regimes of 17β-stradiol or 
progesterone treated groups have no significant difference among the hippocampal 
neurons of the control treated rats. The neuronal cells appear as healthy as those in the 
control treated rats. In figures 5.7-5.10, the neurons posses visible nuclei and 
continuous cell membranes that are absent in the neurons of the Hcy treated group 
(figure 5.6). These results (figure 5.7 – 5.10) indicating that both regimens of 
17β-estradiol or progesterone are able to protect against Hcy-induced apoptotic cell 
death. 
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(a)          (b) 
Figure 5.7. Hippocampal neuronal cells of animals treated with Hcy and 
17β-estradiol (Post-treatment). (a) CA1 region of treated rat group, (b) CA3 region 
treated rat group. (Bar = 10µm). Arrows show neurons lack of apoptotic cell death. 
(Bar= 10µm).   
 
 
 
 
 
 
 
(a  
 
  
(a)          (b) 
Figure 5.8. Hippocampal neuronal cells of animals treated with Hcy and 
17β-estradiol (Pre-treatment). (a) CA1 region of treated rat group, (b) CA3 region 
treated rat group. (Bar = 10µm). Arrows show neurons lack of apoptotic cell death. 
(Bar= 10µm). 
 138
Apoptosis 
 
 
 
 
 
 
 
 
 
  
(a)           (b) 
Figure 5.9. Hippocampal neuronal cells of animals treated with Hcy and 
progesterone (Post-treatment). (a) CA1 region of treated rat group, (b) CA3 region 
treated rat group. (Bar = 10µm). Arrows show neurons lack of apoptotic cell death. 
(Bar= 10µm).   
 
 
 
 
 
 
 
 
 
  
(a)          (b) 
Figure 5.10. Hippocampal neuronal cells of animals treated with Hcy and 
progesterone (Pre-treatment). (a) CA1 region of treated rat group, (b) CA3 region 
treated rat group. (Bar = 10µm). Arrows show neurons lack of apoptotic cell death. 
(Bar= 10µm). 
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5.4. DISCUSSION 
 
The TUNEL kit used in this study is specific and sensitive. This method allows for the 
detection of apoptotic cell death in the CA1 and CA3 regions of the rat hippocampus, 
under light microscopy, induced by Hcy. The DNase 1 treated positive control 
sections (figure 5.3, (a) and (b)), provides evidence that the experiment is carried out 
properly and correctly. The neurons are stained in brown colour intensively, which is 
one of the characteristic of apoptotic cell death. Therefore, the positive control is used 
as a guideline for the identification of apoptotic cells in the treatment sections. 
Several studies showed that elevated Hcy levels increase the vulnerability of cultured 
hippocampal neurons to Aβ-induced death and to promote neuronal degeneration in 
mutant mice (Kruman et al., 2000, 2002). Hcy is also a neurotoxic amino acid that 
potentiated the effects of Aβ on cytosolic calcium and apoptosis in differentiated 
SH-SY-5Y human neuroblastoma cells (Ho, 2001). A similar potentiation of 
Aβ-induced neurodegeneration has previously been proposed for glutamate (Mattson et 
al., 1992a; Gray & Patel, 1995). The synergistic influences of Hcy and Aβ on calcium 
influx are likely to derive from stimulation of distinct calcium channels. Lipton et al., 
(1997) showed that the initial influx of calcium following exposure to Hcy occurs via 
NMDA channels; resultant calcium influx via NMDA channels fosters increased ROS 
(Lipton, 1997). 
  
Moreover, Kruman et al., (2000) has reported that Hcy can induce neuronal apoptosis 
and can increase neuronal vulnerability to excitotoxicity by a mechanism involving 
DNA damage which triggers the cell death cascade, poly-(ADP-ribose) polymerase 
(PARP) and induction of p53. However, Cantoni et al., (1986) stated that one of the 
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potential mechanisms by which Hcy foster increases DNA damage is by inhibition of 
cellular levels of S-adenosylmethionine (SAM) and thus promote apoptosis (Endresen 
et al., 1994, 1996).  
 
The results illustrated in figure 5.6 (a) and (b) demonstrate the dark brown staining of 
CA1 and CA3 regions of hippocampal neuronal cells indicating that Hcy does induce 
apoptotic cell death and is in agreement with the reports mentions. It is clearly evident 
from figure 5.6 (a) and (b) that the apoptotic cells differ greatly in structure and shape 
when compared to the control treatment group (figure 5.5). The hippocampal cells 
shown in figure 5.5 do not exhibit apoptotic cell death characteristics such as cell 
shrinkage, bledding of cell membrane and nuclear fragmentation. The dark brown 
staining of neuronal cells in Hcy treated group indicate the formation of apoptotic 
bodies, which was absent in the control treated group. 
 
The results illustrated in figure 5.7 and 5.8 show that both treatment regimens of 
17β-estradiol significantly attenuate Hcy-induced apoptotic cell death and this is 
clearly evident by the lack of brown staining neuronal cells. Prevention of apoptosis by 
antioxidants indicates that oxidative stress plays an essential role in the combined 
neurotoxic effects of Hcy and Aβ. 17β-estradiol has been reported to attenuate the 
Aβ-induced neuronal death in rat hippocampal cultures via its antioxidant activity 
(Behl, 1995; Goodman, 1996; Gridley, 1997, 1998; Green, 1998; Keller, 1997). Green 
et al., 1998 has shown that with physiological estrogen concentrations of 0.2-2nM can 
protect against Aβ-induced toxicity in murine neuronal HT-22 cell. Behl et al., (1994) 
determined that hydrogen peroxide (H2O2) mediates Aβ toxicity, since Aβ causes the 
intracellular accumulation of H2O2. It has been suggested that high doses of 
17β-estradiol attenuate Aβ toxicity by reducing the oxidative stress caused by it (Behl, 
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1995; Goodman et al., 1996; Gridley et al., 1997).  
 
In addition, one of the anti-apoptotic mechanisms of 17β-estradiol is that it up-regulates 
bcl-2 expression in the brain (Garcia-Segura et al., 1998; Wang & Phang, 1995). Bcl-2 
is an anti-apoptotic protein, which is a survival factor that can block both necrotic and 
apoptotic cell death (Bredesen, 1995) and promotes cell survival in a variety of tissues 
including brain. 17β-estradiol increases bcl-2 expression in cultured hippocampal 
neurons with a reduction in measures of Aβ-induced apoptosis (Pike, 1999). It includes 
the prevention of the activation of capases, inhibition of free radical formation and 
regulation of calcium sequestration (MacManus & Linnik, 1997). However, two in vivo 
studies further support the hypothesis that bcl-2 is a mediator of neuroprotection of 
17β-estradiol. Several reports show that 17β-estradiol protects against neuronal death 
due to excitotoxicity. Chern et al., (2001) shows that Hcy-induced ROS accumulation 
enhances the activation of NF-kappaB and a recent report by Lu et al., (2004) shows 
that 17β-estradiol can inactivate this factor in liver from inflammatory cell injury, thus 
preventing apoptosis.  
 
Moreover, 17β-estradiol has been shown to inhibit NMDA-induced excitotoxicity, by 
reducing Ca2+ influx (Weaver Jr., 1997). Sur et al., (2003) using the light microscope 
using TUNEL method, showed that 17β-estradiol reduce intracellular levels of Ca2+ 
influx in C6 glial cells and thus is neuroprotective against Aβ. The result of this study 
provides visual evidence of the potent neuroprotective effect of 17β-estradiol on 
Hcy-induced apoptotic neuronal cell death.  
 
Alternatively, the results seen in figure 5.9 and 5.10 also demonstrate the anti-apoptotic 
effects of progesterone in Hcy-induced apoptotic neuronal cell death in CA1 and CA3 
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regions of rat hippocampus. The cells of both treatment regimens of progesterone 
illustrate cellular characteristics that were comparable to those of the control group 
(figure 5.4). Progesterone is a free radical scavenger and thus reduces oxidative damage 
(Roof et al., 1997; Olson et al., 1988). Progesterone mediates anti-apoptotic actions in 
rat granulose cells through a progesterone-binding protein with gamma aminobutyric 
acid (GABA)A receptor-like features (Peluso et al., 1998). Progesterone exerts 
GABAergic effects in the brain and inhibits neuronal excitability (Smith, 1991) and 
thus decreases the cerebral ischemic damage (Gonzalez-Vidal et al., 1998).  
 
Progesterone (10µM) also decreases apoptotic cell death in an in vitro system of 
NMDA-mediated cytotoxic cell death in NT2 cell line culture by using TUNEL method 
(Lockhart et al., 2002). Concas et al., (1998) also shows that progesterone protects 
against the glutamate-induced-increases in intracellular Ca2+ in rat hippocampal slices. 
In addition, progesterone protects hippocampal cells against neuronal cell damage 
induced by Aβ and glutamate (Gursoy et al., 2001). These study further support that 
progesterone would be of therapeutic benefit in the Hcy-induced apoptosis.  
 
5.5.  CONCLUSION 
Homocysteine is a neurotoxic amino acid that accumulates in several neurological 
disorders including Alzheimer’s disease (Clark et al., 1998; Gottfries et al., 1998; 
Miller et al., 1999). Recent studies have shown that Hcy can be directly toxic to 
cultured neurons; the mechanism may involve the activation of NMDA receptors 
(Lipton et al., 1997) or apoptosis triggered by DNA damage (Kruman et al., 2000).  
 
In vitro studies have shown that neuronal cell death induced by toxic factors in AD, 
β-amyloid, is protected by estradiol both at higher concentrations (100nM -20µM) 
 143
Apoptosis 
(Keller et al., 1997; Green et al., 1998; Svensson & Nordberg, 1999) or lower 
physiological or therapeutic concentrations (0.2-2nM) (Green et al., 1996; Gridley et 
al., 1997, 1998) and progesterone (Gursoy et al., 2001). Excessive generation of O2˙- 
has been linked to programmed cell death and to the diminution of the life span of 
organisms (Greenland et al., 1995; Orr & Sohal, 1994). The neuroprotective effects of 
both hormones are related to free radical scavenging. The results are confirmed by 
studies conducted in chapter 2 and 3, where both hormones reduced Hcy-induced O2˙- 
generation and lipid peroxidation, respectively. However, this study provides visual 
evidence that the potent antioxidant properties of both hormones are converted to a 
neuroprotective role in the presence of potent neurotoxins, Hcy. The preservation of 
cellular integrity in both CA1 and CA3 regions of the hippocampus, by both 
hormones, implies that these agents could act as antioxidants and reduce 
excitotoxicity. Therefore, the further neuroprotective effects of both hormones, in Hcy 
treated rats, were investigated in chapter 6 and 7, respectively. 
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CHAPTER 6 
 
ENZYMATIC ANTIOXIDANTS: DEFENCE SYSTEM 
 
6.1 INTRODUCTION 
Free radicals are molecules, which have an unpaired electron in the outer orbit 
(Gilbert, 2000). These are generally unstable and very reactive. Oxygen and nitrogen 
free radicals convert to other non-radical reactive species, such as hydrogen peroxide 
and peroxynitrite (Evans et al., 2001). However, excessive production of free radicals 
can potentially damage different macromolecules such as proteins, nucleic acids and 
lipids, thus leading to cellular degeneration (Cohen & d’Arcy Doherty, 1987). Brain 
cells have a highly active oxidative metabolism with elevated levels of ATP 
consumption, yet they contain only low to moderate enzymatic antioxidant defence 
molecules such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) 
activities (Cooper, 1997; Clarke et al., 1999). Consequently, in preventing 
neurodegeneration, it is essential to preserve the antioxidant molecules such as SOD 
and GPx in the brain. 
Brain antioxidant defences function properly during most of human life. However, a 
number of neurodegenerative processes, which involve reactive oxygen (ROS) and 
nitrogen species, become evident with age (Sayre et al., 2000). Brain cells possess a 
complete set of antioxidant defenses, including enzymatic defense molecules such as 
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SOD and GPx, which can react with ROS and neutralize them before inflict damage 
in the brain.  
Hcy can increase oxidative stress by inhibiting expression (Nonaka et al., 2001) or 
function (Yamamoto et al., 2000) of key antioxidant enzymes such as SOD and GPx, 
which might potentiate the toxic effects of ROS (Huang et al., 2001). Upchurch et al., 
(1997) found that Hcy reduced GPx mRNA concentration and enzyme activity in 
bovine aortic endothelial cells. 
Therefore, the aim of this chapter was to investigate the effects of Hcy on SOD and 
GPx activities in rat hippocampus, in vivo, as well as to evaluate whether pre- and 
post-treatments of 17β-estradiol or progesterone altered the effects of Hcy on both 
enzymatic antioxidant activities. 
6.1.1 Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) 
Enhanced ROS production leads to oxidative stress and ultimately to cellular damage. 
Due to their extreme reactivity, it is difficult to detect and quantify ROS. Therefore, 
involvements of ROS in pathological conditions have generally inferred from 
measurement of indirect markers of oxidative stress, such as changes in the activities 
of antioxidative enzymes. SOD and GPX are among the most important members of 
the antioxidant defense system.  
Copper-zinc superoxide dismutase (Cu/Zn-SOD), the cytosolic isoform of SOD, is 
responsible for scavenging superoxide ions (O2˙-), which is the major ROS in the cell. 
GPx, on the other hand, is responsible for scavenging hydrogen peroxide (H2O2) 
(Ramanathan et al., 2002). A steady state level of O2˙- and H2O2 is always present in 
cells due to normal metabolism. Therefore, changes in activities of SOD and GPx 
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would reflect changes in levels of ROS, such as O2˙- and H2O2 (Nohl and Hegner, 
1978). It has been shown that under oxidative stress conditions, the overproduction of 
ROS is able to inhibit SOD activity (Yunoki et al., 1998) and Davies et al., (1987) has 
shown that SOD exposed to hydroxyl radicals is an excellent substrate. Decreased 
SOD activity has been observed under aged rats (Gupta et al., 1991) and in 
Alzheimer’s brains (Chen et al., 1994; Richardson, 1993). 
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6.2 THE EFFECTS OF 17β-ESTRADIOL AND 
PROGESTERONE IN HCY-INDUCED 
MODIFICATION OF SOD FUNCTION IN RAT 
HIPPOCAMPUS IN VIVO. 
 
6.2.1 INTRODUCTION 
 
Superoxide is an anionic radical formed by the reduction of molecular oxygen through 
the acceptance of a single electron. Dismutation of superoxide yields hydrogen 
peroxide, which produced by enzymes such as L-amino acid oxidase, glycolate 
oxidase, and xanthine oxidase (Sies, 1991). The superoxide anion does not cross cell 
membranes and, by itself, is not very reactive towards cell constituents. Hydrogen 
peroxide is also a comparatively inactive molecule, but unlike superoxide, it can 
easily cross cell membranes. This property, combined with the membrane 
permeability of hydrogen peroxide, gives superoxide and hydrogen peroxide the 
ability to affect the integrity of distant molecules within the cell (Cochrane et al., 
1991a; Halliwell & Gutteridge, 1989).  
 
Enzyme antioxidants act on specific ROS after these are formed and degrade them to 
less harmful products. Hydrogen peroxide is first converted from superoxide radical 
by SOD which is not a free radical by itself, but is a precursor of the highly reactive 
hydroxyl radical. Detoxification of hydrogen peroxide is then carried out by GPx, 
which reduces hydrogen peroxide to water in the presence of GSH. Therefore, the 
dismutation of the superoxide anion by SOD serves as one of the antioxidant defense 
mechanism in the brain. 
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The auto-oxidation of Hcy results in the generation superoxide anion, thus leading to 
increased production of hydrogen peroxide (Heinecke et al., 1987). This effect can be 
inhibited by SOD, a scavenger of superoxide anions (Alvarez-Maqueda et al., 2004). 
 
However, the activities of these enzymatic antioxidants have been shown to be 
regulated by hormones (Pereira et al., 1998). Azevedo et al., (2001) shows that the 
total SOD activity is 83% higher in female rats than in male rats. In chapter 2 and 
chapter 3, both 17β-estradiol and progesterone of both treatment regimes show potent 
antioxidant activity, which reduce lipid peroxidation and superoxide anion generation 
in rat hippocampus. 
 
Therefore, the aim of this study is to investigate the effect of Hcy on SOD activity in 
rat hippocampus, in vivo, as well as to assess whether post- and pre-treatment with 
17β-estradiol and progesterone alter the effect of this neurotoxin on SOD activity. 
 
6.2.2 MATERIALS AND METHODS 
 
6.2.2.1 Chemicals and Reagents 
 
All chemicals and reagents were of the highest quality available and purchased from 
commercial distributors. Pyragallol was purchased from Sigma Chemical Corporation, 
St. Louis, MO, U.S.A. EDTA was purchased from Merck, Darmstadt, Germany. 
 
6.2.2.2 Dosing of Animals 
 
As described in chapter 2, section 2.3.2.3. 
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6.2.2.3 Surgical Procedures 
 
As described in chapter 2, section 2.3.2.4. 
 
6.2.2.4 Preparation of Cytosolic/Particulate fractions 
 
The hippocampi were homogenized in potassium phosphate buffer (pH 7.8, 0.1M) 
using a glass Teflon homogenizer. The homogenate was then centrifuged at 100 000 x 
g for 60 min at 4ºC. The supernatant obtained corresponds to the cytosolic fraction 
containing CuZn-SOD. The pellets were resuspended in the buffer, freeze thawed 
three times, and centrifuged at 100 000 x g for 60 min at 4ºC. This supernatant 
corresponds to the particulate fraction containing Mn-SOD. The cytosolic and 
particulate fractions were mixed together in order to obtain the total enzyme fraction. 
 
6.2.2.5 Superoxide Dismutase Assay 
 
The method of Marklund and Marklund (1974) was employed to assay the SOD 
activity, with minor modifications. Pyragallol in the presence of 10mM EDTA 
auto-oxidizes rapidly in alkaline solution (50mM Tris-HCl; pH 8.2). The reaction 
mixture consisted of: supernatant (approximately 500µg protein), 300µl of 2mM 
pyragallol, 300µl of 10mM EDTA and 62.5mM Tris-HCl was used to make up to 3ml. 
Pyragallol auto-oxidation was monitored over a period of 3 minutes with and without 
the enzyme protein. The absorbance was read at 420nm using a SHIMADZU 
UV-Absorbance Spectrophotometer. The auto-oxidation of pyragallol was linear with 
the activity of the enzyme present. Fifty percent inhibition/ (mg protein.min-1) was 
taken as one unit of enzyme activity. 
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6.2.2.6 Statistical Analysis 
 
As described in chapter 2, section 2.2.2.7. 
 
6.2.3 RESULTS 
 
The intrahippocampal injection of Hcy at 0.14µmol/µl in vivo caused a significant 
down-regulation in SOD activity (figure 6.1) when compared to the control. Both pre- 
and post-treatment of 17β-estradiol or progesterone, caused a significant increase in 
SOD activity when compared with the Hcy-treated group. Furthermore, 17β-estradiol 
and progesterone up-regulate the SOD activity and was higher than that of the control 
group. 
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Figure 6.1. The effect of the administration of post- and pre-treatment of 
17β-estradiol or progesterone on SOD activity following intrahippocampal 
administration of Hcy in rat mitochondrial homogenate. Each bar represents the mean 
±SEM, n=5. *(p<0.01) Hcy vs. control; *** (p<0.001) Pre-treatment of 17β-estradiol 
vs. Hcy and post-treatment of progesterone vs. Hcy; ** (p<0.05) post-treatment of 
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17β-estradiol vs. Hcy and pre-treatment of progesterone vs. Hcy. Student 
Newman-Keuls-Multiple Range test.  
 
 
6.2.4 DISCUSSION 
 
Oxidative stress is an imbalance between oxidant and antioxidant activity, which 
occurs during a variety of pathologies (Bast et al., 1991). SOD is the first enzyme 
identified to have a free radical as its substrate (McCord, 1969), provides a first line 
defense against oxidative stress by catalyzing the dismutation of O2˙¯ into H2O2 and 
O2. 
 
Hcy is believed to exert its effects through mechanisms involving O2˙¯ generation 
(chapter 3) and as a result, oxidative damage (Mujumdar et al., 2001). Several reports 
show that Hcy and H2O2 act synergistically to promote mitochondrial damage (Austin 
et al., 1998) or cause cytochrome c release from mitochondria, which is a key 
component involved in mitochondrial-mediated cell death (Toborek et al., 1995). 
However, Outinen et al., (1999) demonstrated that Hcy inhibits gene expression of 
SOD in human umbilical vein endothelial cells and compromised hepatic Cu-Zn SOD 
activities (Huang et al., 2001). The results from figure 6.1 show that Hcy significantly 
down-regulates the SOD activity, as compared to the control treated group. 
 
Pre- and post treatment of 17β-estradiol significant enhances the SOD activity in the 
hippocampus (figure 6.1). Hall and Sutter et al., (1998) compared Cu-Zn SOD in 
male and female transgenic mice and provide evidence for 17β-estradiol’s in vivo 
antioxidant neuroprotective effect. The results shown in figure 6.1 also indicate that 
17β-estradiol interferes with the Hcy neurotoxicity.  
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Pre- and post treatment of progesterone show significant enhanced SOD activity in 
the hippocampus (figure 6.1). Progesterone is a free radical scavenger (Roof et al., 
1992; 1994) and is able reduce lipid peroxidation (Roof et al., 1992; chapter 2). The 
up-regulated SOD activity, in comparison to Hcy treated group, could therefore be 
due to the O2•¯ scavenging properties of progesterone (chapter 3). 
 
Therefore, the results presented in this experiment provide more understanding of the 
free radical scavenging and antioxidant mechanisms of both hormones involving Hcy 
induced neurotoxicity. 
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6.3 THE EFFECTS OF 17β-ESTRADIOL AND 
PROGESTERONE IN HCY-INDUCED 
MODIFICATION OF GLUTATHIONE 
PEROXIDASE ACTIVITY IN RAT 
HIPPOCAMPUS IN VIVO 
 
6.3.1 INTRODUCTION 
 
In particular, changes in glutathione (GSH) levels occur in AD. Elevated GSH levels 
in hippocampus and midbrain were reported in AD (Adams et al., 1991). GSH 
protects cells against oxidative and free radical damage and provides cells with their 
reducing power (Meister, 1988; 1994b). The functions of GSH include maintenance 
of thiol groups in proteins as well as in synthesis and repair of DNA (Meister, 1988; 
1994b).  
H2O2 is produced during neurotransmitter turnover in brain mitochondria and is 
detoxified through reduction to water. If H2O2 is not reduced, it can lead to formation 
of reactive hydroxyl radicals and cause formation of lipid hydroperoxides, which can 
damage the mitochondrial membrane and thus, inhibit brain mitochondrial function 
(Zoccarato et al., 1988). However, GPx is the enzyme that involved in the reduction 
of H2O2 to water. The reduction of H2O2 through GPx in the mitochondria, results in 
the formation of GSSG, which is reduced back to GSH (Meister, 1988; 1994b). GPx 
therefore is an antioxidant enzyme that scavenges H2O2. 
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Hcy is a well known thiol, which induces ROS through its auto-oxidation to H2O2 
(Loscalzo, 1996) and initiates lipid peroxidation via inhibition of GPx activity in 
intracerebroventricularly administered Hcy rats (Baydas et al., 2003). 
The aim of this study is to investigate the effects of Hcy in GPx activity in rat 
hippocampus as well as to establish whether pre- and post-treatment of 17β-estradiol 
and progesterone would alter the effects that Hcy may have. 
 
 
6.3.2 MATERIALS AND METHODS 
 
6.3.2.1 Chemicals and Reagents 
 
All chemicals and reagents were of the highest quality available and were purchased 
from commercial distributors. NADPH, reduced glutathione, glutathione reductase 
(Sigma type III) and tert-butyl-hydroperoxide (t-butyl-HPx) were purchased from 
Sigma Chemical Corporation, St. Louis, MO, U.S.A. 
 
6.3.2.2 Dosing of animals 
 
As described in chapter 2, section 2.3.2.3. 
 
6.3.2.3 Surgical Procedures 
 
As described in chapter 2, section 2.3.2.4. 
 
6.3.2.4 Glutathione Peroxidase Activity 
 
GPx activity was measured by the method described by Sinet et al. (1975) using 
t-butyl-HPx as a substrate. The hippocampi were homogenized in PBS 0.05M (pH 7.4) 
in buffer solution (1mg/5µl) using a Teflon homogenizer. Hippocampal protein (30µg) 
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of was added to 500 µl of PBS containing 10-3 M reduced glutathione, 2 units of yeast 
glutathione reductase (Sigma type III) and 2 x 10-4 NADPH and incubated for 10 
minutes at 37 ºC. The reaction was initiated by the addition of t-butyl-HPx to a final 
concentration of 10-3 M, under constant agitation. One enzyme unit was defined as 
1µM NADPH/mU per mg protein. The results were analyzed using a one-way 
analysis of variance (ANOVA). If the F values were significant, the Student’s 
Newmans-Keuls Multiple Range test was used to compare the treated and control 
groups. The level of significance was accepted at p<0.05 (Zar, 1974). 
 
6.3.2.5 Statistical analysis 
 
As described in chapter 2, section 2.2.2.7. 
 
6.3.3 RESULTS 
 
There is a significant down-regulation in GPx activity after the intrahippocampal 
administration of Hcy as compared to the control treated group (figure 6.2). 
 
The results from figure 6.2 also show that pre- and post-treatments of either 
17β-estradiol or progesterone cause a significant increase in GPx activity as compared 
to the Hcy treated group. 
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Figure 6.2. The effect of the administration of post- and pre-treatment of 
17β-estradiol or progesterone on GPx activity following intrahippocampal 
administration of Hcy in rat hippocampal homogenate. Each bar represents the mean 
±SEM, n=5. *** (p<0.001) Control vs. Hcy; ### (p<0.001) post- and pre-treatment of 
17β-estradiol vs. Hcy and post- and pre-treatment of progesterone vs. Hcy. Student 
Newman-Keuls-Multiple Range test. 
 
 
6.3.4 DISCUSSION 
 
The results obtained from this study demonstrate that intrahippocampal injection of 
Hcy results in a significant reduction of GPx activity when compared to the control 
group (figure 6.2). This demonstrates that Hcy, down-regulates GPx activity and thus 
potentiates the generation of reactive oxygen species. Baydas et al., (2003) show that 
intracerebroventricular Hcy (143µg/kg) injection significantlys down-regulates GPx 
activity in hippocampus and cerebellum. However Baydas et al., (2003) also shows 
that Hcy can initiate lipid peroxidation via the inhibition of GPx activity, which 
correlates with the results obtained in chapter 2, section 2.3.3.  
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The pre- and post-treatment of 17β-estradiol and progesterone up-regulate the GPx 
activity, in comparison to the Hcy-treated group (figure 6.2) could result from an 
inhibition of lipid peroxidation (chapter 2) and free radical scavenging properties 
(chapter 3). Azevedo et al., (2001) showed that both 17β-estradiol and progesterone 
increase GPx activity in male and female rat macrophages. There is evidence that 
estrogen decreases ROS and free radical production both in vitro and in vivo, and 
suppresses estrogen synthesis in postmenopausal women and is responsible for 
enhanced oxidative stress (Ayres et al., 1998; Gura, 1995; Trevisan et al., 2001). This 
evokes concern regarding adverse effects on antioxidant defense in premenopausal 
females (Tiidus, 2000). Nevertheless, ovarian hormones control the involvement of 
endogenous antioxidant enzymes in the protective effect against oxidative stress in 
nervous tissue. A number of studies imply that there exists a correlation between the 
antioxidant status and hormonal levels (Inal et al., 1997; Rapoport et al., 1998; 
Cardozo-Pelaez et al., 2000). A recently report by Baydas et al., (2001) showed that 
Hcy inhibits GPx activity in hippocampus and thus initiates lipid peroxidation. 
Further evidence to support the antioxidant effects of both hormones was the reduced 
MDA levels, a lipid peroxidation by-product observed in chapter 2.    
 
Furthermore, Ayres et al., (1998) and Behl et al., (1995) show that, estrogen-mediated 
antioxidant activity may prevent the formation of radicals, following exposure to 
H2O2. Chapter 3 demonstrates that both hormones are potent scavengers of O2-•. Thus, 
it provides another mechanism whereby these hormones could prevent the formation 
of H2O2. 
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6.3.5 CONCLUSION 
 
Enhanced ROS production leads to oxidative stress and in due course to cellular 
damage and is a causative factor of a variety of neurodegenerative disease including 
AD is associated with a decreased antioxidant capacity of the brain (Benzi & Moretti, 
1995). Because of their extreme reactivity, it is difficult to detect and quantify ROS. 
Therefore, measurements of indirect markers of oxidative stress, such as changes in 
the activities of antioxidative enzymes, which involve ROS in pathological conditions 
is used. SOD and GPx are among the most important members of the antioxidant 
defense system. The ability of pre- and post treatment of both hormones to modify the 
antioxidant defense mechanism of SOD and GPx, in the presence of Hcy provide 
further evidence that the neuroprotective mechanisms of 17β-estradiol and 
progesterone can be multifactor. These results however, correlate and associate with 
the results obtained in chapter 3, which indicate that these agents are free radical 
scavengers. 
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CHAPTER 7 
 
RADIOLIGAND BINDING STUDIES 
 
7.1. INTRODUCTION 
 
NMDA sensitive L-[H3]-glutamate binding sites located in the CA1 region of the 
hippocampus constitute the major glutamatergic system of the neurotransmitter 
system in the hippocampus (Monaghan & Cotman, 1986). Overstimulation of NMDA 
receptors, plays a key role in excitotoxic calcium influx to neurons (Mayer & 
Westbrook, 1987; Michaels & Rothman, 1990), resulting in excitotoxic neuronal 
injury (Gosh & Griffiths, 1994). 
 
The receptor binding assay is an important tool in many disciplines in the biological 
sciences and that is one procedure that has improved the development of neuroscience 
research (Bylund & Yamamura, 1990). This provides data regarding quantitation, 
pharmacological specificity, modulation and distribution of NMDA receptors. 
 
Hcy is an endogenous ligand (Zeise et al., 1988) and an agonist at the glutamate site 
(Kim, 1999) of the NMDA receptor and part of its neurotoxicity is caused by 
overstiumlation of NMDA receptors and thus a resultant Ca2+ influx (Lipton et al., 
1997; Kruman et al., 2000). Hcy elicits excitation of cerebellar neurons (Lee et al., 
1988; Kruman et al., 2000). These authors show that Hcy enhances glutamate 
excitotoxicity and is as least as excitotoxic as glutamate. 
 
 160
Radioligand Binding Studies 
In this experiment the effect of Hcy and 17β-estradiol or progesterone with Hcy on 
NMDA receptors was investigated, in order to determine whether these hormones 
could offer protection against Hcy-induced neurotoxicity.  
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7.2. THE EFFECTS OF 17β-ESTRADIOL, 
PROGESTERONE, AND INTRAHIPPOCAMPAL 
HCY ADMINISTRATION ON GLUTAMATE 
BINDING IN VIVO AND IN VITRO 
 
7.2.1. INTRODUCTION 
 
Excessive stimulation of NMDA receptors is known to mediate brain damage (Simon, 
1984; Lipton, 1994). The NMDA receptor is a complex molecular entity with a 
number of distinct recognition sites. One of these sites is a transmitter binding site 
that binds L-glutamate and related agonists (Cooper et al., 1996). 
 
In the previous experiment in chapter 4, it was determined that both treatment 
regimens of 17β-estradiol and progesterone appeared to offer protection against 
Hcy-induced neurotoxicity in the hippocampus. The neurons in CA1 region of the 
hippocampus did not appear to swell, nor undergo neurodegeneration in CA3 region. 
However, the previous studies (chapter 4) were not able to quantify the protection 
offered by both hormones. 
 
Moreover, in chapter 6, the results show that the role of 17β-estradiol and 
progesterone in protect against Hcy-induced neurotoxicity due to their abilities to 
upregulate the enzymatic antioxidant activities. Therefore, the mechanism by which 
17β-estradiol and progesterone are neuroprotective may extend beyond that of an 
antioxidant. The present study aims to investigate the effect of 17β-estradiol and 
progesterone on glutamate binding to the NMDA receptor in comparison to Hcy. 
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7.2.2. MATERIALS AND METHODS 
 
7.2.2.1. Chemicals and Reagents 
 
17β-estradiol, progesterone (4-Pregnene-3,20-dione), DL-homocysteine and 
N-methyl-D-aspartate (NMDA) were purchased from Sigma (St. Louis, USA). 
[H3]Glutamate (43.0 Ci/mmol) was purchased from Amersham Pharmacia Biotech 
(Buckinghamshire, England). Scintillation cocktail was purchased from Packard 
(USA). All reagents were of the highest quality available. 
 
7.2.2.2. Animals 
 
Adult male rats of the Wistar strain, weighing between 250-300g were used for the 
experiment, and were housed and maintained under the conditions described in 
section 2.2.2.2. 
 
7.2.2.3. Dosing of Animals 
 
As described in section 2.3.2.3. 
 
7.2.2.4. Surgical Procedures 
 
As described in section 2.3.2.4. 
 
7.2.2.5. Preparation of Synaptic Membranes 
 
Hippocampal neuronal membranes were prepared using the method of Bylund & 
Yamamura, 1990. Hippocampi were homogenized in 50 volumes 50 mM Tris-HCl 
buffer (pH 7.4) containing 1mM EDTA. This was centrifuged at 50 000 x g for 15 min. 
The pellets were resuspended in 50 volumes 50mM Tris-HCl buffer (pH 7.4) and 
centrifuged as before. The centrifugation step was repeated once more and the final 
 163
Radioligand Binding Studies 
pellets were resuspended in 15 volumes 50mM Tris-HCl buffer (pH 7.4). The pellets 
were then resuspended in 20ml of 0.32M sucrose and rapidly frozen in liquid nitrogen 
and stored at -70˚C until use. 
 
7.2.2.6. Saturation Glutamate Binding Studies 
 
In a saturation experiment the radioligand concentration is variable, whereas the 
receptor concentration, the drug concentration and time are all constant. The synaptic 
membranes prepared from the three brains in each treated group were used for these 
studies. Therefore, this study was considered to be an in vivo investigation.  
 
On the day of the binding study, the frozen synaptic membranes were thawed, diluted 
up to 40 volumes with buffer and centrifuged at 50 000 x g at 4˚C for 20 minutes. The 
pellets were resuspended and treated with 0.08% Triton X-100 for 10 minutes. This 
was followed by centrifugation at 50 000 x g at 4˚C for 20 minutes. The pellets were 
resuspended in 50mM Tris acetate buffer. Protein concentration was determined as in 
3.2.2.8. 
 
For total binding, incubation mixtures consisted of 425µl membrane suspension, 
stock solution of [H3] Glutamate ranging from 0.5nM to 5nM final concentration, and 
50mM Tris-HCL buffer pH 7.4 to give a final incubation volume of 500µl. A series 
of uncapped scintillation vials with GF/A filters on top were prepared. Aliquots (20µl) 
of each concentration of ‘hot' glutamate was pipetted directly onto the filter paper to 
determine total added radioactivity. 
 
Non-specific binding was determined by adding NMDA (1mM final concentration) to 
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a separate set of tubes prepared as before. The tubes were incubated at 25°C for 
100min and the reaction was terminated by the addition of 4ml ice cold Tris buffer 
followed immediately by rapid filtration through Whatman glass fiber (GF/A) filters 
under negative pressure. The filters were washed twice with 4ml cold buffer and 
placed into scintillation vials containing 3ml scintillation cocktail. The vials were left 
overnight and the radioactivity measured using a Beckman Liquid Scintillation 
Counter. Radioactivity was expressed as pmoles glutamate bound. 
 
7.2.2.7. Glutamate Receptor-Displacement Binding Studies 
 
In this experiment, the receptor concentration, the radioligand concentration and time 
are all constant, whereas the concentration of the tested agent/drug is variable. Brains 
were removed from untreated, intact female rats and membrane suspensions prepared 
as in 7.2.2.5. Eight tubes were set up in triplicate. Tube 1 (total binding) contained 
25µl [H3]-Glutamate to give a final concentration of 5nM, 50µl of 50mM Tris-HCL 
buffer pH 7.4, and 25µl of 100% ethanol. Tubes 2 through 7 contained 25µl of 
17β-estradiol or progesterone dissolved in ethanol or Hcy dissolved in MilliQ water 
ranging from 0.05nM to 5µM final concentration, 25µl [H3]-Glutamate to give a final 
concentration of 5nM, and 50µl of buffer. Tube 8 (non-specific binding) contained 
25µl [H3]-Glutamate to give a final concentration of 5nM, 25µl ethanol and 50µl 
NMDA to give a final concentration of 1mM. An aliquot of 400µl of membrane 
suspension was added to all the tubes. Results were expressed as percent glutamate 
bound in the presence of 17β-estradiol, progesterone or Hcy. 
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7.2.3. RESULTS 
 
7.2.3.1. Saturation Binding Studies – calculation and data analysis 
 
The radioactivity measured by the liquid scintillation counter is in CPM (counts per 
minute). Once the mean of the triplicate CPM values are calculated, the non-specific 
binding values are subtracted from the total binding values, to give specific binding 
data. A saturation plot can be constructed by plotting the specific binding of the 
radioligand versus the ligand concentration. The specific binding can be plotted in 
units of fmol/mg protein, which is calculated by multiplying the specific binding by a 
factor and dividing by the protein concentration. The factor calculated in this 
experiment was as follows: 
 f = specific activity-1 x volume-1 x efficiency-1 x Ci/ 2.2 x 1012dpm 
Efficiency refers to the efficiency of the scintillation counter (65%), volume is the 
incubation volume i.e. 0.5ml and the final number is the definition of a curie in terms 
of dpm (disintegrations per minute). The unit of this factor is pmoles/cpm (Bylund & 
Yamamura, 1991). The KD and Bmax values were obtained from Graphpad Prism 4®. 
 
Saturation binding plots were generated for control (figure 7.1), Hcy (figure 7.3), both 
regimens of 17β-estradiol (figure 7.5 and 7.7) and progesterone (figure 7.9 and 7.11). 
The data was converted to Scatchard plots so as to determine the Bmax for each of the 
treated groups (see figure 7.2, 7.4, 7.6, 7.8, 7.10 and 7.12). 
 
The Bmax values obtained in each case are shown in Table 7.1. Hcy caused a 
significant down-regulation in the number of glutamate binding sites when compared 
to control groups. Moreover, animals which received a combination of Hcy and 
17β-estradiol or progesterone of both treatment regimens showed a similar number of 
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glutamate binding sites compared to control animals. Therefore both regimens of 
either hormone appear to be able to up-regulate the number of glutamate binding sites 
compared to the control and Hcy only treated group. 
 
Simultaneously, the glutamate receptors of 17β-estradiol or progesterone treated 
groups in combination with Hcy injections had very similar KD values compared to 
the control group. The receptors of the Hcy only treated group had a much higher 
glutamate binding affinity than either control or drug treated groups, with a KD value 
10 fold lower than the control. 
 
Table 7.1. Summary of Bmax values obtained from glutamate receptor binding 
studies. 
 
Group 
 
KD (nM) Bmax (pmoles/mg 
protein) 
Control (PBS) 
 
2.57 245.8±57.3 
Hcy  
 
0.28 81.45±4.3 
Hcy + 17β-estradiol 
(post-treatment) 
1.70 227.30±54.6 
Hcy + 17β-estradiol 
(pre-treatment) 
2.31 184.64±42.2 
Hcy + progesterone 
(post-treatment) 
1.51 195.75±24.9 
Hcy + progesterone 
(pre-treatment) 
2.68 226.62±66.9 
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Figure 7.1.  Saturation binding plot of [H3]-Glutamate binding to hippocampal 
synaptic membranes from control rats. Three animals from each group were used in 
saturation binding experiments. 
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Figure 7.2.  Scatchard plot of [H3]-Glutamate binding to hippocampal synaptic 
membranes from control rats. 
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Figure 7.3.  Saturation binding plot of [H3]-Glutamate binding to hippocampal 
synaptic membranes from Hcy only treated rats. Three animals from each group were 
used in saturation binding experiments. 
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Figure 7.4.  Scatchard plot of [H3]-Glutamate binding to hippocampal synaptic 
membranes from Hcy only treated rats. 
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Figure 7.5. Saturation binding plot of [H3]-Glutamate binding to hippocampal 
synaptic membranes from post-treatment of 17β-estradiol and Hcy treated rats. Three 
animals from each group were used in saturation binding experiments. 
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Figure 7.6.  Scatchard plot of [H3]-Glutamate binding to hippocampal synaptic 
membranes from post-treatment of 17β-estradiol and Hcy treated rats. 
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Figure 7.7.  Saturation binding plot of [H3]-Glutamate binding to hippocampal 
synaptic membranes from pre-treatment of 17β-estradiol and Hcy treated rats. Three 
animals from each group were used in saturation binding experiments. 
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Figure 7.8.  Scatchard plot of [H3]-Glutamate binding to hippocampal synaptic 
membranes from pre-treatment of 17β-estradiol and Hcy treated rats. 
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Figure 7.9.  Saturation binding plot of [H3]-Glutamate binding to hippocampal 
synaptic membranes from pre-treatment of progesterone and Hcy treated rats. Three 
animals from each group were used in saturation binding experiments. 
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Figure 7.10.  Scatchard plot of [H3]-Glutamate binding to hippocampal synaptic 
membranes from pre-treatment of 17β-estradiol and Hcy treated rats. 
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Figure 7.11.  Saturation binding plot of [H3]-Glutamate binding to hippocampal 
synaptic membranes from post-treatment of progesterone and Hcy treated rats. Three 
animals from each group were used in saturation binding experiments. 
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Figure 7.12.  Scatchard plot of [H3]-Glutamate binding to hippocampal synaptic 
membranes from pre-treatment of progesterone and Hcy treated rats. 
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7.2.3.2. Receptor-Displacement Studies – calculations and data 
analysis 
 
The affinity of the unlabelled ligand for the receptor can be determined directly by 
measuring its ability to compete with, and thus inhibit, the binding of a radioactive 
ligand to its receptor. A competition curve can be generated by plotting the percentage 
of total binding in the presence of the different concentrations of drug versus drug 
concentration. This plot is not well suited to determining the IC50 value. Thus a 
logit-log plot is constructed where the data is first calculated in terms of percent 
bound (P) where 100% is the amount specifically bound in the absence of drug. This 
was done by taking the mean of the diluents tube (tubes 1 in this case) and subtracting 
the mean of the non-specific values (NSB; tube 8). For tubes 2 through 7 P were 
calculated by subtracting the non-specific binding from the amount bound (B), 
dividing by B0 and multiplying by 100: 
P = B-NSB / B0 x 100 
The logit transformation is the natural logarithm (ln) of the ratio of percent bound to 
100 minus the percent bound. 
Logit = ln[P/(100-P)] 
The IC50 is 50% binding, and the logit of 50% [ln(1)] is 0. Thus the IC50 can be 
calculated by direct correlation or as in these studies by extrapolating the values from 
the logit of 0. The Ki was determined by the following equation: 
Ki = IC50 / 1 + F/KD
The KD is determined from the saturation experiment and F is the free radioligand 
(Bylund & Yamamura, 1991). 
 
Glutamate receptor-displacement binding studies show that both treatment regimes of 
17β-estradiol or progesterone are more effective in reducing the amount of glutamate 
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bound compared to Hcy. 17β-estradiol and progesterone exhibit a greater inhibition of 
glutamate binding as opposed to Hcy as evidenced by the sharper decrease in percent 
glutamate bound at low concentrations of 17β-estradiol and progesterone (figure 7.13). 
However, the IC50 values obtained are lower to that obtained for Hcy at the same 
concentrations, calculated from the plots in figure 7.13. Furthermore, the Ki for both 
regimes of 17β-estradiol or progesterone in comparison to that for Hcy is generally 
the same, which indicates equal inhibition of glutamate binding by 17β-estradiol or 
progesterone (Table 5.2.).  
 
Table 7.2.  Summary of the data obtained for inhibition binding studies. 
[H3]-Glutamate binding was observed in the presence of 17β-estradiol, progesterone 
or Hcy. 
 
Tested Ligand IC50 (nM) Ki (nM) 
Hcy 1.36 5.03 
17β- estradiol 0.22 3.16 
Progesterone 0.34 2.97 
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Figure 7.13. Inhibition curves of [H3]-Glutamate binding in the presence of 
17β-estradiol or progesterone or Hcy. The graph shows a greater inhibition of 
glutamate binding with 17β-estradiol or progesterone as opposed to Hcy as shown by 
the sharp decrease in percent glutamate binding with both agents.  
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Logit Plot: Estradiol
0.2 
0 
ln
 [P
/(1
00
-P
)] -0.2 
-0.4 
-0.6 
-0.8 
-1
-1.2 
0.05 nM 0.5 nM 5 nM 50 nM 500 nM 5µM
Drug Concentration
 
(b) 
Logit Plot: Progesterone
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(c) 
Figure 7.14. Logit plots generated from inhibition binding studies. [H3]-Glutamate 
binding was decreased in presence of 17β-estradiol or Hcy. 
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7.2.4. DISCUSSION 
 
The results of the saturation binding studies demonstrate the effect of treatment with 
Hcy alone or in combination with 17β-estradiol or progesterone of both treatment 
regimes on the ability of glutamate to bind to the receptor. The KD and Bmax values 
determined (Table 7.1) show that the intrahippocampal injection of Hcy results in a 
reduction in the number of binding sites. Hcy treatment also changed the nature of 
those receptors that were present on the neurons, in that these had a higher affinity for 
glutamate than did the control neurons. This could be explained by the histology 
results in previous chapter (chapter 4), which demonstrate the neurotoxic effects of 
Hcy and the destruction of the neuronal cells, thus causing a decrease in the number 
of membrane bound receptor sites. In addition, it has been shown that Hcy itself acts 
as an agonist at the glutamate binding site of the NMDA receptor (Lipton et al., 1997) 
and leads to an imbalance in excitatory: inhibitory neurotransmission in the 
hippocampus (Bleich & Degner, 2000). 
 
Treatment with either 17β-estradiol or progesterone prior to and after the 
intrahippocampal injection of Hcy results in up-regulation in the number of binding 
sites of the receptor in comparison to the control and to treatment with Hcy alone. 
These receptors however show similar affinity for glutamate as do receptors from 
neurons in the control group. These results demonstrate that 17β-estradiol and 
progesterone protect hippocampal neurons against Hcy-induced degeneration. 
 
It has been previously reported that 17β-estradiol increases the number of agonist 
binding sites (Weiland, 1992). Progesterone blocks the glutamate in NMDA neuron 
(Gentile & McIntosh, 1993; Smith, 1994), thus limiting secondary neuronal death that 
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occurs due to excessive release of glutamate. However, the displacement binding 
studies show that both hormones are as effective as Hcy at reducing the amount of 
glutamate bound. The Ki values obtained for 17β-estradiol and progesterone are not 
significantly different for Hcy. 
 
In addition to the results of the histological studies, both 17β-estradiol and 
progesterone protect hippocampal neurons against Hcy-induced damage. This is a 
direct result of Hcy action on the NMDA receptor. Therefore the protection of either 
hormone against Hcy-induced damage requires an interaction with the NMDA 
receptor, thus reducing the amount of Hcy binding to this receptor. Moreover, the 
results from the displacement studies support the hypothesis that 17β-estradiol and 
progesterone bind to the receptor with an equal affinity to Hcy, thus competing with 
Hcy for the receptor and protecting against neuronal damage. 
 
The results imply that 17β-estradiol and progesterone may be able to protect neurons 
from increase risk of glutamate receptor overstiumlation, by up-regulating the number 
of glutamate binding sites. 
 
7.2.5. CONCLUSION 
 
The results of the experiments presented in this chapter show that 17β-estradiol and 
progesterone in both treatment regimes offer protection against Hcy-induced 
neurotoxicity via a NMDA receptor-dependent mechanism. The histological analysis 
of the hippocampus of the animals treated with Hcy shows that there is a swelling of 
neurons in the CA1 region and degeneration of neurons in the CA3 region. However, 
neurons from both treatment regimes of either 17β-estradiol or progesterone do not 
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appear to have been affected by Hcy. These results show that both hormones offer 
neuroprotection against intrahippocampal injections of Hcy. Unfortunately, these 
studies do not explain the method by which these hormones offer protection, nor the 
level of protection offered. This would be the subject of another study. 
 
The binding studies attempt to quantify any neurodegeneration that may be induced 
by Hcy. The reduction in receptor numbers induced by Hcy could be a result of a loss 
of neurons. Results show that there is a significant increase in the Bmax values for 
animals which received either 17β-estradiol or progesterone prior to and following the 
Hcy injection. The increase in Bmax values were however similar to those in the 
control group. However, several authors report that Hcy-induced excitotoxicity is 
evoked by glutamate and is mediated by NMDA receptors, whose activation leads to 
massive accumulation of extracellular Ca2+ in the cells (Kruman et al., 2000; Lipton et 
al., 1997). 
 
Heron et al., (2001) showed that 17β-estradiol appears to act directly on NMDA 
receptors. Weaver et al., (1997) has shown that 17β-estradiol inhibits NMDA-induced 
cell death in glial cells, by reducing Ca2+ influx. It has also been shown that 
17β-estradiol attenuates neurotoxicity produced by glutamate exposure of primary rat 
hippocampal cultures (Goodman et al., 1996; Behl, 1995), as measured by cell 
viability and lysis (Behl, 1995). Furthermore, Weiland et al., (1992) showed that 
17β-estradiol may influence learning behaviors and seizure activity by altering the 
sensitivity of hippocampal neurons to glutamate activation. 
 
Progesterone, on the other hand, blocks the glutamate in the NMDA neurons, which is 
similar to NMDA antagonists MK-801 (Barth et al., 1990; Gentile et al., 1993; Smith, 
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1994). Thus progesterone has the potential to limit secondary neuronal death that 
occurs because of an excessive release of glutamate (Gentile et al., 1993; Smith, 
1994). Smith et al., (1994) showed that progesterone may block glutamate via 
conversion into its metabolite, allopregnanolone, within the brain, which has a weak 
affinity for GABAA receptor. Moreover, Misztal et al., (1996) showed that chronic 
treatment of progesterone provides protection against glutamate-induced 
excitotoxicity in rat models by acting as a NMDA antagonist. 
 
The results of this study thus show that both treatment regimes of 17β-estradiol or 
progesterone appear to protect hippocampal neurons from degeneration caused by 
intrahippocampal injections of Hcy. In conjunction with the results obtained from 
histological studies in chapter 4, it could be argued that these hormones appear to be 
effective at protecting neurons from Hcy-induced neuronal damage. 
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CHAPTER 8 
 
SUMMARY OF RESULTS 
 
8.1. CHAPTER 2 
 
The effects of the pre- and post- treatments of 17β-estradiol and progesterone on the 
levels of Hcy-induced lipid peroxidation was investigated in the rat brain in vitro and 
in vivo. Lipid peroxidation involves the destruction of lipid membranes by a process 
initiated by ROS. Intrahippocampal injections of Hcy were used to cause 
neurodegeneration in the in vivo study. Both female hormones showed a significant 
reduction in lipid peroxidation induced by Hcy in vitro and in vivo. 
 
8.2. CHAPTER 3 
 
The experiment was performed to determine if both regimes of 17β-estradiol or 
progesterone could act as superoxide radical scavengers, to reduce the superoxide 
production induced by intrahippocampal injections of Hcy. Hcy is a well known 
sulphur-containing amino acid which induces generation of O2˙¯ during auto-oxidation 
reactions. However, it was theorized that the antioxidant effects of 17β-estradiol and 
progesterone offered neuroprotection in response to superoxide anions. Under the 
experimental conditions, both female hormones were able to reduce superoxide 
anions. Therefore, the extent of protection of both female hormones as antioxidants 
against oxidative stress in the form of O2˙¯ was investigated in this chapter. 
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8.3. CHAPTER 4 
 
Histological techniques were employed in this chapter. Microscopic examination of 
the hippocampal neurons was performed following intrahippocampal injection of Hcy, 
and post- and pre-treatment with subcutaneous injection of 17β-estradiol or 
progesterone. Both regimes of 17β-estradiol or progesterone were shown to protect 
the neurons in both CA1 and CA3 regions of the hippocampus in Hcy-induced 
neurodegeneration. 
 
8.4. CHAPTER 5 
 
In Situ Cell Death Detection Kit, POD and light microscopy were used to investigate 
the ability of Hcy to promote apoptosis in the hippocampus and protection offered by 
the treatment with 17β-estradiol and progesterone. From the micrographs obtained, 
both regimes of 17β-estradiol or progesterone were able to protect against the 
Hcy-induced apoptotic cell death in both CA1 and CA3 regions of the hippocampus. 
There are no brown stained neurons observed in 17β-estradiol or progesterone 
treatment which could be observed in the Hcy-treated group. 
 
8.5. CHAPTER 6 
 
These experiments were performed to investigate the effects of Hcy on indirect 
markers of oxidative stress, SOD and GPx activities, in rat hippocampus in vivo, and 
both regimes of 17β-estradiol or progesterone on the effects of Hcy on SOD and GPx 
activities. From the results obtained, both regimes of either hormone were able to 
cause a significant increase in SOD and GPx activities as compared to the Hcy treated 
group. These results however, correlate with the results obtained in chapter 3, which 
indicate that these agents are free radical scavengers and antioxidants. 
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8.6. CHAPTER 7 
 
Radiolabelled glutamate saturation binding studies were performed. The results 
demonstrate that the intrahippocampal injection of Hcy alone had higher affinity of 
glutamate to bind to the NMDA receptor as well as causing reduction in the number 
of binding sites. However, treatment with either 17β-estradiol or progesterone prior to 
and after the intrahippocampal injection of Hcy resulted in up-regulation in the 
number of binding sites and showed similar affinity for glutamate receptors from 
neurons in the control group. These results demonstrate that 17β-estradiol and 
progesterone protect hippocampal neurons against Hcy-induced degeneration. 
 184
